Breaking News

Friday Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
Conference/Events	Alliance for Regenerative Medicine to hold a virtual meeting » 04:55 04/09/21 04/09 04:55 04/09/21 04:55 BLUE Bluebird Bio $28.86 / -1.2 (-3.99%) , GILD Gilead $65.03 / -0.56 (-0.85%) , TMO Thermo Fisher $471.57 / +5.26 (+1.13%) , SGTX Sigilon Therapeutics $17.81 / -0.5 (-2.73%) , ADAP Adaptimmune $5.12 / +0.16 (+3.23%) , AGTC Applied Genetic $4.57 / +0.115 (+2.58%) , ATRA Atara Biotherapeutics $14.18 / -0.035 (-0.25%) , CABA Cabaletta Bio $10.77 / +0.155 (+1.46%) , FLXN Flexion $8.30 / -0.03 (-0.36%) , DTIL Precision BioSciences $8.94 / +0.025 (+0.28%) , DOV Dover $138.50 / -0.465 (-0.33%) , GNPX Genprex $4.88 / +0.805 (+19.78%) , DBTX Decibel Therapeutics $10.71 / -0.35 (-3.16%) , CYRX Cryoport $53.88 / +2.68 (+5.23%) , GLW Corning $44.57 / +0.27 (+0.61%) , FTV Fortive $70.23 / -1.16 (-1.62%) , KRYS Krystal Biotech $73.50 / -0.25 (-0.34%) , NVO Novo Nordisk $69.24 / +1.375 (+2.03%) , NVS Novartis $87.02 / +0.705 (+0.82%) , ORTX Orchard Therapeutics $6.96 / +0.09 (+1.31%) , MRK Merck $75.48 / -0.65 (-0.85%) , MEDP Medpace $169.50 / +1.6 (+0.95%) , IOVA Iovance Biotherapeutics $31.30 / +0.31 (+1.00%) , FOLD Amicus $9.27 / -0.0999 (-1.07%) Cell & Gene Virtual… Cell & Gene Virtual Meeting on the Mediterranean will be held on April 6-9. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options TMO SGTX ORTX NVS NVO MRK KRYS IOVA GNPX GLW GILD FTV FOLD FLXN DTIL DOV DBTX CYRX CABA BLUE ATRA AGTC ADAP TMO Thermo Fisher $471.57 / +5.26 (+1.13%) 03/24/21 Thermo Fisher to offer integrated COVID-19 testing to U.S. school districts 03/24/21 Thermo Fisher announces launch of in-air SARS-CoV-2 surveillance solution 03/10/21 Thermo Fisher investing over $600M to expand bioprocessing production 03/08/21 Chembio Diagnostics appoints David Bespalko to board of directors SGTX Sigilon Therapeutics $17.81 / -0.5 (-2.73%) 03/05/21 Sigilon Therapeutics receives Orphan Drug Designation for SIG-007 12/17/20 Sigilon Therapeutics receives Orphan Drug designation for SIG-005 12/14/20 Sigilon Therapeutics gets FDA orphan drug designation for Arpe-19 ORTX Orchard Therapeutics $6.96 / +0.09 (+1.31%) 03/03/21 Orchard Therapeutics, Be The Match BioTherapies, extend Libmeldy pact 03/02/21 Orchard Therapeutics expects cash to fund requirements into 1H23 03/02/21 Orchard Therapeutics CTO, CMO step down from positions 03/02/21 Orchard Therapeutics appoints Anne Dupraz as CDO NVS Novartis $87.02 / +0.705 (+0.82%) 04/07/21 Immutep announces European patent grant for LAG525 antibody 03/30/21 Novartis expands targeted radioligand therapy pipeline with in-license 03/30/21 Genmab announces Novartis marketing authorization for Kesimpta granted by EC 03/23/21 Novartis reports 177Lu-PSMA-617 Phase 3 VISION study met both primary endpoints NVO Novo Nordisk $69.24 / +1.375 (+2.03%) 03/26/21 Novo Nordisk reports Saxenda recommended for expanded approval by EMA's CHMP 03/23/21 Novo Nordisk reports full results of STEP 4 trial were presented at ENDO meeting 03/22/21 Novo Nordisk discloses FDA Refusal to File letter for semaglutide 03/18/21 Gilead and Novo Nordisk expand NASH clinical collaboration, to conduct study MRK Merck $75.48 / -0.65 (-0.85%) 04/08/21 Immutep achieves fast track designation from FDA for Efti 04/08/21 Merck says Phase 3 KEYNOTE-564 trial met primary endpoint 04/07/21 Alkermes announces nemvaleukin trial collaboration, supply agreement with Merck 04/07/21 IMV Inc. enters agreement with Merck to initiate maveropepimut-S, Keytruda trial KRYS Krystal Biotech $73.50 / -0.25 (-0.34%) 03/30/21 Krystal Biotech announces completion of patient enrollment in GEM-3 trial 03/24/21 Krystal Biotech appoints Bhushan Hardas as president of Jeune 03/24/21 Krystal Biotech launches Jeune subsidiary, reports Phase 1 safety data for KB301 10/28/20 Rhythm Pharmaceuticals appoints Jennifer Chien as EVP, head of North America IOVA Iovance Biotherapeutics $31.30 / +0.31 (+1.00%) 03/15/21 Iovance Biotherapeutics appoints Igor Bilinsky as COO 12/14/20 Iovance Biotherapeutics appoints Jean-Marc Bellemin as CFO 11/09/20 Iovance Biotherapeutics presents interim data for LN-145 w/ pembrolizumab 10/14/20 Iovance Biotherapeutics says LN-145 can be combined w/ pembrolizumab GNPX Genprex $4.88 / +0.805 (+19.78%) 02/01/21 Genprex gives update on 2020 developments and anticipated milestones 01/13/21 Genprex achieves manufacturing milestone for Reqorsa for upcoming trials 12/22/20 Genprex completes manufacturing scale-up for Reqorsa production 11/30/20 Genprex initiates site recruitment for Acclaim-1 clinical trial GLW Corning $44.57 / +0.27 (+0.61%) 04/05/21 Corning announces resumption of share repurchases 04/05/21 Corning, Samsung Display extend long-term investment relationship 04/05/21 Verizon Business, AWS expand 5G collaboration to deliver private MEC 03/26/21 Corning announces expansion of contract with DoD, HHS GILD Gilead $65.03 / -0.56 (-0.85%) 04/08/21 Galapagos Gilead extend lock-up period to 2024 04/07/21 Gilead's Trodelvy approved by FDA in TNBC 04/07/21 FDA grants regular approval to Trodelvy for triple-negative breast cancer 04/07/21 FDA grants regular approval to sacituzumab govitecan FTV Fortive $70.23 / -1.16 (-1.62%) 11/13/20 Third Point takes stake in PG&E, boosts Alibaba stake, exits Baxter 10/09/20 Vontier completes separation from Fortive 10/09/20 Vontier to replace Noble Energy in S&P 500 at open on 10/9 FOLD Amicus $9.27 / -0.0999 (-1.07%) 03/01/21 Amicus sees FY21 total Galafold revenue $300M-$315M 02/11/21 Amicus AT-GAA not stat. significant for superiority vs. alglucosidasa alfa 02/11/21 Amicus trading resumes 02/11/21 Amicus trading halted, news pending FLXN Flexion $8.30 / -0.03 (-0.36%) 03/31/21 Flexion announces first patient treated in FX201 Phase 1b trial 03/01/21 Flexion announces FDA clearance for FX301 IND application 02/18/21 Flexion to advance FX201 into high dose cohort of Phase 1 trial 02/01/21 NBRPA, Sheryl Swoopes, Flexion partner to raise ZILRETTA awarness DTIL Precision BioSciences $8.94 / +0.025 (+0.28%) 04/06/21 Precision BioSciences announces initiation of public search for new CEO 03/18/21 Precision BioSciences expects cash to continue operations into 2023 02/19/21 Precision announces 3-year preclinical study results of ARCUS gene editing 01/25/21 Precision BioSciences granted patent for candidate for Non-Hodgkin Lymphoma DOV Dover $138.50 / -0.465 (-0.33%) 12/03/20 Dover CFO sells 33.7K shares of common stock 10/13/20 Dover's Pole/Zero awarded $24M contract by U.S. Navy DBTX Decibel Therapeutics $10.71 / -0.35 (-3.16%) 03/22/21 Decibel Therapeutics added to Russell 2000 Index 02/24/21 Decibel Therapeutics presents preclinical findings on DB-OTO CYRX Cryoport $53.88 / +2.68 (+5.23%) 04/06/21 Cryoport acquires Critical Transport Solutions Australia for $5M 12/08/20 Cryoport, CCRM enter three-year agreement CABA Cabaletta Bio $10.77 / +0.155 (+1.46%) 03/16/21 Cabaletta Bio expects cash to fund operating plan through at least 3Q22 11/10/20 Cabaletta Bio plans to initiate validation of cell processing for trials by year BLUE Bluebird Bio $28.86 / -1.2 (-3.99%) 03/28/21 FDA approves Bristol Myers Squibb, Bluebird Bio's Abecma 03/17/21 Bluebird Bio Chief Medical Officer to leave company on April 16 03/15/21 Bluebird Bio announces new data from livaldogene autotemcel gene therapy program 03/10/21 Bluebird Bio updates findings from AML case in LentiGlobin for SCD gene therapy ATRA Atara Biotherapeutics $14.18 / -0.035 (-0.25%) 03/14/21 Atara Biotherapeutics presents long-term OS data from Phase 2 Tab-cel studies 02/08/21 Atara Biotherapeutics to present tabelecleucel data at ASTCT meeting 01/04/21 Atara Biotherapeutics provides update on BLA submission for tab-cel 12/07/20 Atara presents evaluation of CAR T Cell Therapy ATA3219 at ASH AGTC Applied Genetic $4.57 / +0.115 (+2.58%) 03/25/21 Applied Genetic announces initiatives to enhance patient journey in XLRP trials 02/11/21 Applied Genetic expects cash, cash equivalents to fund programs into 2023 11/11/20 Applied Genetic reports additional data from Phase 1/2 trial in XLRP ADAP Adaptimmune $5.12 / +0.16 (+3.23%) 02/25/21 Adaptimmune to initiate Phase 2 SURPASS-2 trial with ADP-A2M4CD8 11/20/20 Adaptimmune sees current cash runway into early 2023 11/20/20 Adaptimmune to showcase market potential for SPEAR T-cell portfolio, pipeline 11/19/20 Adaptimmune presents durability of response data from Phase 1 ADP-A2M4 trial BLUE GILD TMO SGTX ADAP AGTC ATRA CABA FLXN DTIL DOV GNPX DBTX CYRX GLW FTV KRYS NVO NVS ORTX MRK MEDP IOVA FOLD BLUE Bluebird Bio $28.86 / -1.2 (-3.99%) 03/29/21 BMO Capital Bluebird Bio price target raised to $35 from $31 at BMO Capital 03/29/21 Mizuho Bluebird Bio approval could improve sentiment on shares, says Mizuho 03/29/21 Piper Sandler Bluebird Bio price target raised to $35 from $30 at Piper Sandler 03/17/21 Stifel Stifel says Bluebird Bio CMO exit 'a bit concerning but not thesis changing' GILD Gilead $65.03 / -0.56 (-0.85%) 04/01/21 Fly Intel: Top five analyst upgrades 04/01/21 Bernstein Gilead upgraded to Outperform from Market Perform at Bernstein 03/30/21 Redburn Gilead upgraded to Buy from Neutral at Redburn 03/15/21 Mizuho Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho TMO Thermo Fisher $471.57 / +5.26 (+1.13%) 03/29/21 UBS Thermo Fisher price target lowered to $560 from $588 at UBS 03/18/21 KeyBanc Thermo Fisher upgraded to Overweight at KeyBanc after Sartorius guidance 03/18/21 KeyBanc Thermo Fisher upgraded to Overweight from Sector Weight at KeyBanc 03/02/21 Barclays Thermo Fisher initiated with an Overweight at Barclays SGTX Sigilon Therapeutics $17.81 / -0.5 (-2.73%) 12/29/20 Barclays Sigilon Therapeutics initiated with an Overweight at Barclays 12/29/20 Morgan Stanley Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley 12/29/20 Jefferies Sigilon Therapeutics initiated with a Buy at Jefferies ADAP Adaptimmune $5.12 / +0.16 (+3.23%) 08/12/20 Piper Sandler TCR2 Therapeutics initiated with an Overweight at Piper Sandler 06/01/20 Mizuho Adaptimmune price target raised to $9 from $3 at Mizuho 05/29/20 JonesTrading JonesTrading upgrades Adaptimmune to Buy after data alleviates 'key concern' 05/29/20 JonesTrading Adaptimmune upgraded to Buy from Hold at JonesTrading AGTC Applied Genetic $4.57 / +0.115 (+2.58%) 03/01/21 Stifel Applied Genetic initiated with a Buy at Stifel 02/02/21 H.C. Wainwright Applied Genetic price target raised to $24 from $18 at H.C. Wainwright 02/01/21 Roth Capital Applied Genetic price target raised to $35 from $30 at Roth Capital 11/17/20 Roth Capital Applied Genetic price target raised to $30 from $26 at Roth Capital ATRA Atara Biotherapeutics $14.18 / -0.035 (-0.25%) 03/25/21 Evercore ISI Viracta Therapeutics initiated with an Outperform at Evercore ISI 03/02/21 Citi Atara Biotherapeutics upgraded to Buy at Citi following 35% pullback 03/02/21 Citi Atara Biotherapeutics upgraded to Buy from Neutral at Citi 01/04/21 Roth Capital Roth keeps Buy rating on Atara Biotherapeutics after filing delay CABA Cabaletta Bio $10.77 / +0.155 (+1.46%) 03/17/21 H.C. Wainwright Cabaletta Bio price target raised to $22 from $20 at H.C. Wainwright 01/08/21 Chardan Cabaletta Bio initiated with a Buy at Chardan 10/13/20 H.C. Wainwright Cabaletta Bio initiated with a Buy at H.C. Wainwright FLXN Flexion $8.30 / -0.03 (-0.36%) 04/06/21 RBC Capital Flexion transferred with an Outperform at RBC Capital 08/20/20 Goldman Sachs Flexion initiated with a Neutral at Goldman Sachs 07/30/20 Oppenheimer Flexion initiated with an Outperform at Oppenheimer 07/29/20 Fly Intel: Top five analyst initiations DTIL Precision BioSciences $8.94 / +0.025 (+0.28%) 04/06/21 Stifel Stifel sees Precision BioSciences' CEO transition as 'disconcerting' 02/24/21 Fly Intel: Top five analyst initiations 02/24/21 JonesTrading Precision BioSciences initiated with a Buy at JonesTrading 01/29/21 JPMorgan Precision BioSciences price target raised to $14 from $10 at JPMorgan DOV Dover $138.50 / -0.465 (-0.33%) 04/06/21 Barclays Dover price target raised to $155 from $145 at Barclays 01/28/21 Baird Dover price target raised to $147 from $140 at Baird 01/28/21 Baird Dover results a solid beat with guidance above consensus, says Baird 01/05/21 Barclays Dover price target raised to $141 from $138 at Barclays GNPX Genprex $4.88 / +0.805 (+19.78%) 01/26/21 National Securities Genprex initiated with a Buy at National Securities 04/22/20 Alliance Global Partners Genprex initiated with a Buy at Alliance Global Partners DBTX Decibel Therapeutics $10.71 / -0.35 (-3.16%) 03/09/21 Citi Decibel Therapeutics initiated with a Buy at Citi 03/09/21 SVB Leerink Decibel Therapeutics initiated with an Outperform at SVB Leerink 03/09/21 Barclays Decibel Therapeutics initiated with an Overweight at Barclays 03/09/21 BMO Capital Decibel Therapeutics initiated with an Outperform at BMO Capital CYRX Cryoport $53.88 / +2.68 (+5.23%) 03/15/21 Fly Intel: Top five analyst initiations 03/15/21 UBS Cryoport initiated with a Buy at UBS 03/02/21 Fly Intel: Top five analyst initiations 03/02/21 Needham Cryoport assumed with a Buy at Needham GLW Corning $44.57 / +0.27 (+0.61%) 04/07/21 Argus Corning price target raised to $54 from $42 at Argus 01/28/21 Oppenheimer Corning upgraded to Outperform from Perform at Oppenheimer 01/14/21 Barclays Corning upgraded to Overweight with $44 target at Barclays 01/14/21 Barclays Corning upgraded to Overweight from Equal Weight at Barclays FTV Fortive $70.23 / -1.16 (-1.62%) 04/06/21 Barclays Fortive price target raised to $73 from $72 at Barclays 02/17/21 Fly Intel: Top five analyst downgrades 02/17/21 Morgan Stanley Fortive downgraded to Equal Weight at Morgan Stanley after re-rating 02/17/21 Morgan Stanley Fortive downgraded to Equal Weight from Overweight at Morgan Stanley KRYS Krystal Biotech $73.50 / -0.25 (-0.34%) 03/01/21 H.C. Wainwright Krystal Biotech price target raised to $103 from $84 at H.C. Wainwright 03/01/21 William Blair Krystal Biotech has 'catalyst-rich year ahead,' says William Blair 02/09/21 JonesTrading Krystal Biotech initiated with a Buy at JonesTrading 01/15/21 Chardan Krystal Biotech named a 'Top Pick for 2021' at Chardan NVO Novo Nordisk $69.24 / +1.375 (+2.03%) 02/11/21 UBS Novo Nordisk price target raised to DKK 425 from DKK 415 at UBS 02/04/21 Barclays Novo Nordisk price target raised to DKK 495 from DKK 485 at Barclays 01/20/21 Citi Citi opens 'Positive Catalyst Watch' on Novo Nordisk 01/20/21 Credit Suisse Novo Nordisk downgraded to Neutral from Outperform at Credit Suisse NVS Novartis $87.02 / +0.705 (+0.82%) 04/05/21 Morgan Stanley Regenxbio AAV9 patent challenged by Passage Bio, says Morgan Stanley 03/23/21 Societe Generale Novartis price target raised to CHF 107 from CHF 104 at Societe Generale 03/22/21 Bernstein Novartis initiated with a Market Perform at Bernstein 03/10/21 Fly Intel: Top five analyst downgrades ORTX Orchard Therapeutics $6.96 / +0.09 (+1.31%) 03/10/21 Stifel Stifel says Bluebird update on AML provides 'some relief' to other LV players 03/02/21 JPMorgan Orchard Therapeutics assumed with an Overweight at JPMorgan 03/01/21 Stifel Orchard Therapeutics initiated with a Buy at Stifel 02/18/21 Goldman Sachs Orchard selloff on Bluebird Bio news overdone, says Goldman Sachs MRK Merck $75.48 / -0.65 (-0.85%) 04/08/21 Alliance Global Partners Alliance Global Partners sees Fast Track for Immutep efti as meaningful positive 04/08/21 H.C. Wainwright Alkermes collaboration not as big as investors wanted, says H.C. Wainwright 04/07/21 Mizuho Mizuho sees Alkermes, Merck collaboration as important next step for nemvaleukin 04/06/21 RBC Capital Merck transferred with a Sector Perform at RBC Capital MEDP Medpace $169.50 / +1.6 (+0.95%) 02/17/21 Truist Medpace price target raised to $180 from $135 at Truist 02/16/21 Credit Suisse Medpace price target raised to $178 from $155 at Credit Suisse 10/02/20 Truist Medpace upgraded to Buy from Hold at Truist 07/29/20 Truist Medpace price target raised to $124 from $95 at SunTrust IOVA Iovance Biotherapeutics $31.30 / +0.31 (+1.00%) 03/08/21 H.C. Wainwright Iovance Biotherapeutics upgraded to Buy from Neutral at H.C. Wainwright 01/29/21 Baird Iovance Biotherapeutics assumed at Outperform at Baird 01/14/21 Oppenheimer Iovance Biotherapeutics price target raised to $57 from $43 at Oppenheimer 12/17/20 Barclays Iovance Biotherapeutics price target raised to $55 from $43 at Barclays FOLD Amicus $9.27 / -0.0999 (-1.07%) 03/01/21 Stifel Amicus initiated with a Hold at Stifel 02/12/21 Fly Intel: Top five analyst downgrades 02/12/21 JPMorgan Amicus downgraded to Neutral on Pompe disease miss at JPMorgan 02/12/21 SVB Leerink Amicus downgraded to Market Perform from Outperform at SVB Leerink TMO SGTX ORTX NVS NVO MRK MEDP KRYS IOVA GLW GILD FTV FOLD FLXN DTIL DOV CYRX CABA BLUE ATRA AGTC ADAP TMO Thermo Fisher $471.57 / +5.26 (+1.13%) 02/01/21 Thermo Fisher sees FY21 EPS $21.62, consensus $20.74 02/01/21 Thermo Fisher reports Q4 adjusted EPS $7.09, consensus $6.56 12/01/20 Thermo Fisher raises FY20 adjusted EPS view to $19.17, consensus $18.34 10/21/20 Thermo Fisher sees FY20 EPS $18.27, consensus $15.92 SGTX Sigilon Therapeutics $17.81 / -0.5 (-2.73%) 03/18/21 Sigilon Therapeutics reports Q4 EPS ($1.15), consensus ($1.37) ORTX Orchard Therapeutics $6.96 / +0.09 (+1.31%) 03/02/21 Orchard Therapeutics reports Q4 net loss $33.6M vs. $45.4M last year 11/03/20 Orchard Therapeutics reports Q3 EPS (20c), consensus (46c) NVS Novartis $87.02 / +0.705 (+0.82%) 01/26/21 Novartis sees 2021 core operating income to grow mid single digit 01/26/21 Novartis reports Q4 core EPS $1.34, consensus $1.36 11/05/20 Xoma reports Q3 EPS (10c), consensus (21c) 10/27/20 Novartis raises FY20 core operating income growth outlook NVO Novo Nordisk $69.24 / +1.375 (+2.03%) 02/03/21 Novo Nordisk sees FY21 sales growth up 5%-9%, operating profit up 4%-8% 02/03/21 Novo Nordisk report FY20 EPS DKK 18.01 vs. DKK 16.38 last year 10/30/20 Novo Nordisk reports operating profit up 7% at CER in first nine months of 2020 MRK Merck $75.48 / -0.65 (-0.85%) 02/04/21 Merck sees FY21 adjusted EPS $6.48-$6.68, consensus $6.41 02/04/21 Merck reports Q4 adjusted EPS $1.32, consensus $1.38 02/03/21 Notable companies reporting before tomorrow's open MEDP Medpace $169.50 / +1.6 (+0.95%) 02/17/21 Medpace sees FY21 GAAP EPS $4.08-$4.50 02/17/21 Medpace reports Q4 EPS $1.35 vs. 78c last year 10/26/20 Medpace sees FY21 revenue $1.05B-$1.125B, consensus $1.11B 10/26/20 Medpace sees FY20 EPS $3.62-$3.83, consensus $3.74 KRYS Krystal Biotech $73.50 / -0.25 (-0.34%) 03/01/21 Krystal Biotech reports Q4 EPS (53c), consensus (59c) 11/09/20 Krystal Biotech reports Q3 EPS (49c), consensus (47c) IOVA Iovance Biotherapeutics $31.30 / +0.31 (+1.00%) 02/25/21 Iovance Biotherapeutics reports Q4 EPS (47c), consensus (44c) GLW Corning $44.57 / +0.27 (+0.61%) 01/27/21 Corning sees Q1 EPS 40c-44c, consensus 39c 01/27/21 Corning reports Q4 core EPS 52c, consensus 48c 01/26/21 Notable companies reporting before tomorrow's open GILD Gilead $65.03 / -0.56 (-0.85%) 02/04/21 Gilead sees FY21 adjusted EPS $6.75-$7.45, consensus $6.85 02/04/21 Gilead reports Q4 adjusted EPS $2.19, consensus $2.15 02/04/21 Notable companies reporting after market close 01/11/21 Gilead raises FY20 adjusted EPS view to $6.98 - $7.08 from $6.25 - $6.60 FTV Fortive $70.23 / -1.16 (-1.62%) 02/04/21 Fortive sees FY21 adjusted EPS $2.40-$2.55, consensus $2.42 02/04/21 Fortive sees Q1 adjusted EPS 56c-60c, consensus 55c 02/04/21 Fortive reports Q4 adjusted EPS 70c, consensus 62c FOLD Amicus $9.27 / -0.0999 (-1.07%) 03/01/21 Amicus reports FY20 EPS ($1.07), consensus ($1.02) 11/05/20 Amicus reports Q3 EPS (25c), consensus (22c) FLXN Flexion $8.30 / -0.03 (-0.36%) 01/13/21 Flexion sees 2020 revenue $85.5M, consensus $84.88M 01/13/21 Flexion sees Q4 revenue $26.3M, consensus $25.66M 11/04/20 Flexion reports Q3 EPS (50c), consensus (51c) DTIL Precision BioSciences $8.94 / +0.025 (+0.28%) 03/18/21 Precision BioSciences reports 2020 EPS ($2.09), consensus ($1.77) 11/10/20 Precision BioSciences reports Q3 EPS (50c), consensus (66c) DOV Dover $138.50 / -0.465 (-0.33%) 01/28/21 Dover sees FY21 adjusted EPS $6.25-$6.45, consensus $6.24 01/28/21 Dover reports Q4 adjusted EPS $1.55, consensus $1.38 10/20/20 Dover raises FY20 adj. EPS view to $5.40-$5.45 from $5.00-$5.25, consensus $5.24 10/20/20 Dover reports Q3 adj. EPS $1.60, consensus $1.32 CYRX Cryoport $53.88 / +2.68 (+5.23%) 03/01/21 Cryoport reports Q4 EPS ($1.32), consensus (11c) 11/05/20 Cryoport reports Q3 EPS (29c), consensus (12c) CABA Cabaletta Bio $10.77 / +0.155 (+1.46%) 03/16/21 Cabaletta Bio reports Q4 EPS (40c), consensus (36c) 11/10/20 Cabaletta Bio reports Q3 EPS (36c), consensus (44c) BLUE Bluebird Bio $28.86 / -1.2 (-3.99%) 02/23/21 Bluebird Bio reports Q4 EPS ($3.01), consensus ($2.92) 11/04/20 Bluebird Bio reports Q3 EPS ($2.94), consensus ($3.01) ATRA Atara Biotherapeutics $14.18 / -0.035 (-0.25%) 03/01/21 Atara Biotherapeutics reports Q4 EPS (95c), consensus (74c) 11/12/20 Atara Biotherapeutics to present preclinical data on ATA3271 at SITC 2020 11/09/20 Atara Biotherapeutics reports Q3 EPS (92c), consensus ($1.09) AGTC Applied Genetic $4.57 / +0.115 (+2.58%) 02/11/21 Applied Genetic reports Q4 EPS (60c), consensus (59c) 11/16/20 Applied Genetic reports Q4 EPS (60c), consensus (53c) ADAP Adaptimmune $5.12 / +0.16 (+3.23%) 02/25/21 Adaptimmune reports Q4 EPS (15c), consensus (23c) 11/05/20 Adaptimmune reports Q3 EPS (4c), consensus (25c) 12 Feb 03 Feb 28 Jan 21 Jan 09 Dec 04 Dec 02 Jun 29 May 27 May 21 May 19 May 19 May TMO NVS MRK GLW GILD FTV FOLD CYRX BLUE TMO Thermo Fisher $471.57 / +5.26 (+1.13%) 02/08/21 Quidel weighs combining with Qiagen, Bloomberg reports NVS Novartis $87.02 / +0.705 (+0.82%) 03/15/21 BioNTech recruits Novartis, Sanofi to boost vaccine production, WSJ reports 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says 11/20/20 Trump to release new rules aimed at lowering drug prices, WSJ reports MRK Merck $75.48 / -0.65 (-0.85%) 03/10/21 Biden to announce U.S. buying 100M more doses of J&J vaccine, NBC reports 03/08/21 Biden to meet with CEOs of J&J, Merck at White House, Reuters reports 03/02/21 Merck to help produce J&J Covid vaccine, Washington Post reports GLW Corning $44.57 / +0.27 (+0.61%) 02/13/21 Corning growing like a chip stock, Barron's says GILD Gilead $65.03 / -0.56 (-0.85%) 03/15/21 Gilead, Merck to develop long-acting HIV therapy treatment, WSJ reports 11/19/20 WHO urges doctors not to use Gilead's remdesivir for coronavirus, Bloomberg says 10/15/20 WHO study says Gilead's remdesivir has little impact on COVID mortality, FT says 10/09/20 Takeda, others testing convalescent plasma treatment in Covid, WSJ reports FTV Fortive $70.23 / -1.16 (-1.62%) 03/26/21 Danaher, Fortive interested in joint bid for Renishaw, Bloomberg reports 03/26/21 Danaher said to mull joint bid with Fortive for Renishaw, Bloomberg says FOLD Amicus $9.27 / -0.0999 (-1.07%) 02/02/21 Amicus, BioMarin speculated by Dealreporter as possible Vertex targets 10/16/20 Amicus 'a name to watch' if Vertex seeks M&A, Dealreporter says CYRX Cryoport $53.88 / +2.68 (+5.23%) 12/21/20 Advisors skeptical vaccine logistics lead to consolidation, Dealreporter says BLUE Bluebird Bio $28.86 / -1.2 (-3.99%) 01/11/21 Bluebird Bio plans cancer-drug unit spinoff, WSJ reports TMO SGTX NVS MRK GLW GILD FOLD DTIL DOV DBTX BLUE ATRA AGTC TMO Thermo Fisher $471.57 / +5.26 (+1.13%) 02/01/21 Fly Intel: Pre-market Movers 12/01/20 Fly Intel: Wall Street's top stories for Tuesday 10/21/20 Fly Intel: Pre-market Movers SGTX Sigilon Therapeutics $17.81 / -0.5 (-2.73%) 12/06/20 Opening Day: Kinnate Biopharma soars in trading debut 11/29/20 Opening Day: Russian online retailer raises $990M in U.S. IPO 11/22/20 Opening Day: Yatsen soars in debut, raises $617M in U.S. IPO 11/15/20 Opening Day: DoorDash files to go public as Airbnb delays IPO NVS Novartis $87.02 / +0.705 (+0.82%) 03/10/21 Novartis downgrade, HP Enterprise upgrade among today's top calls on Wall Street 02/11/21 Fly Intel: Wall Street's top stories for Thursday 02/11/21 Fly Intel: Wall Street's top stories at midday 02/11/21 Fly Intel: Pre-market Movers MRK Merck $75.48 / -0.65 (-0.85%) 03/08/21 Fly Intel: Wall Street's top stories for Monday 03/08/21 Fly Intel: Wall Street's top stories at midday 03/02/21 Fly Intel: Wall Street's top stories for Tuesday 03/02/21 Fly Intel: Wall Street's top stories at midday GLW Corning $44.57 / +0.27 (+0.61%) 01/27/21 Fly Intel: Pre-market Movers 11/30/20 Fly Intel: Pre-market Movers 10/27/20 Fly Intel: What to watch in Apple earnings report 10/27/20 Fly Intel: Pre-market Movers GILD Gilead $65.03 / -0.56 (-0.85%) 04/01/21 Fly Intel: Wall Street's top stories for Thursday 04/01/21 Fly Intel: Wall Street's top stories at midday 02/04/21 Fly Intel: After-Hours Movers 01/11/21 Fly Intel: Pre-market Movers FOLD Amicus $9.27 / -0.0999 (-1.07%) 02/12/21 Fly Intel: Wall Street's top stories for Friday 02/12/21 Fly Intel: Wall Street's top stories at midday 02/11/21 Fly Intel: After-Hours Movers 12/28/20 Kinnate initiations, Nikola target change among today's top calls on Wall Street DTIL Precision BioSciences $8.94 / +0.025 (+0.28%) 12/04/20 Fly Intel: Wall Street's top stories for Friday 12/04/20 Fly Intel: Wall Street's top stories at midday 12/04/20 Fly Intel: Pre-market Movers 11/20/20 Fly Intel: Pre-market Movers DOV Dover $138.50 / -0.465 (-0.33%) 01/28/21 Fly Intel: Pre-market Movers DBTX Decibel Therapeutics $10.71 / -0.35 (-3.16%) 02/14/21 Opening Day: Bumble, Viant soar in market debuts BLUE Bluebird Bio $28.86 / -1.2 (-3.99%) 03/29/21 Fly Intel: Pre-market Movers 02/17/21 Under Armour downgrade, Amazon target raise among top calls on Wall Street 02/16/21 Fly Intel: Wall Street's top stories for Tuesday 02/16/21 Bluebird bio slides after pausing sickle cell studies ATRA Atara Biotherapeutics $14.18 / -0.035 (-0.25%) 12/07/20 Fly Intel: Pre-market Movers AGTC Applied Genetic $4.57 / +0.115 (+2.58%) 11/11/20 Hilton upgrade, AIG downgrade among today's top calls on Wall Street 04/09/21 Pharma/Biopharma 05/24/21 Global Technology, Media & Communications Virtual Conference 05/24/21 Global Healthcare Virtual Conference 2021 04/13/21 Precision BioSciences - DTIL 04/27/21 Corning - GLW 04/27/21 Medpace - MEDP 04/29/21 Merck - MRK 04/29/21 Thermo Fisher - TMO 04/29/21 Fortive - FTV 04/13/21 PDUFA Date for Keytrude w/Chemotherapy 04/28/21 Oncologic Drugs Advisory Committee Virtual Meeting 04/29/21 Oncologic Drugs Advisory Committee Virtual Meeting 07/18/21 PDUFA Date for V114 09/15/21 PDUFA Date for Belzutifan (MK-6482) 11/28/21 PDUFA Date for KEYTRUDA (Phase 3 KEYNOTE-355 Trial) 12/21/21 PDUFA Date for Gefapixant 04/29/21 Corning Inc. 04/30/21 Cryoport, Inc. 05/03/21 Merck & Co. Inc. 05/07/21 Dover Corp 05/12/21 Gilead Sciences Inc. 05/14/21 Medpace Holdings, Inc. 05/20/21 Medpace 05/21/21 Krystal Biotech, Inc. 05/25/21 Merck & Co. Inc. NVO MRK GLW GILD FOLD CABA BLUE NVO Novo Nordisk $69.24 / +1.375 (+2.03%) 12/16/20 Unusually active option classes on open December 16th MRK Merck $75.48 / -0.65 (-0.85%) 03/02/21 Unusually active option classes on open March 2nd 02/17/21 Merck call volume above normal and directionally bullish 12/23/20 Merck call volume above normal and directionally bullish 10/20/20 Merck put volume heavy and directionally bearish GLW Corning $44.57 / +0.27 (+0.61%) 12/14/20 Early notable gainers among liquid option names on December 14th GILD Gilead $65.03 / -0.56 (-0.85%) 03/04/21 Gilead call volume above normal and directionally bullish 01/19/21 Early notable gainers among liquid option names on January 19th 01/11/21 Gilead call volume above normal and directionally bullish 12/31/20 Unusually active option classes on open December 31st FOLD Amicus $9.27 / -0.0999 (-1.07%) 02/11/21 Amicus put volume heavy and directionally bearish 02/03/21 Amicus call volume above normal and directionally bullish CABA Cabaletta Bio $10.77 / +0.155 (+1.46%) 02/03/21 new option listings on February 3rd BLUE Bluebird Bio $28.86 / -1.2 (-3.99%) 02/19/21 Bluebird Bio options imply 5.4% move in share price post-earnings

Thursday
Conference/Events	Alliance for Regenerative Medicine to hold a virtual meeting » 04:55 04/08/21 04/08 04:55 04/08/21 04:55 BLUE Bluebird Bio $30.06 / -0.1 (-0.33%) , GILD Gilead $65.59 / -0.67 (-1.01%) , TMO Thermo Fisher $466.27 / -2.75 (-0.59%) , SGTX Sigilon Therapeutics $18.35 / -0.64 (-3.37%) , ADAP Adaptimmune $4.96 / -0.3 (-5.70%) , AGTC Applied Genetic $4.45 / -0.29 (-6.12%) , ATRA Atara Biotherapeutics $14.22 / +0.065 (+0.46%) , CABA Cabaletta Bio $10.54 / -1.02 (-8.82%) , FLXN Flexion $8.34 / -0.37 (-4.25%) , DTIL Precision BioSciences $8.92 / -0.34 (-3.67%) , DOV Dover $139.17 / -0.27 (-0.19%) , GNPX Genprex $4.07 / -0.23 (-5.35%) , DBTX Decibel Therapeutics $11.06 / -0.44 (-3.83%) , CYRX Cryoport $51.23 / -0.27 (-0.52%) , GLW Corning $44.30 / -0.38 (-0.85%) , FTV Fortive $71.39 / +0.25 (+0.35%) , KRYS Krystal Biotech $73.72 / -0.23 (-0.31%) , NVO Novo Nordisk $67.86 / -0.185 (-0.27%) , NVS Novartis $86.30 / -0.09 (-0.10%) , ORTX Orchard Therapeutics $6.87 / -0.22 (-3.10%) , MRK Merck $76.13 / +0.34 (+0.45%) , MEDP Medpace $167.40 / -7.13 (-4.09%) , IOVA Iovance Biotherapeutics $31.02 / -0.98 (-3.06%) , FOLD Amicus $9.37 / -0.19 (-1.99%) Cell & Gene Virtual… Cell & Gene Virtual Meeting on the Mediterranean will be held on April 6-9. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options TMO SGTX ORTX NVS NVO MRK KRYS IOVA GNPX GLW GILD FTV FOLD FLXN DTIL DOV DBTX CYRX CABA BLUE ATRA AGTC ADAP TMO Thermo Fisher $466.27 / -2.75 (-0.59%) 03/24/21 Thermo Fisher to offer integrated COVID-19 testing to U.S. school districts 03/24/21 Thermo Fisher announces launch of in-air SARS-CoV-2 surveillance solution 03/10/21 Thermo Fisher investing over $600M to expand bioprocessing production 03/08/21 Chembio Diagnostics appoints David Bespalko to board of directors SGTX Sigilon Therapeutics $18.35 / -0.64 (-3.37%) 03/05/21 Sigilon Therapeutics receives Orphan Drug Designation for SIG-007 12/17/20 Sigilon Therapeutics receives Orphan Drug designation for SIG-005 12/14/20 Sigilon Therapeutics gets FDA orphan drug designation for Arpe-19 ORTX Orchard Therapeutics $6.87 / -0.22 (-3.10%) 03/03/21 Orchard Therapeutics, Be The Match BioTherapies, extend Libmeldy pact 03/02/21 Orchard Therapeutics expects cash to fund requirements into 1H23 03/02/21 Orchard Therapeutics CTO, CMO step down from positions 03/02/21 Orchard Therapeutics appoints Anne Dupraz as CDO NVS Novartis $86.30 / -0.09 (-0.10%) 04/07/21 Immutep announces European patent grant for LAG525 antibody 03/30/21 Novartis expands targeted radioligand therapy pipeline with in-license 03/30/21 Genmab announces Novartis marketing authorization for Kesimpta granted by EC 03/23/21 Novartis reports 177Lu-PSMA-617 Phase 3 VISION study met both primary endpoints NVO Novo Nordisk $67.86 / -0.185 (-0.27%) 03/26/21 Novo Nordisk reports Saxenda recommended for expanded approval by EMA's CHMP 03/23/21 Novo Nordisk reports full results of STEP 4 trial were presented at ENDO meeting 03/22/21 Novo Nordisk discloses FDA Refusal to File letter for semaglutide 03/18/21 Gilead and Novo Nordisk expand NASH clinical collaboration, to conduct study MRK Merck $76.13 / +0.34 (+0.45%) 04/07/21 Alkermes announces nemvaleukin trial collaboration, supply agreement with Merck 04/07/21 IMV Inc. enters agreement with Merck to initiate maveropepimut-S, Keytruda trial 03/30/21 Merck to acquire Alydia Health for up to $240M on behalf of Organon spin off 03/30/21 Merck receives positive EU CHMP opinion for updated label of KEYTRUDA KRYS Krystal Biotech $73.72 / -0.23 (-0.31%) 03/30/21 Krystal Biotech announces completion of patient enrollment in GEM-3 trial 03/24/21 Krystal Biotech appoints Bhushan Hardas as president of Jeune 03/24/21 Krystal Biotech launches Jeune subsidiary, reports Phase 1 safety data for KB301 10/28/20 Rhythm Pharmaceuticals appoints Jennifer Chien as EVP, head of North America IOVA Iovance Biotherapeutics $31.02 / -0.98 (-3.06%) 03/15/21 Iovance Biotherapeutics appoints Igor Bilinsky as COO 12/14/20 Iovance Biotherapeutics appoints Jean-Marc Bellemin as CFO 11/09/20 Iovance Biotherapeutics presents interim data for LN-145 w/ pembrolizumab 10/14/20 Iovance Biotherapeutics says LN-145 can be combined w/ pembrolizumab GNPX Genprex $4.07 / -0.23 (-5.35%) 02/01/21 Genprex gives update on 2020 developments and anticipated milestones 01/13/21 Genprex achieves manufacturing milestone for Reqorsa for upcoming trials 12/22/20 Genprex completes manufacturing scale-up for Reqorsa production 11/30/20 Genprex initiates site recruitment for Acclaim-1 clinical trial GLW Corning $44.30 / -0.38 (-0.85%) 04/05/21 Corning announces resumption of share repurchases 04/05/21 Corning, Samsung Display extend long-term investment relationship 04/05/21 Verizon Business, AWS expand 5G collaboration to deliver private MEC 03/26/21 Corning announces expansion of contract with DoD, HHS GILD Gilead $65.59 / -0.67 (-1.01%) 04/07/21 Gilead's Trodelvy approved by FDA in TNBC 04/07/21 FDA grants regular approval to Trodelvy for triple-negative breast cancer 04/07/21 FDA grants regular approval to sacituzumab govitecan 04/01/21 Kite submits Tecartus sBLA to FDA for treatment of ALL FTV Fortive $71.39 / +0.25 (+0.35%) 11/13/20 Third Point takes stake in PG&E, boosts Alibaba stake, exits Baxter 10/09/20 Vontier completes separation from Fortive 10/09/20 Vontier to replace Noble Energy in S&P 500 at open on 10/9 FOLD Amicus $9.37 / -0.19 (-1.99%) 03/01/21 Amicus sees FY21 total Galafold revenue $300M-$315M 02/11/21 Amicus AT-GAA not stat. significant for superiority vs. alglucosidasa alfa 02/11/21 Amicus trading resumes 02/11/21 Amicus trading halted, news pending FLXN Flexion $8.34 / -0.37 (-4.25%) 03/31/21 Flexion announces first patient treated in FX201 Phase 1b trial 03/01/21 Flexion announces FDA clearance for FX301 IND application 02/18/21 Flexion to advance FX201 into high dose cohort of Phase 1 trial 02/01/21 NBRPA, Sheryl Swoopes, Flexion partner to raise ZILRETTA awarness DTIL Precision BioSciences $8.92 / -0.34 (-3.67%) 04/06/21 Precision BioSciences announces initiation of public search for new CEO 03/18/21 Precision BioSciences expects cash to continue operations into 2023 02/19/21 Precision announces 3-year preclinical study results of ARCUS gene editing 01/25/21 Precision BioSciences granted patent for candidate for Non-Hodgkin Lymphoma DOV Dover $139.17 / -0.27 (-0.19%) 12/03/20 Dover CFO sells 33.7K shares of common stock 10/13/20 Dover's Pole/Zero awarded $24M contract by U.S. Navy DBTX Decibel Therapeutics $11.06 / -0.44 (-3.83%) 03/22/21 Decibel Therapeutics added to Russell 2000 Index 02/24/21 Decibel Therapeutics presents preclinical findings on DB-OTO CYRX Cryoport $51.23 / -0.27 (-0.52%) 04/06/21 Cryoport acquires Critical Transport Solutions Australia for $5M 12/08/20 Cryoport, CCRM enter three-year agreement CABA Cabaletta Bio $10.54 / -1.02 (-8.82%) 03/16/21 Cabaletta Bio expects cash to fund operating plan through at least 3Q22 11/10/20 Cabaletta Bio plans to initiate validation of cell processing for trials by year BLUE Bluebird Bio $30.06 / -0.1 (-0.33%) 03/28/21 FDA approves Bristol Myers Squibb, Bluebird Bio's Abecma 03/17/21 Bluebird Bio Chief Medical Officer to leave company on April 16 03/15/21 Bluebird Bio announces new data from livaldogene autotemcel gene therapy program 03/10/21 Bluebird Bio updates findings from AML case in LentiGlobin for SCD gene therapy ATRA Atara Biotherapeutics $14.22 / +0.065 (+0.46%) 03/14/21 Atara Biotherapeutics presents long-term OS data from Phase 2 Tab-cel studies 02/08/21 Atara Biotherapeutics to present tabelecleucel data at ASTCT meeting 01/04/21 Atara Biotherapeutics provides update on BLA submission for tab-cel 12/07/20 Atara presents evaluation of CAR T Cell Therapy ATA3219 at ASH AGTC Applied Genetic $4.45 / -0.29 (-6.12%) 03/25/21 Applied Genetic announces initiatives to enhance patient journey in XLRP trials 02/11/21 Applied Genetic expects cash, cash equivalents to fund programs into 2023 11/11/20 Applied Genetic reports additional data from Phase 1/2 trial in XLRP ADAP Adaptimmune $4.96 / -0.3 (-5.70%) 02/25/21 Adaptimmune to initiate Phase 2 SURPASS-2 trial with ADP-A2M4CD8 11/20/20 Adaptimmune sees current cash runway into early 2023 11/20/20 Adaptimmune to showcase market potential for SPEAR T-cell portfolio, pipeline 11/19/20 Adaptimmune presents durability of response data from Phase 1 ADP-A2M4 trial BLUE GILD TMO SGTX ADAP AGTC ATRA CABA FLXN DTIL DOV GNPX DBTX CYRX GLW FTV KRYS NVO NVS ORTX MRK MEDP IOVA FOLD BLUE Bluebird Bio $30.06 / -0.1 (-0.33%) 03/29/21 BMO Capital Bluebird Bio price target raised to $35 from $31 at BMO Capital 03/29/21 Mizuho Bluebird Bio approval could improve sentiment on shares, says Mizuho 03/29/21 Piper Sandler Bluebird Bio price target raised to $35 from $30 at Piper Sandler 03/17/21 Stifel Stifel says Bluebird Bio CMO exit 'a bit concerning but not thesis changing' GILD Gilead $65.59 / -0.67 (-1.01%) 04/01/21 Fly Intel: Top five analyst upgrades 04/01/21 Bernstein Gilead upgraded to Outperform from Market Perform at Bernstein 03/30/21 Redburn Gilead upgraded to Buy from Neutral at Redburn 03/15/21 Mizuho Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho TMO Thermo Fisher $466.27 / -2.75 (-0.59%) 03/29/21 UBS Thermo Fisher price target lowered to $560 from $588 at UBS 03/18/21 KeyBanc Thermo Fisher upgraded to Overweight at KeyBanc after Sartorius guidance 03/18/21 KeyBanc Thermo Fisher upgraded to Overweight from Sector Weight at KeyBanc 03/02/21 Barclays Thermo Fisher initiated with an Overweight at Barclays SGTX Sigilon Therapeutics $18.35 / -0.64 (-3.37%) 12/29/20 Barclays Sigilon Therapeutics initiated with an Overweight at Barclays 12/29/20 Morgan Stanley Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley 12/29/20 Jefferies Sigilon Therapeutics initiated with a Buy at Jefferies ADAP Adaptimmune $4.96 / -0.3 (-5.70%) 08/12/20 Piper Sandler TCR2 Therapeutics initiated with an Overweight at Piper Sandler 06/01/20 Mizuho Adaptimmune price target raised to $9 from $3 at Mizuho 05/29/20 JonesTrading JonesTrading upgrades Adaptimmune to Buy after data alleviates 'key concern' 05/29/20 JonesTrading Adaptimmune upgraded to Buy from Hold at JonesTrading AGTC Applied Genetic $4.45 / -0.29 (-6.12%) 03/01/21 Stifel Applied Genetic initiated with a Buy at Stifel 02/02/21 H.C. Wainwright Applied Genetic price target raised to $24 from $18 at H.C. Wainwright 02/01/21 Roth Capital Applied Genetic price target raised to $35 from $30 at Roth Capital 11/17/20 Roth Capital Applied Genetic price target raised to $30 from $26 at Roth Capital ATRA Atara Biotherapeutics $14.22 / +0.065 (+0.46%) 03/25/21 Evercore ISI Viracta Therapeutics initiated with an Outperform at Evercore ISI 03/02/21 Citi Atara Biotherapeutics upgraded to Buy at Citi following 35% pullback 03/02/21 Citi Atara Biotherapeutics upgraded to Buy from Neutral at Citi 01/04/21 Roth Capital Roth keeps Buy rating on Atara Biotherapeutics after filing delay CABA Cabaletta Bio $10.54 / -1.02 (-8.82%) 03/17/21 H.C. Wainwright Cabaletta Bio price target raised to $22 from $20 at H.C. Wainwright 01/08/21 Chardan Cabaletta Bio initiated with a Buy at Chardan 10/13/20 H.C. Wainwright Cabaletta Bio initiated with a Buy at H.C. Wainwright FLXN Flexion $8.34 / -0.37 (-4.25%) 04/06/21 RBC Capital Flexion transferred with an Outperform at RBC Capital 08/20/20 Goldman Sachs Flexion initiated with a Neutral at Goldman Sachs 07/30/20 Oppenheimer Flexion initiated with an Outperform at Oppenheimer 07/29/20 Fly Intel: Top five analyst initiations DTIL Precision BioSciences $8.92 / -0.34 (-3.67%) 04/06/21 Stifel Stifel sees Precision BioSciences' CEO transition as 'disconcerting' 02/24/21 Fly Intel: Top five analyst initiations 02/24/21 JonesTrading Precision BioSciences initiated with a Buy at JonesTrading 01/29/21 JPMorgan Precision BioSciences price target raised to $14 from $10 at JPMorgan DOV Dover $139.17 / -0.27 (-0.19%) 04/06/21 Barclays Dover price target raised to $155 from $145 at Barclays 01/28/21 Baird Dover price target raised to $147 from $140 at Baird 01/28/21 Baird Dover results a solid beat with guidance above consensus, says Baird 01/05/21 Barclays Dover price target raised to $141 from $138 at Barclays GNPX Genprex $4.07 / -0.23 (-5.35%) 01/26/21 National Securities Genprex initiated with a Buy at National Securities 04/22/20 Alliance Global Partners Genprex initiated with a Buy at Alliance Global Partners DBTX Decibel Therapeutics $11.06 / -0.44 (-3.83%) 03/09/21 Citi Decibel Therapeutics initiated with a Buy at Citi 03/09/21 SVB Leerink Decibel Therapeutics initiated with an Outperform at SVB Leerink 03/09/21 Barclays Decibel Therapeutics initiated with an Overweight at Barclays 03/09/21 BMO Capital Decibel Therapeutics initiated with an Outperform at BMO Capital CYRX Cryoport $51.23 / -0.27 (-0.52%) 03/15/21 Fly Intel: Top five analyst initiations 03/15/21 UBS Cryoport initiated with a Buy at UBS 03/02/21 Fly Intel: Top five analyst initiations 03/02/21 Needham Cryoport assumed with a Buy at Needham GLW Corning $44.30 / -0.38 (-0.85%) 04/07/21 Argus Corning price target raised to $54 from $42 at Argus 01/28/21 Oppenheimer Corning upgraded to Outperform from Perform at Oppenheimer 01/14/21 Barclays Corning upgraded to Overweight with $44 target at Barclays 01/14/21 Barclays Corning upgraded to Overweight from Equal Weight at Barclays FTV Fortive $71.39 / +0.25 (+0.35%) 04/06/21 Barclays Fortive price target raised to $73 from $72 at Barclays 02/17/21 Fly Intel: Top five analyst downgrades 02/17/21 Morgan Stanley Fortive downgraded to Equal Weight at Morgan Stanley after re-rating 02/17/21 Morgan Stanley Fortive downgraded to Equal Weight from Overweight at Morgan Stanley KRYS Krystal Biotech $73.72 / -0.23 (-0.31%) 03/01/21 H.C. Wainwright Krystal Biotech price target raised to $103 from $84 at H.C. Wainwright 03/01/21 William Blair Krystal Biotech has 'catalyst-rich year ahead,' says William Blair 02/09/21 JonesTrading Krystal Biotech initiated with a Buy at JonesTrading 01/15/21 Chardan Krystal Biotech named a 'Top Pick for 2021' at Chardan NVO Novo Nordisk $67.86 / -0.185 (-0.27%) 02/11/21 UBS Novo Nordisk price target raised to DKK 425 from DKK 415 at UBS 02/04/21 Barclays Novo Nordisk price target raised to DKK 495 from DKK 485 at Barclays 01/20/21 Citi Citi opens 'Positive Catalyst Watch' on Novo Nordisk 01/20/21 Credit Suisse Novo Nordisk downgraded to Neutral from Outperform at Credit Suisse NVS Novartis $86.30 / -0.09 (-0.10%) 04/05/21 Morgan Stanley Regenxbio AAV9 patent challenged by Passage Bio, says Morgan Stanley 03/23/21 Societe Generale Novartis price target raised to CHF 107 from CHF 104 at Societe Generale 03/22/21 Bernstein Novartis initiated with a Market Perform at Bernstein 03/10/21 Fly Intel: Top five analyst downgrades ORTX Orchard Therapeutics $6.87 / -0.22 (-3.10%) 03/10/21 Stifel Stifel says Bluebird update on AML provides 'some relief' to other LV players 03/02/21 JPMorgan Orchard Therapeutics assumed with an Overweight at JPMorgan 03/01/21 Stifel Orchard Therapeutics initiated with a Buy at Stifel 02/18/21 Goldman Sachs Orchard selloff on Bluebird Bio news overdone, says Goldman Sachs MRK Merck $76.13 / +0.34 (+0.45%) 04/07/21 Mizuho Mizuho sees Alkermes, Merck collaboration as important next step for nemvaleukin 04/06/21 RBC Capital Merck transferred with a Sector Perform at RBC Capital 04/01/21 Morgan Stanley Merck cancer pipeline underappreciated and 'set to flow,' says Morgan Stanley MEDP Medpace $167.40 / -7.13 (-4.09%) 02/17/21 Truist Medpace price target raised to $180 from $135 at Truist 02/16/21 Credit Suisse Medpace price target raised to $178 from $155 at Credit Suisse 10/02/20 Truist Medpace upgraded to Buy from Hold at Truist 07/29/20 Truist Medpace price target raised to $124 from $95 at SunTrust IOVA Iovance Biotherapeutics $31.02 / -0.98 (-3.06%) 03/08/21 H.C. Wainwright Iovance Biotherapeutics upgraded to Buy from Neutral at H.C. Wainwright 01/29/21 Baird Iovance Biotherapeutics assumed at Outperform at Baird 01/14/21 Oppenheimer Iovance Biotherapeutics price target raised to $57 from $43 at Oppenheimer 12/17/20 Barclays Iovance Biotherapeutics price target raised to $55 from $43 at Barclays FOLD Amicus $9.37 / -0.19 (-1.99%) 03/01/21 Stifel Amicus initiated with a Hold at Stifel 02/12/21 Fly Intel: Top five analyst downgrades 02/12/21 JPMorgan Amicus downgraded to Neutral on Pompe disease miss at JPMorgan 02/12/21 SVB Leerink Amicus downgraded to Market Perform from Outperform at SVB Leerink TMO SGTX ORTX NVS NVO MRK MEDP KRYS IOVA GLW GILD FTV FOLD FLXN DTIL DOV CYRX CABA BLUE ATRA AGTC ADAP TMO Thermo Fisher $466.27 / -2.75 (-0.59%) 02/01/21 Thermo Fisher sees FY21 EPS $21.62, consensus $20.74 02/01/21 Thermo Fisher reports Q4 adjusted EPS $7.09, consensus $6.56 12/01/20 Thermo Fisher raises FY20 adjusted EPS view to $19.17, consensus $18.34 10/21/20 Thermo Fisher sees FY20 EPS $18.27, consensus $15.92 SGTX Sigilon Therapeutics $18.35 / -0.64 (-3.37%) 03/18/21 Sigilon Therapeutics reports Q4 EPS ($1.15), consensus ($1.37) ORTX Orchard Therapeutics $6.87 / -0.22 (-3.10%) 03/02/21 Orchard Therapeutics reports Q4 net loss $33.6M vs. $45.4M last year 11/03/20 Orchard Therapeutics reports Q3 EPS (20c), consensus (46c) NVS Novartis $86.30 / -0.09 (-0.10%) 01/26/21 Novartis sees 2021 core operating income to grow mid single digit 01/26/21 Novartis reports Q4 core EPS $1.34, consensus $1.36 11/05/20 Xoma reports Q3 EPS (10c), consensus (21c) 10/27/20 Novartis raises FY20 core operating income growth outlook NVO Novo Nordisk $67.86 / -0.185 (-0.27%) 02/03/21 Novo Nordisk sees FY21 sales growth up 5%-9%, operating profit up 4%-8% 02/03/21 Novo Nordisk report FY20 EPS DKK 18.01 vs. DKK 16.38 last year 10/30/20 Novo Nordisk reports operating profit up 7% at CER in first nine months of 2020 10/08/20 Novo Nordisk boosts 2020 sales growth outlook to 5%-8% from 3%-6% MRK Merck $76.13 / +0.34 (+0.45%) 02/04/21 Merck sees FY21 adjusted EPS $6.48-$6.68, consensus $6.41 02/04/21 Merck reports Q4 adjusted EPS $1.32, consensus $1.38 02/03/21 Notable companies reporting before tomorrow's open MEDP Medpace $167.40 / -7.13 (-4.09%) 02/17/21 Medpace sees FY21 GAAP EPS $4.08-$4.50 02/17/21 Medpace reports Q4 EPS $1.35 vs. 78c last year 10/26/20 Medpace sees FY21 revenue $1.05B-$1.125B, consensus $1.11B 10/26/20 Medpace sees FY20 EPS $3.62-$3.83, consensus $3.74 KRYS Krystal Biotech $73.72 / -0.23 (-0.31%) 03/01/21 Krystal Biotech reports Q4 EPS (53c), consensus (59c) 11/09/20 Krystal Biotech reports Q3 EPS (49c), consensus (47c) IOVA Iovance Biotherapeutics $31.02 / -0.98 (-3.06%) 02/25/21 Iovance Biotherapeutics reports Q4 EPS (47c), consensus (44c) GLW Corning $44.30 / -0.38 (-0.85%) 01/27/21 Corning sees Q1 EPS 40c-44c, consensus 39c 01/27/21 Corning reports Q4 core EPS 52c, consensus 48c 01/26/21 Notable companies reporting before tomorrow's open GILD Gilead $65.59 / -0.67 (-1.01%) 02/04/21 Gilead sees FY21 adjusted EPS $6.75-$7.45, consensus $6.85 02/04/21 Gilead reports Q4 adjusted EPS $2.19, consensus $2.15 02/04/21 Notable companies reporting after market close 01/11/21 Gilead raises FY20 adjusted EPS view to $6.98 - $7.08 from $6.25 - $6.60 FTV Fortive $71.39 / +0.25 (+0.35%) 02/04/21 Fortive sees FY21 adjusted EPS $2.40-$2.55, consensus $2.42 02/04/21 Fortive sees Q1 adjusted EPS 56c-60c, consensus 55c 02/04/21 Fortive reports Q4 adjusted EPS 70c, consensus 62c FOLD Amicus $9.37 / -0.19 (-1.99%) 03/01/21 Amicus reports FY20 EPS ($1.07), consensus ($1.02) 11/05/20 Amicus reports Q3 EPS (25c), consensus (22c) FLXN Flexion $8.34 / -0.37 (-4.25%) 01/13/21 Flexion sees 2020 revenue $85.5M, consensus $84.88M 01/13/21 Flexion sees Q4 revenue $26.3M, consensus $25.66M 11/04/20 Flexion reports Q3 EPS (50c), consensus (51c) DTIL Precision BioSciences $8.92 / -0.34 (-3.67%) 03/18/21 Precision BioSciences reports 2020 EPS ($2.09), consensus ($1.77) 11/10/20 Precision BioSciences reports Q3 EPS (50c), consensus (66c) DOV Dover $139.17 / -0.27 (-0.19%) 01/28/21 Dover sees FY21 adjusted EPS $6.25-$6.45, consensus $6.24 01/28/21 Dover reports Q4 adjusted EPS $1.55, consensus $1.38 10/20/20 Dover raises FY20 adj. EPS view to $5.40-$5.45 from $5.00-$5.25, consensus $5.24 10/20/20 Dover reports Q3 adj. EPS $1.60, consensus $1.32 CYRX Cryoport $51.23 / -0.27 (-0.52%) 03/01/21 Cryoport reports Q4 EPS ($1.32), consensus (11c) 11/05/20 Cryoport reports Q3 EPS (29c), consensus (12c) CABA Cabaletta Bio $10.54 / -1.02 (-8.82%) 03/16/21 Cabaletta Bio reports Q4 EPS (40c), consensus (36c) 11/10/20 Cabaletta Bio reports Q3 EPS (36c), consensus (44c) BLUE Bluebird Bio $30.06 / -0.1 (-0.33%) 02/23/21 Bluebird Bio reports Q4 EPS ($3.01), consensus ($2.92) 11/04/20 Bluebird Bio reports Q3 EPS ($2.94), consensus ($3.01) ATRA Atara Biotherapeutics $14.22 / +0.065 (+0.46%) 03/01/21 Atara Biotherapeutics reports Q4 EPS (95c), consensus (74c) 11/12/20 Atara Biotherapeutics to present preclinical data on ATA3271 at SITC 2020 11/09/20 Atara Biotherapeutics reports Q3 EPS (92c), consensus ($1.09) AGTC Applied Genetic $4.45 / -0.29 (-6.12%) 02/11/21 Applied Genetic reports Q4 EPS (60c), consensus (59c) 11/16/20 Applied Genetic reports Q4 EPS (60c), consensus (53c) ADAP Adaptimmune $4.96 / -0.3 (-5.70%) 02/25/21 Adaptimmune reports Q4 EPS (15c), consensus (23c) 11/05/20 Adaptimmune reports Q3 EPS (4c), consensus (25c) 12 Feb 03 Feb 28 Jan 21 Jan 09 Dec 04 Dec 02 Jun 29 May 27 May 21 May 19 May 19 May TMO NVS MRK GLW GILD FTV FOLD CYRX BLUE TMO Thermo Fisher $466.27 / -2.75 (-0.59%) 02/08/21 Quidel weighs combining with Qiagen, Bloomberg reports NVS Novartis $86.30 / -0.09 (-0.10%) 03/15/21 BioNTech recruits Novartis, Sanofi to boost vaccine production, WSJ reports 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says 11/20/20 Trump to release new rules aimed at lowering drug prices, WSJ reports MRK Merck $76.13 / +0.34 (+0.45%) 03/10/21 Biden to announce U.S. buying 100M more doses of J&J vaccine, NBC reports 03/08/21 Biden to meet with CEOs of J&J, Merck at White House, Reuters reports 03/02/21 Merck to help produce J&J Covid vaccine, Washington Post reports GLW Corning $44.30 / -0.38 (-0.85%) 02/13/21 Corning growing like a chip stock, Barron's says GILD Gilead $65.59 / -0.67 (-1.01%) 03/15/21 Gilead, Merck to develop long-acting HIV therapy treatment, WSJ reports 11/19/20 WHO urges doctors not to use Gilead's remdesivir for coronavirus, Bloomberg says 10/15/20 WHO study says Gilead's remdesivir has little impact on COVID mortality, FT says 10/09/20 Takeda, others testing convalescent plasma treatment in Covid, WSJ reports FTV Fortive $71.39 / +0.25 (+0.35%) 03/26/21 Danaher, Fortive interested in joint bid for Renishaw, Bloomberg reports 03/26/21 Danaher said to mull joint bid with Fortive for Renishaw, Bloomberg says FOLD Amicus $9.37 / -0.19 (-1.99%) 02/02/21 Amicus, BioMarin speculated by Dealreporter as possible Vertex targets 10/16/20 Amicus 'a name to watch' if Vertex seeks M&A, Dealreporter says CYRX Cryoport $51.23 / -0.27 (-0.52%) 12/21/20 Advisors skeptical vaccine logistics lead to consolidation, Dealreporter says BLUE Bluebird Bio $30.06 / -0.1 (-0.33%) 01/11/21 Bluebird Bio plans cancer-drug unit spinoff, WSJ reports TMO SGTX NVS MRK GLW GILD FOLD DTIL DOV DBTX BLUE ATRA AGTC TMO Thermo Fisher $466.27 / -2.75 (-0.59%) 02/01/21 Fly Intel: Pre-market Movers 12/01/20 Fly Intel: Wall Street's top stories for Tuesday 10/21/20 Fly Intel: Pre-market Movers SGTX Sigilon Therapeutics $18.35 / -0.64 (-3.37%) 12/06/20 Opening Day: Kinnate Biopharma soars in trading debut 11/29/20 Opening Day: Russian online retailer raises $990M in U.S. IPO 11/22/20 Opening Day: Yatsen soars in debut, raises $617M in U.S. IPO 11/15/20 Opening Day: DoorDash files to go public as Airbnb delays IPO NVS Novartis $86.30 / -0.09 (-0.10%) 03/10/21 Novartis downgrade, HP Enterprise upgrade among today's top calls on Wall Street 02/11/21 Fly Intel: Wall Street's top stories for Thursday 02/11/21 Fly Intel: Wall Street's top stories at midday 02/11/21 Fly Intel: Pre-market Movers MRK Merck $76.13 / +0.34 (+0.45%) 03/08/21 Fly Intel: Wall Street's top stories for Monday 03/08/21 Fly Intel: Wall Street's top stories at midday 03/02/21 Fly Intel: Wall Street's top stories for Tuesday 03/02/21 Fly Intel: Wall Street's top stories at midday GLW Corning $44.30 / -0.38 (-0.85%) 01/27/21 Fly Intel: Pre-market Movers 11/30/20 Fly Intel: Pre-market Movers 10/27/20 Fly Intel: What to watch in Apple earnings report 10/27/20 Fly Intel: Pre-market Movers GILD Gilead $65.59 / -0.67 (-1.01%) 04/01/21 Fly Intel: Wall Street's top stories for Thursday 04/01/21 Fly Intel: Wall Street's top stories at midday 02/04/21 Fly Intel: After-Hours Movers 01/11/21 Fly Intel: Pre-market Movers FOLD Amicus $9.37 / -0.19 (-1.99%) 02/12/21 Fly Intel: Wall Street's top stories for Friday 02/12/21 Fly Intel: Wall Street's top stories at midday 02/11/21 Fly Intel: After-Hours Movers 12/28/20 Kinnate initiations, Nikola target change among today's top calls on Wall Street DTIL Precision BioSciences $8.92 / -0.34 (-3.67%) 12/04/20 Fly Intel: Wall Street's top stories for Friday 12/04/20 Fly Intel: Wall Street's top stories at midday 12/04/20 Fly Intel: Pre-market Movers 11/20/20 Fly Intel: Pre-market Movers DOV Dover $139.17 / -0.27 (-0.19%) 01/28/21 Fly Intel: Pre-market Movers DBTX Decibel Therapeutics $11.06 / -0.44 (-3.83%) 02/14/21 Opening Day: Bumble, Viant soar in market debuts BLUE Bluebird Bio $30.06 / -0.1 (-0.33%) 03/29/21 Fly Intel: Pre-market Movers 02/17/21 Under Armour downgrade, Amazon target raise among top calls on Wall Street 02/16/21 Fly Intel: Wall Street's top stories for Tuesday 02/16/21 Bluebird bio slides after pausing sickle cell studies ATRA Atara Biotherapeutics $14.22 / +0.065 (+0.46%) 12/07/20 Fly Intel: Pre-market Movers AGTC Applied Genetic $4.45 / -0.29 (-6.12%) 11/11/20 Hilton upgrade, AIG downgrade among today's top calls on Wall Street 04/09/21 Pharma/Biopharma 05/24/21 Global Technology, Media & Communications Virtual Conference 05/24/21 Global Healthcare Virtual Conference 2021 04/13/21 Precision BioSciences - DTIL 04/27/21 Corning - GLW 04/27/21 Medpace - MEDP 04/29/21 Merck - MRK 04/29/21 Thermo Fisher - TMO 04/29/21 Fortive - FTV 04/13/21 PDUFA Date for Keytrude w/Chemotherapy 04/28/21 Oncologic Drugs Advisory Committee Virtual Meeting 04/29/21 Oncologic Drugs Advisory Committee Virtual Meeting 07/18/21 PDUFA Date for V114 09/15/21 PDUFA Date for Belzutifan (MK-6482) 11/28/21 PDUFA Date for KEYTRUDA (Phase 3 KEYNOTE-355 Trial) 12/21/21 PDUFA Date for Gefapixant 04/29/21 Corning Inc. 04/30/21 Cryoport, Inc. 05/03/21 Merck & Co. Inc. 05/07/21 Dover Corp 05/12/21 Gilead Sciences Inc. 05/14/21 Medpace Holdings, Inc. 05/20/21 Medpace 05/21/21 Krystal Biotech, Inc. 05/25/21 Merck & Co. Inc. NVO MRK GLW GILD FOLD CABA BLUE NVO Novo Nordisk $67.86 / -0.185 (-0.27%) 12/16/20 Unusually active option classes on open December 16th MRK Merck $76.13 / +0.34 (+0.45%) 03/02/21 Unusually active option classes on open March 2nd 02/17/21 Merck call volume above normal and directionally bullish 12/23/20 Merck call volume above normal and directionally bullish 10/20/20 Merck put volume heavy and directionally bearish GLW Corning $44.30 / -0.38 (-0.85%) 12/14/20 Early notable gainers among liquid option names on December 14th GILD Gilead $65.59 / -0.67 (-1.01%) 03/04/21 Gilead call volume above normal and directionally bullish 01/19/21 Early notable gainers among liquid option names on January 19th 01/11/21 Gilead call volume above normal and directionally bullish 12/31/20 Unusually active option classes on open December 31st FOLD Amicus $9.37 / -0.19 (-1.99%) 02/11/21 Amicus put volume heavy and directionally bearish 02/03/21 Amicus call volume above normal and directionally bullish CABA Cabaletta Bio $10.54 / -1.02 (-8.82%) 02/03/21 new option listings on February 3rd BLUE Bluebird Bio $30.06 / -0.1 (-0.33%) 02/19/21 Bluebird Bio options imply 5.4% move in share price post-earnings

Wednesday
Conference/Events	Alliance for Regenerative Medicine to hold a virtual meeting » 04:55 04/07/21 04/07 04:55 04/07/21 04:55 BLUE Bluebird Bio $30.15 / -0.95 (-3.05%) , GILD Gilead $66.26 / -0.09 (-0.14%) , TMO Thermo Fisher $469.09 / +3.53 (+0.76%) , SGTX Sigilon Therapeutics $19.05 / -0.965 (-4.82%) , ADAP Adaptimmune $5.26 / -0.35 (-6.24%) , AGTC Applied Genetic $4.74 / -0.26 (-5.20%) , ATRA Atara Biotherapeutics $14.15 / -0.53 (-3.61%) , CABA Cabaletta Bio $11.21 / -0.4 (-3.45%) , FLXN Flexion $8.71 / -0.11 (-1.25%) , DTIL Precision BioSciences $9.23 / -1.24 (-11.84%) , DOV Dover $139.44 / -0.74 (-0.53%) , GNPX Genprex $4.29 / +0.06 (+1.42%) , DBTX Decibel Therapeutics $11.48 / +0.09 (+0.79%) , CYRX Cryoport $51.47 / +1.1 (+2.18%) , GLW Corning $44.68 / -0.81 (-1.78%) , FTV Fortive $71.18 / -0.78 (-1.08%) , KRYS Krystal Biotech $74.13 / -4.6 (-5.84%) , NVO Novo Nordisk $68.05 / -0.235 (-0.34%) , NVS Novartis $86.40 / -0.89 (-1.02%) , ORTX Orchard Therapeutics $7.09 / -0.14 (-1.94%) , MRK Merck $75.79 / -1.21 (-1.57%) , MEDP Medpace $171.71 / +0.78 (+0.46%) , IOVA Iovance Biotherapeutics $31.99 / -0.16 (-0.50%) , FOLD Amicus $9.56 / -0.3848 (-3.87%) Cell & Gene Virtual… Cell & Gene Virtual Meeting on the Mediterranean will be held on April 6-9. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options TMO SGTX ORTX NVS NVO MRK KRYS IOVA GNPX GLW GILD FTV FOLD FLXN DTIL DOV DBTX CYRX CABA BLUE ATRA AGTC ADAP TMO Thermo Fisher $469.09 / +3.53 (+0.76%) 03/24/21 Thermo Fisher to offer integrated COVID-19 testing to U.S. school districts 03/24/21 Thermo Fisher announces launch of in-air SARS-CoV-2 surveillance solution 03/10/21 Thermo Fisher investing over $600M to expand bioprocessing production 03/08/21 Chembio Diagnostics appoints David Bespalko to board of directors SGTX Sigilon Therapeutics $19.05 / -0.965 (-4.82%) 03/05/21 Sigilon Therapeutics receives Orphan Drug Designation for SIG-007 12/17/20 Sigilon Therapeutics receives Orphan Drug designation for SIG-005 12/14/20 Sigilon Therapeutics gets FDA orphan drug designation for Arpe-19 ORTX Orchard Therapeutics $7.09 / -0.14 (-1.94%) 03/03/21 Orchard Therapeutics, Be The Match BioTherapies, extend Libmeldy pact 03/02/21 Orchard Therapeutics expects cash to fund requirements into 1H23 03/02/21 Orchard Therapeutics CTO, CMO step down from positions 03/02/21 Orchard Therapeutics appoints Anne Dupraz as CDO NVS Novartis $86.40 / -0.89 (-1.02%) 03/30/21 Novartis expands targeted radioligand therapy pipeline with in-license 03/30/21 Genmab announces Novartis marketing authorization for Kesimpta granted by EC 03/23/21 Novartis reports 177Lu-PSMA-617 Phase 3 VISION study met both primary endpoints 03/22/21 Novartis appoints Karen Hale as Chief Legal Officer NVO Novo Nordisk $68.05 / -0.235 (-0.34%) 03/26/21 Novo Nordisk reports Saxenda recommended for expanded approval by EMA's CHMP 03/23/21 Novo Nordisk reports full results of STEP 4 trial were presented at ENDO meeting 03/22/21 Novo Nordisk discloses FDA Refusal to File letter for semaglutide 03/18/21 Gilead and Novo Nordisk expand NASH clinical collaboration, to conduct study MRK Merck $75.79 / -1.21 (-1.57%) 03/30/21 Merck to acquire Alydia Health for up to $240M on behalf of Organon spin off 03/30/21 Merck receives positive EU CHMP opinion for updated label of KEYTRUDA 03/29/21 Merck gets CRL from FDA for KEYTRUDA in high-risk TNBC 03/24/21 Merck names Caroline Litchfield as CFO, succeeding Robert Davis KRYS Krystal Biotech $74.13 / -4.6 (-5.84%) 03/30/21 Krystal Biotech announces completion of patient enrollment in GEM-3 trial 03/24/21 Krystal Biotech appoints Bhushan Hardas as president of Jeune 03/24/21 Krystal Biotech launches Jeune subsidiary, reports Phase 1 safety data for KB301 10/28/20 Rhythm Pharmaceuticals appoints Jennifer Chien as EVP, head of North America IOVA Iovance Biotherapeutics $31.99 / -0.16 (-0.50%) 03/15/21 Iovance Biotherapeutics appoints Igor Bilinsky as COO 12/14/20 Iovance Biotherapeutics appoints Jean-Marc Bellemin as CFO 11/09/20 Iovance Biotherapeutics presents interim data for LN-145 w/ pembrolizumab 10/14/20 Iovance Biotherapeutics says LN-145 can be combined w/ pembrolizumab GNPX Genprex $4.29 / +0.06 (+1.42%) 02/01/21 Genprex gives update on 2020 developments and anticipated milestones 01/13/21 Genprex achieves manufacturing milestone for Reqorsa for upcoming trials 12/22/20 Genprex completes manufacturing scale-up for Reqorsa production 11/30/20 Genprex initiates site recruitment for Acclaim-1 clinical trial GLW Corning $44.68 / -0.81 (-1.78%) 04/05/21 Corning announces resumption of share repurchases 04/05/21 Corning, Samsung Display extend long-term investment relationship 04/05/21 Verizon Business, AWS expand 5G collaboration to deliver private MEC 03/26/21 Corning announces expansion of contract with DoD, HHS GILD Gilead $66.26 / -0.09 (-0.14%) 04/01/21 Kite submits Tecartus sBLA to FDA for treatment of ALL 04/01/21 AbCellera, Gilead announce new multi-Year, multi-target antibody discovery pact 03/30/21 Adverum Biotechnologies announces senior appointments for patient access 03/26/21 Arcutis Biotherapeutics announces updates to its executive team FTV Fortive $71.18 / -0.78 (-1.08%) 11/13/20 Third Point takes stake in PG&E, boosts Alibaba stake, exits Baxter 10/09/20 Vontier completes separation from Fortive 10/09/20 Vontier to replace Noble Energy in S&P 500 at open on 10/9 FOLD Amicus $9.56 / -0.3848 (-3.87%) 03/01/21 Amicus sees FY21 total Galafold revenue $300M-$315M 02/11/21 Amicus AT-GAA not stat. significant for superiority vs. alglucosidasa alfa 02/11/21 Amicus trading resumes 02/11/21 Amicus trading halted, news pending FLXN Flexion $8.71 / -0.11 (-1.25%) 03/31/21 Flexion announces first patient treated in FX201 Phase 1b trial 03/01/21 Flexion announces FDA clearance for FX301 IND application 02/18/21 Flexion to advance FX201 into high dose cohort of Phase 1 trial 02/01/21 NBRPA, Sheryl Swoopes, Flexion partner to raise ZILRETTA awarness DTIL Precision BioSciences $9.23 / -1.24 (-11.84%) 04/06/21 Precision BioSciences announces initiation of public search for new CEO 03/18/21 Precision BioSciences expects cash to continue operations into 2023 02/19/21 Precision announces 3-year preclinical study results of ARCUS gene editing 01/25/21 Precision BioSciences granted patent for candidate for Non-Hodgkin Lymphoma DOV Dover $139.44 / -0.74 (-0.53%) 12/03/20 Dover CFO sells 33.7K shares of common stock 10/13/20 Dover's Pole/Zero awarded $24M contract by U.S. Navy DBTX Decibel Therapeutics $11.48 / +0.09 (+0.79%) 03/22/21 Decibel Therapeutics added to Russell 2000 Index 02/24/21 Decibel Therapeutics presents preclinical findings on DB-OTO CYRX Cryoport $51.47 / +1.1 (+2.18%) 04/06/21 Cryoport acquires Critical Transport Solutions Australia for $5M 12/08/20 Cryoport, CCRM enter three-year agreement CABA Cabaletta Bio $11.21 / -0.4 (-3.45%) 03/16/21 Cabaletta Bio expects cash to fund operating plan through at least 3Q22 11/10/20 Cabaletta Bio plans to initiate validation of cell processing for trials by year BLUE Bluebird Bio $30.15 / -0.95 (-3.05%) 03/28/21 FDA approves Bristol Myers Squibb, Bluebird Bio's Abecma 03/17/21 Bluebird Bio Chief Medical Officer to leave company on April 16 03/15/21 Bluebird Bio announces new data from livaldogene autotemcel gene therapy program 03/10/21 Bluebird Bio updates findings from AML case in LentiGlobin for SCD gene therapy ATRA Atara Biotherapeutics $14.15 / -0.53 (-3.61%) 03/14/21 Atara Biotherapeutics presents long-term OS data from Phase 2 Tab-cel studies 02/08/21 Atara Biotherapeutics to present tabelecleucel data at ASTCT meeting 01/04/21 Atara Biotherapeutics provides update on BLA submission for tab-cel 12/07/20 Atara presents evaluation of CAR T Cell Therapy ATA3219 at ASH AGTC Applied Genetic $4.74 / -0.26 (-5.20%) 03/25/21 Applied Genetic announces initiatives to enhance patient journey in XLRP trials 02/11/21 Applied Genetic expects cash, cash equivalents to fund programs into 2023 11/11/20 Applied Genetic reports additional data from Phase 1/2 trial in XLRP 10/07/20 Applied Genetic joins My Retina Tracker program as scientific collaborator ADAP Adaptimmune $5.26 / -0.35 (-6.24%) 02/25/21 Adaptimmune to initiate Phase 2 SURPASS-2 trial with ADP-A2M4CD8 11/20/20 Adaptimmune sees current cash runway into early 2023 11/20/20 Adaptimmune to showcase market potential for SPEAR T-cell portfolio, pipeline 11/19/20 Adaptimmune presents durability of response data from Phase 1 ADP-A2M4 trial BLUE GILD TMO SGTX ADAP AGTC ATRA CABA FLXN DTIL DOV GNPX DBTX CYRX GLW FTV KRYS NVO NVS ORTX MRK MEDP IOVA FOLD BLUE Bluebird Bio $30.15 / -0.95 (-3.05%) 03/29/21 BMO Capital Bluebird Bio price target raised to $35 from $31 at BMO Capital 03/29/21 Mizuho Bluebird Bio approval could improve sentiment on shares, says Mizuho 03/29/21 Piper Sandler Bluebird Bio price target raised to $35 from $30 at Piper Sandler 03/17/21 Stifel Stifel says Bluebird Bio CMO exit 'a bit concerning but not thesis changing' GILD Gilead $66.26 / -0.09 (-0.14%) 04/01/21 Fly Intel: Top five analyst upgrades 04/01/21 Bernstein Gilead upgraded to Outperform from Market Perform at Bernstein 03/30/21 Redburn Gilead upgraded to Buy from Neutral at Redburn 03/15/21 Mizuho Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho TMO Thermo Fisher $469.09 / +3.53 (+0.76%) 03/29/21 UBS Thermo Fisher price target lowered to $560 from $588 at UBS 03/18/21 KeyBanc Thermo Fisher upgraded to Overweight at KeyBanc after Sartorius guidance 03/18/21 KeyBanc Thermo Fisher upgraded to Overweight from Sector Weight at KeyBanc 03/02/21 Barclays Thermo Fisher initiated with an Overweight at Barclays SGTX Sigilon Therapeutics $19.05 / -0.965 (-4.82%) 12/29/20 Barclays Sigilon Therapeutics initiated with an Overweight at Barclays 12/29/20 Morgan Stanley Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley 12/29/20 Jefferies Sigilon Therapeutics initiated with a Buy at Jefferies ADAP Adaptimmune $5.26 / -0.35 (-6.24%) 08/12/20 Piper Sandler TCR2 Therapeutics initiated with an Overweight at Piper Sandler 06/01/20 Mizuho Adaptimmune price target raised to $9 from $3 at Mizuho 05/29/20 JonesTrading JonesTrading upgrades Adaptimmune to Buy after data alleviates 'key concern' 05/29/20 JonesTrading Adaptimmune upgraded to Buy from Hold at JonesTrading AGTC Applied Genetic $4.74 / -0.26 (-5.20%) 03/01/21 Stifel Applied Genetic initiated with a Buy at Stifel 02/02/21 H.C. Wainwright Applied Genetic price target raised to $24 from $18 at H.C. Wainwright 02/01/21 Roth Capital Applied Genetic price target raised to $35 from $30 at Roth Capital 11/17/20 Roth Capital Applied Genetic price target raised to $30 from $26 at Roth Capital ATRA Atara Biotherapeutics $14.15 / -0.53 (-3.61%) 03/25/21 Evercore ISI Viracta Therapeutics initiated with an Outperform at Evercore ISI 03/02/21 Citi Atara Biotherapeutics upgraded to Buy at Citi following 35% pullback 03/02/21 Citi Atara Biotherapeutics upgraded to Buy from Neutral at Citi 01/04/21 Roth Capital Roth keeps Buy rating on Atara Biotherapeutics after filing delay CABA Cabaletta Bio $11.21 / -0.4 (-3.45%) 03/17/21 H.C. Wainwright Cabaletta Bio price target raised to $22 from $20 at H.C. Wainwright 01/08/21 Chardan Cabaletta Bio initiated with a Buy at Chardan 10/13/20 H.C. Wainwright Cabaletta Bio initiated with a Buy at H.C. Wainwright FLXN Flexion $8.71 / -0.11 (-1.25%) 04/06/21 RBC Capital Flexion transferred with an Outperform at RBC Capital 08/20/20 Goldman Sachs Flexion initiated with a Neutral at Goldman Sachs 07/30/20 Oppenheimer Flexion initiated with an Outperform at Oppenheimer 07/29/20 Fly Intel: Top five analyst initiations DTIL Precision BioSciences $9.23 / -1.24 (-11.84%) 04/06/21 Stifel Stifel sees Precision BioSciences' CEO transition as 'disconcerting' 02/24/21 Fly Intel: Top five analyst initiations 02/24/21 JonesTrading Precision BioSciences initiated with a Buy at JonesTrading 01/29/21 JPMorgan Precision BioSciences price target raised to $14 from $10 at JPMorgan DOV Dover $139.44 / -0.74 (-0.53%) 04/06/21 Barclays Dover price target raised to $155 from $145 at Barclays 01/28/21 Baird Dover price target raised to $147 from $140 at Baird 01/28/21 Baird Dover results a solid beat with guidance above consensus, says Baird 01/05/21 Barclays Dover price target raised to $141 from $138 at Barclays GNPX Genprex $4.29 / +0.06 (+1.42%) 01/26/21 National Securities Genprex initiated with a Buy at National Securities 04/22/20 Alliance Global Partners Genprex initiated with a Buy at Alliance Global Partners DBTX Decibel Therapeutics $11.48 / +0.09 (+0.79%) 03/09/21 Citi Decibel Therapeutics initiated with a Buy at Citi 03/09/21 SVB Leerink Decibel Therapeutics initiated with an Outperform at SVB Leerink 03/09/21 Barclays Decibel Therapeutics initiated with an Overweight at Barclays 03/09/21 BMO Capital Decibel Therapeutics initiated with an Outperform at BMO Capital CYRX Cryoport $51.47 / +1.1 (+2.18%) 03/15/21 Fly Intel: Top five analyst initiations 03/15/21 UBS Cryoport initiated with a Buy at UBS 03/02/21 Fly Intel: Top five analyst initiations 03/02/21 Needham Cryoport assumed with a Buy at Needham GLW Corning $44.68 / -0.81 (-1.78%) 01/28/21 Oppenheimer Corning upgraded to Outperform from Perform at Oppenheimer 01/14/21 Barclays Corning upgraded to Overweight with $44 target at Barclays 01/14/21 Barclays Corning upgraded to Overweight from Equal Weight at Barclays 01/06/21 Fly Intel: Top five analyst initiations FTV Fortive $71.18 / -0.78 (-1.08%) 04/06/21 Barclays Fortive price target raised to $73 from $72 at Barclays 02/17/21 Fly Intel: Top five analyst downgrades 02/17/21 Morgan Stanley Fortive downgraded to Equal Weight at Morgan Stanley after re-rating 02/17/21 Morgan Stanley Fortive downgraded to Equal Weight from Overweight at Morgan Stanley KRYS Krystal Biotech $74.13 / -4.6 (-5.84%) 03/01/21 H.C. Wainwright Krystal Biotech price target raised to $103 from $84 at H.C. Wainwright 03/01/21 William Blair Krystal Biotech has 'catalyst-rich year ahead,' says William Blair 02/09/21 JonesTrading Krystal Biotech initiated with a Buy at JonesTrading 01/15/21 Chardan Krystal Biotech named a 'Top Pick for 2021' at Chardan NVO Novo Nordisk $68.05 / -0.235 (-0.34%) 02/11/21 UBS Novo Nordisk price target raised to DKK 425 from DKK 415 at UBS 02/04/21 Barclays Novo Nordisk price target raised to DKK 495 from DKK 485 at Barclays 01/20/21 Citi Citi opens 'Positive Catalyst Watch' on Novo Nordisk 01/20/21 Credit Suisse Novo Nordisk downgraded to Neutral from Outperform at Credit Suisse NVS Novartis $86.40 / -0.89 (-1.02%) 04/05/21 Morgan Stanley Regenxbio AAV9 patent challenged by Passage Bio, says Morgan Stanley 03/23/21 Societe Generale Novartis price target raised to CHF 107 from CHF 104 at Societe Generale 03/22/21 Bernstein Novartis initiated with a Market Perform at Bernstein 03/10/21 Fly Intel: Top five analyst downgrades ORTX Orchard Therapeutics $7.09 / -0.14 (-1.94%) 03/10/21 Stifel Stifel says Bluebird update on AML provides 'some relief' to other LV players 03/02/21 JPMorgan Orchard Therapeutics assumed with an Overweight at JPMorgan 03/01/21 Stifel Orchard Therapeutics initiated with a Buy at Stifel 02/18/21 Goldman Sachs Orchard selloff on Bluebird Bio news overdone, says Goldman Sachs MRK Merck $75.79 / -1.21 (-1.57%) 04/06/21 RBC Capital Merck transferred with a Sector Perform at RBC Capital 04/01/21 Morgan Stanley Merck cancer pipeline underappreciated and 'set to flow,' says Morgan Stanley 03/15/21 Piper Sandler Gilead pact with Merck can bring HIV sustainability, says Piper Sandler MEDP Medpace $171.71 / +0.78 (+0.46%) 02/17/21 Truist Medpace price target raised to $180 from $135 at Truist 02/16/21 Credit Suisse Medpace price target raised to $178 from $155 at Credit Suisse 10/02/20 Truist Medpace upgraded to Buy from Hold at Truist 07/29/20 Truist Medpace price target raised to $124 from $95 at SunTrust IOVA Iovance Biotherapeutics $31.99 / -0.16 (-0.50%) 03/08/21 H.C. Wainwright Iovance Biotherapeutics upgraded to Buy from Neutral at H.C. Wainwright 01/29/21 Baird Iovance Biotherapeutics assumed at Outperform at Baird 01/14/21 Oppenheimer Iovance Biotherapeutics price target raised to $57 from $43 at Oppenheimer 12/17/20 Barclays Iovance Biotherapeutics price target raised to $55 from $43 at Barclays FOLD Amicus $9.56 / -0.3848 (-3.87%) 03/01/21 Stifel Amicus initiated with a Hold at Stifel 02/12/21 Fly Intel: Top five analyst downgrades 02/12/21 JPMorgan Amicus downgraded to Neutral on Pompe disease miss at JPMorgan 02/12/21 SVB Leerink Amicus downgraded to Market Perform from Outperform at SVB Leerink TMO SGTX ORTX NVS NVO MRK MEDP KRYS IOVA GLW GILD FTV FOLD FLXN DTIL DOV CYRX CABA BLUE ATRA AGTC ADAP TMO Thermo Fisher $469.09 / +3.53 (+0.76%) 02/01/21 Thermo Fisher sees FY21 EPS $21.62, consensus $20.74 02/01/21 Thermo Fisher reports Q4 adjusted EPS $7.09, consensus $6.56 12/01/20 Thermo Fisher raises FY20 adjusted EPS view to $19.17, consensus $18.34 10/21/20 Thermo Fisher sees FY20 EPS $18.27, consensus $15.92 SGTX Sigilon Therapeutics $19.05 / -0.965 (-4.82%) 03/18/21 Sigilon Therapeutics reports Q4 EPS ($1.15), consensus ($1.37) ORTX Orchard Therapeutics $7.09 / -0.14 (-1.94%) 03/02/21 Orchard Therapeutics reports Q4 net loss $33.6M vs. $45.4M last year 11/03/20 Orchard Therapeutics reports Q3 EPS (20c), consensus (46c) NVS Novartis $86.40 / -0.89 (-1.02%) 01/26/21 Novartis sees 2021 core operating income to grow mid single digit 01/26/21 Novartis reports Q4 core EPS $1.34, consensus $1.36 11/05/20 Xoma reports Q3 EPS (10c), consensus (21c) 10/27/20 Novartis raises FY20 core operating income growth outlook NVO Novo Nordisk $68.05 / -0.235 (-0.34%) 02/03/21 Novo Nordisk sees FY21 sales growth up 5%-9%, operating profit up 4%-8% 02/03/21 Novo Nordisk report FY20 EPS DKK 18.01 vs. DKK 16.38 last year 10/30/20 Novo Nordisk reports operating profit up 7% at CER in first nine months of 2020 10/08/20 Novo Nordisk boosts 2020 sales growth outlook to 5%-8% from 3%-6% MRK Merck $75.79 / -1.21 (-1.57%) 02/04/21 Merck sees FY21 adjusted EPS $6.48-$6.68, consensus $6.41 02/04/21 Merck reports Q4 adjusted EPS $1.32, consensus $1.38 02/03/21 Notable companies reporting before tomorrow's open MEDP Medpace $171.71 / +0.78 (+0.46%) 02/17/21 Medpace sees FY21 GAAP EPS $4.08-$4.50 02/17/21 Medpace reports Q4 EPS $1.35 vs. 78c last year 10/26/20 Medpace sees FY21 revenue $1.05B-$1.125B, consensus $1.11B 10/26/20 Medpace sees FY20 EPS $3.62-$3.83, consensus $3.74 KRYS Krystal Biotech $74.13 / -4.6 (-5.84%) 03/01/21 Krystal Biotech reports Q4 EPS (53c), consensus (59c) 11/09/20 Krystal Biotech reports Q3 EPS (49c), consensus (47c) IOVA Iovance Biotherapeutics $31.99 / -0.16 (-0.50%) 02/25/21 Iovance Biotherapeutics reports Q4 EPS (47c), consensus (44c) GLW Corning $44.68 / -0.81 (-1.78%) 01/27/21 Corning sees Q1 EPS 40c-44c, consensus 39c 01/27/21 Corning reports Q4 core EPS 52c, consensus 48c 01/26/21 Notable companies reporting before tomorrow's open GILD Gilead $66.26 / -0.09 (-0.14%) 02/04/21 Gilead sees FY21 adjusted EPS $6.75-$7.45, consensus $6.85 02/04/21 Gilead reports Q4 adjusted EPS $2.19, consensus $2.15 02/04/21 Notable companies reporting after market close 01/11/21 Gilead raises FY20 adjusted EPS view to $6.98 - $7.08 from $6.25 - $6.60 FTV Fortive $71.18 / -0.78 (-1.08%) 02/04/21 Fortive sees FY21 adjusted EPS $2.40-$2.55, consensus $2.42 02/04/21 Fortive sees Q1 adjusted EPS 56c-60c, consensus 55c 02/04/21 Fortive reports Q4 adjusted EPS 70c, consensus 62c FOLD Amicus $9.56 / -0.3848 (-3.87%) 03/01/21 Amicus reports FY20 EPS ($1.07), consensus ($1.02) 11/05/20 Amicus reports Q3 EPS (25c), consensus (22c) FLXN Flexion $8.71 / -0.11 (-1.25%) 01/13/21 Flexion sees 2020 revenue $85.5M, consensus $84.88M 01/13/21 Flexion sees Q4 revenue $26.3M, consensus $25.66M 11/04/20 Flexion reports Q3 EPS (50c), consensus (51c) DTIL Precision BioSciences $9.23 / -1.24 (-11.84%) 03/18/21 Precision BioSciences reports 2020 EPS ($2.09), consensus ($1.77) 11/10/20 Precision BioSciences reports Q3 EPS (50c), consensus (66c) DOV Dover $139.44 / -0.74 (-0.53%) 01/28/21 Dover sees FY21 adjusted EPS $6.25-$6.45, consensus $6.24 01/28/21 Dover reports Q4 adjusted EPS $1.55, consensus $1.38 10/20/20 Dover raises FY20 adj. EPS view to $5.40-$5.45 from $5.00-$5.25, consensus $5.24 10/20/20 Dover reports Q3 adj. EPS $1.60, consensus $1.32 CYRX Cryoport $51.47 / +1.1 (+2.18%) 03/01/21 Cryoport reports Q4 EPS ($1.32), consensus (11c) 11/05/20 Cryoport reports Q3 EPS (29c), consensus (12c) CABA Cabaletta Bio $11.21 / -0.4 (-3.45%) 03/16/21 Cabaletta Bio reports Q4 EPS (40c), consensus (36c) 11/10/20 Cabaletta Bio reports Q3 EPS (36c), consensus (44c) BLUE Bluebird Bio $30.15 / -0.95 (-3.05%) 02/23/21 Bluebird Bio reports Q4 EPS ($3.01), consensus ($2.92) 11/04/20 Bluebird Bio reports Q3 EPS ($2.94), consensus ($3.01) ATRA Atara Biotherapeutics $14.15 / -0.53 (-3.61%) 03/01/21 Atara Biotherapeutics reports Q4 EPS (95c), consensus (74c) 11/12/20 Atara Biotherapeutics to present preclinical data on ATA3271 at SITC 2020 11/09/20 Atara Biotherapeutics reports Q3 EPS (92c), consensus ($1.09) AGTC Applied Genetic $4.74 / -0.26 (-5.20%) 02/11/21 Applied Genetic reports Q4 EPS (60c), consensus (59c) 11/16/20 Applied Genetic reports Q4 EPS (60c), consensus (53c) ADAP Adaptimmune $5.26 / -0.35 (-6.24%) 02/25/21 Adaptimmune reports Q4 EPS (15c), consensus (23c) 11/05/20 Adaptimmune reports Q3 EPS (4c), consensus (25c) 12 Feb 03 Feb 28 Jan 21 Jan 09 Dec 04 Dec 02 Jun 29 May 27 May 21 May 19 May 19 May TMO NVS MRK GLW GILD FTV FOLD CYRX BLUE TMO Thermo Fisher $469.09 / +3.53 (+0.76%) 02/08/21 Quidel weighs combining with Qiagen, Bloomberg reports NVS Novartis $86.40 / -0.89 (-1.02%) 03/15/21 BioNTech recruits Novartis, Sanofi to boost vaccine production, WSJ reports 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says 11/20/20 Trump to release new rules aimed at lowering drug prices, WSJ reports MRK Merck $75.79 / -1.21 (-1.57%) 03/10/21 Biden to announce U.S. buying 100M more doses of J&J vaccine, NBC reports 03/08/21 Biden to meet with CEOs of J&J, Merck at White House, Reuters reports 03/02/21 Merck to help produce J&J Covid vaccine, Washington Post reports GLW Corning $44.68 / -0.81 (-1.78%) 02/13/21 Corning growing like a chip stock, Barron's says GILD Gilead $66.26 / -0.09 (-0.14%) 03/15/21 Gilead, Merck to develop long-acting HIV therapy treatment, WSJ reports 11/19/20 WHO urges doctors not to use Gilead's remdesivir for coronavirus, Bloomberg says 10/15/20 WHO study says Gilead's remdesivir has little impact on COVID mortality, FT says 10/09/20 Takeda, others testing convalescent plasma treatment in Covid, WSJ reports FTV Fortive $71.18 / -0.78 (-1.08%) 03/26/21 Danaher, Fortive interested in joint bid for Renishaw, Bloomberg reports 03/26/21 Danaher said to mull joint bid with Fortive for Renishaw, Bloomberg says FOLD Amicus $9.56 / -0.3848 (-3.87%) 02/02/21 Amicus, BioMarin speculated by Dealreporter as possible Vertex targets 10/16/20 Amicus 'a name to watch' if Vertex seeks M&A, Dealreporter says CYRX Cryoport $51.47 / +1.1 (+2.18%) 12/21/20 Advisors skeptical vaccine logistics lead to consolidation, Dealreporter says BLUE Bluebird Bio $30.15 / -0.95 (-3.05%) 01/11/21 Bluebird Bio plans cancer-drug unit spinoff, WSJ reports TMO SGTX NVS MRK GLW GILD FOLD DTIL DOV DBTX BLUE ATRA AGTC TMO Thermo Fisher $469.09 / +3.53 (+0.76%) 02/01/21 Fly Intel: Pre-market Movers 12/01/20 Fly Intel: Wall Street's top stories for Tuesday 10/21/20 Fly Intel: Pre-market Movers SGTX Sigilon Therapeutics $19.05 / -0.965 (-4.82%) 12/06/20 Opening Day: Kinnate Biopharma soars in trading debut 11/29/20 Opening Day: Russian online retailer raises $990M in U.S. IPO 11/22/20 Opening Day: Yatsen soars in debut, raises $617M in U.S. IPO 11/15/20 Opening Day: DoorDash files to go public as Airbnb delays IPO NVS Novartis $86.40 / -0.89 (-1.02%) 03/10/21 Novartis downgrade, HP Enterprise upgrade among today's top calls on Wall Street 02/11/21 Fly Intel: Wall Street's top stories for Thursday 02/11/21 Fly Intel: Wall Street's top stories at midday 02/11/21 Fly Intel: Pre-market Movers MRK Merck $75.79 / -1.21 (-1.57%) 03/08/21 Fly Intel: Wall Street's top stories for Monday 03/08/21 Fly Intel: Wall Street's top stories at midday 03/02/21 Fly Intel: Wall Street's top stories for Tuesday 03/02/21 Fly Intel: Wall Street's top stories at midday GLW Corning $44.68 / -0.81 (-1.78%) 01/27/21 Fly Intel: Pre-market Movers 11/30/20 Fly Intel: Pre-market Movers 10/27/20 Fly Intel: What to watch in Apple earnings report 10/27/20 Fly Intel: Pre-market Movers GILD Gilead $66.26 / -0.09 (-0.14%) 04/01/21 Fly Intel: Wall Street's top stories for Thursday 04/01/21 Fly Intel: Wall Street's top stories at midday 02/04/21 Fly Intel: After-Hours Movers 01/11/21 Fly Intel: Pre-market Movers FOLD Amicus $9.56 / -0.3848 (-3.87%) 02/12/21 Fly Intel: Wall Street's top stories for Friday 02/12/21 Fly Intel: Wall Street's top stories at midday 02/11/21 Fly Intel: After-Hours Movers 12/28/20 Kinnate initiations, Nikola target change among today's top calls on Wall Street DTIL Precision BioSciences $9.23 / -1.24 (-11.84%) 12/04/20 Fly Intel: Wall Street's top stories for Friday 12/04/20 Fly Intel: Wall Street's top stories at midday 12/04/20 Fly Intel: Pre-market Movers 11/20/20 Fly Intel: Pre-market Movers DOV Dover $139.44 / -0.74 (-0.53%) 01/28/21 Fly Intel: Pre-market Movers DBTX Decibel Therapeutics $11.48 / +0.09 (+0.79%) 02/14/21 Opening Day: Bumble, Viant soar in market debuts BLUE Bluebird Bio $30.15 / -0.95 (-3.05%) 03/29/21 Fly Intel: Pre-market Movers 02/17/21 Under Armour downgrade, Amazon target raise among top calls on Wall Street 02/16/21 Fly Intel: Wall Street's top stories for Tuesday 02/16/21 Bluebird bio slides after pausing sickle cell studies ATRA Atara Biotherapeutics $14.15 / -0.53 (-3.61%) 12/07/20 Fly Intel: Pre-market Movers AGTC Applied Genetic $4.74 / -0.26 (-5.20%) 11/11/20 Hilton upgrade, AIG downgrade among today's top calls on Wall Street 04/09/21 Pharma/Biopharma 05/24/21 Global Technology, Media & Communications Virtual Conference 05/24/21 Global Healthcare Virtual Conference 2021 04/13/21 Precision BioSciences - DTIL 04/27/21 Corning - GLW 04/27/21 Medpace - MEDP 04/29/21 Merck - MRK 04/29/21 Thermo Fisher - TMO 04/29/21 Fortive - FTV 04/13/21 PDUFA Date for Keytrude w/Chemotherapy 04/28/21 Oncologic Drugs Advisory Committee Virtual Meeting 04/29/21 Oncologic Drugs Advisory Committee Virtual Meeting 07/18/21 PDUFA Date for V114 09/15/21 PDUFA Date for Belzutifan (MK-6482) 11/28/21 PDUFA Date for KEYTRUDA (Phase 3 KEYNOTE-355 Trial) 12/21/21 PDUFA Date for Gefapixant 04/29/21 Corning Inc. 04/30/21 Cryoport, Inc. 05/03/21 Merck & Co. Inc. 05/07/21 Dover Corp 05/12/21 Gilead Sciences Inc. 05/14/21 Medpace Holdings, Inc. 05/20/21 Medpace 05/25/21 Merck & Co. Inc. NVO MRK IOVA GLW GILD FOLD CABA BLUE NVO Novo Nordisk $68.05 / -0.235 (-0.34%) 12/16/20 Unusually active option classes on open December 16th MRK Merck $75.79 / -1.21 (-1.57%) 03/02/21 Unusually active option classes on open March 2nd 02/17/21 Merck call volume above normal and directionally bullish 12/23/20 Merck call volume above normal and directionally bullish 10/20/20 Merck put volume heavy and directionally bearish IOVA Iovance Biotherapeutics $31.99 / -0.16 (-0.50%) 10/07/20 Iovance Biotherapeutics put volume heavy and directionally bearish GLW Corning $44.68 / -0.81 (-1.78%) 12/14/20 Early notable gainers among liquid option names on December 14th GILD Gilead $66.26 / -0.09 (-0.14%) 03/04/21 Gilead call volume above normal and directionally bullish 01/19/21 Early notable gainers among liquid option names on January 19th 01/11/21 Gilead call volume above normal and directionally bullish 12/31/20 Unusually active option classes on open December 31st FOLD Amicus $9.56 / -0.3848 (-3.87%) 02/11/21 Amicus put volume heavy and directionally bearish 02/03/21 Amicus call volume above normal and directionally bullish CABA Cabaletta Bio $11.21 / -0.4 (-3.45%) 02/03/21 new option listings on February 3rd BLUE Bluebird Bio $30.15 / -0.95 (-3.05%) 02/19/21 Bluebird Bio options imply 5.4% move in share price post-earnings

Tuesday
Conference/Events	Alliance for Regenerative Medicine to hold a virtual meeting » 09:55 04/06/21 04/06 09:55 04/06/21 09:55 BLUE Bluebird Bio $30.45 / -0.65 (-2.09%) , GILD Gilead $66.10 / -0.25 (-0.38%) , TMO Thermo Fisher $465.69 / +0.13 (+0.03%) , SGTX Sigilon Therapeutics $20.04 / +0.02 (+0.10%) , ADAP Adaptimmune $5.58 / -0.03 (-0.53%) , AGTC Applied Genetic $4.95 / -0.05 (-1.00%) , ATRA Atara Biotherapeutics $14.68 / + (+0.00%) , CABA Cabaletta Bio $11.61 / + (+0.00%) , FLXN Flexion $8.65 / -0.17 (-1.93%) , DTIL Precision BioSciences $10.30 / -0.17 (-1.62%) , DOV Dover $140.45 / +0.27 (+0.19%) , GNPX Genprex $4.14 / -0.09 (-2.13%) , DBTX Decibel Therapeutics $11.36 / -0.03 (-0.26%) , CYRX Cryoport $50.71 / +0.34 (+0.68%) , GLW Corning $45.30 / -0.19 (-0.42%) , FTV Fortive $72.04 / +0.08 (+0.11%) , KRYS Krystal Biotech $78.76 / +0.03 (+0.04%) , NVO Novo Nordisk $68.09 / -0.19 (-0.28%) , NVS Novartis $87.06 / -0.23 (-0.26%) , ORTX Orchard Therapeutics $7.19 / -0.04 (-0.55%) , MRK Merck $76.44 / -0.56 (-0.73%) , MEDP Medpace $173.03 / +2.1 (+1.23%) , IOVA Iovance Biotherapeutics $31.80 / -0.35 (-1.09%) , FOLD Amicus $9.89 / -0.055 (-0.55%) Cell & Gene Virtual… Cell & Gene Virtual Meeting on the Mediterranean will be held on April 6-9. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options TMO SGTX ORTX NVS NVO MRK KRYS IOVA GNPX GLW GILD FTV FOLD FLXN DTIL DOV DBTX CYRX CABA BLUE ATRA AGTC ADAP TMO Thermo Fisher $465.69 / +0.13 (+0.03%) 03/24/21 Thermo Fisher to offer integrated COVID-19 testing to U.S. school districts 03/24/21 Thermo Fisher announces launch of in-air SARS-CoV-2 surveillance solution 03/10/21 Thermo Fisher investing over $600M to expand bioprocessing production 03/08/21 Chembio Diagnostics appoints David Bespalko to board of directors SGTX Sigilon Therapeutics $20.04 / +0.02 (+0.10%) 03/05/21 Sigilon Therapeutics receives Orphan Drug Designation for SIG-007 12/17/20 Sigilon Therapeutics receives Orphan Drug designation for SIG-005 12/14/20 Sigilon Therapeutics gets FDA orphan drug designation for Arpe-19 ORTX Orchard Therapeutics $7.19 / -0.04 (-0.55%) 03/03/21 Orchard Therapeutics, Be The Match BioTherapies, extend Libmeldy pact 03/02/21 Orchard Therapeutics expects cash to fund requirements into 1H23 03/02/21 Orchard Therapeutics CTO, CMO step down from positions 03/02/21 Orchard Therapeutics appoints Anne Dupraz as CDO NVS Novartis $87.06 / -0.23 (-0.26%) 03/30/21 Novartis expands targeted radioligand therapy pipeline with in-license 03/30/21 Genmab announces Novartis marketing authorization for Kesimpta granted by EC 03/23/21 Novartis reports 177Lu-PSMA-617 Phase 3 VISION study met both primary endpoints 03/22/21 Novartis appoints Karen Hale as Chief Legal Officer NVO Novo Nordisk $68.09 / -0.19 (-0.28%) 03/26/21 Novo Nordisk reports Saxenda recommended for expanded approval by EMA's CHMP 03/23/21 Novo Nordisk reports full results of STEP 4 trial were presented at ENDO meeting 03/22/21 Novo Nordisk discloses FDA Refusal to File letter for semaglutide 03/18/21 Gilead and Novo Nordisk expand NASH clinical collaboration, to conduct study MRK Merck $76.44 / -0.56 (-0.73%) 03/30/21 Merck to acquire Alydia Health for up to $240M on behalf of Organon spin off 03/30/21 Merck receives positive EU CHMP opinion for updated label of KEYTRUDA 03/29/21 Merck gets CRL from FDA for KEYTRUDA in high-risk TNBC 03/24/21 Merck names Caroline Litchfield as CFO, succeeding Robert Davis KRYS Krystal Biotech $78.76 / +0.03 (+0.04%) 03/30/21 Krystal Biotech announces completion of patient enrollment in GEM-3 trial 03/24/21 Krystal Biotech appoints Bhushan Hardas as president of Jeune 03/24/21 Krystal Biotech launches Jeune subsidiary, reports Phase 1 safety data for KB301 10/28/20 Rhythm Pharmaceuticals appoints Jennifer Chien as EVP, head of North America IOVA Iovance Biotherapeutics $31.80 / -0.35 (-1.09%) 03/15/21 Iovance Biotherapeutics appoints Igor Bilinsky as COO 12/14/20 Iovance Biotherapeutics appoints Jean-Marc Bellemin as CFO 11/09/20 Iovance Biotherapeutics presents interim data for LN-145 w/ pembrolizumab 10/14/20 Iovance Biotherapeutics says LN-145 can be combined w/ pembrolizumab GNPX Genprex $4.14 / -0.09 (-2.13%) 02/01/21 Genprex gives update on 2020 developments and anticipated milestones 01/13/21 Genprex achieves manufacturing milestone for Reqorsa for upcoming trials 12/22/20 Genprex completes manufacturing scale-up for Reqorsa production 11/30/20 Genprex initiates site recruitment for Acclaim-1 clinical trial GLW Corning $45.30 / -0.19 (-0.42%) 04/05/21 Corning announces resumption of share repurchases 04/05/21 Corning, Samsung Display extend long-term investment relationship 04/05/21 Verizon Business, AWS expand 5G collaboration to deliver private MEC 03/26/21 Corning announces expansion of contract with DoD, HHS GILD Gilead $66.10 / -0.25 (-0.38%) 04/01/21 Kite submits Tecartus sBLA to FDA for treatment of ALL 04/01/21 AbCellera, Gilead announce new multi-Year, multi-target antibody discovery pact 03/30/21 Adverum Biotechnologies announces senior appointments for patient access 03/26/21 Arcutis Biotherapeutics announces updates to its executive team FTV Fortive $72.04 / +0.08 (+0.11%) 11/13/20 Third Point takes stake in PG&E, boosts Alibaba stake, exits Baxter 10/09/20 Vontier completes separation from Fortive 10/09/20 Vontier to replace Noble Energy in S&P 500 at open on 10/9 FOLD Amicus $9.89 / -0.055 (-0.55%) 03/01/21 Amicus sees FY21 total Galafold revenue $300M-$315M 02/11/21 Amicus AT-GAA not stat. significant for superiority vs. alglucosidasa alfa 02/11/21 Amicus trading resumes 02/11/21 Amicus trading halted, news pending FLXN Flexion $8.65 / -0.17 (-1.93%) 03/31/21 Flexion announces first patient treated in FX201 Phase 1b trial 03/01/21 Flexion announces FDA clearance for FX301 IND application 02/18/21 Flexion to advance FX201 into high dose cohort of Phase 1 trial 02/01/21 NBRPA, Sheryl Swoopes, Flexion partner to raise ZILRETTA awarness DTIL Precision BioSciences $10.30 / -0.17 (-1.62%) 04/06/21 Precision BioSciences announces initiation of public search for new CEO 03/18/21 Precision BioSciences expects cash to continue operations into 2023 02/19/21 Precision announces 3-year preclinical study results of ARCUS gene editing 01/25/21 Precision BioSciences granted patent for candidate for Non-Hodgkin Lymphoma DOV Dover $140.45 / +0.27 (+0.19%) 12/03/20 Dover CFO sells 33.7K shares of common stock 10/13/20 Dover's Pole/Zero awarded $24M contract by U.S. Navy DBTX Decibel Therapeutics $11.36 / -0.03 (-0.26%) 03/22/21 Decibel Therapeutics added to Russell 2000 Index 02/24/21 Decibel Therapeutics presents preclinical findings on DB-OTO CYRX Cryoport $50.71 / +0.34 (+0.68%) 04/06/21 Cryoport acquires Critical Transport Solutions Australia for $5M 12/08/20 Cryoport, CCRM enter three-year agreement CABA Cabaletta Bio $11.61 / + (+0.00%) 03/16/21 Cabaletta Bio expects cash to fund operating plan through at least 3Q22 11/10/20 Cabaletta Bio plans to initiate validation of cell processing for trials by year BLUE Bluebird Bio $30.45 / -0.65 (-2.09%) 03/28/21 FDA approves Bristol Myers Squibb, Bluebird Bio's Abecma 03/17/21 Bluebird Bio Chief Medical Officer to leave company on April 16 03/15/21 Bluebird Bio announces new data from livaldogene autotemcel gene therapy program 03/10/21 Bluebird Bio updates findings from AML case in LentiGlobin for SCD gene therapy ATRA Atara Biotherapeutics $14.68 / + (+0.00%) 03/14/21 Atara Biotherapeutics presents long-term OS data from Phase 2 Tab-cel studies 02/08/21 Atara Biotherapeutics to present tabelecleucel data at ASTCT meeting 01/04/21 Atara Biotherapeutics provides update on BLA submission for tab-cel 12/07/20 Atara presents evaluation of CAR T Cell Therapy ATA3219 at ASH AGTC Applied Genetic $4.95 / -0.05 (-1.00%) 03/25/21 Applied Genetic announces initiatives to enhance patient journey in XLRP trials 02/11/21 Applied Genetic expects cash, cash equivalents to fund programs into 2023 11/11/20 Applied Genetic reports additional data from Phase 1/2 trial in XLRP 10/07/20 Applied Genetic joins My Retina Tracker program as scientific collaborator ADAP Adaptimmune $5.58 / -0.03 (-0.53%) 02/25/21 Adaptimmune to initiate Phase 2 SURPASS-2 trial with ADP-A2M4CD8 11/20/20 Adaptimmune sees current cash runway into early 2023 11/20/20 Adaptimmune to showcase market potential for SPEAR T-cell portfolio, pipeline 11/19/20 Adaptimmune presents durability of response data from Phase 1 ADP-A2M4 trial BLUE GILD TMO SGTX ADAP AGTC ATRA CABA FLXN DTIL DOV GNPX DBTX CYRX GLW FTV KRYS NVO NVS ORTX MRK MEDP IOVA FOLD BLUE Bluebird Bio $30.45 / -0.65 (-2.09%) 03/29/21 BMO Capital Bluebird Bio price target raised to $35 from $31 at BMO Capital 03/29/21 Mizuho Bluebird Bio approval could improve sentiment on shares, says Mizuho 03/29/21 Piper Sandler Bluebird Bio price target raised to $35 from $30 at Piper Sandler 03/17/21 Stifel Stifel says Bluebird Bio CMO exit 'a bit concerning but not thesis changing' GILD Gilead $66.10 / -0.25 (-0.38%) 04/01/21 Fly Intel: Top five analyst upgrades 04/01/21 Bernstein Gilead upgraded to Outperform from Market Perform at Bernstein 03/30/21 Redburn Gilead upgraded to Buy from Neutral at Redburn 03/15/21 Mizuho Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho TMO Thermo Fisher $465.69 / +0.13 (+0.03%) 03/29/21 UBS Thermo Fisher price target lowered to $560 from $588 at UBS 03/18/21 KeyBanc Thermo Fisher upgraded to Overweight at KeyBanc after Sartorius guidance 03/18/21 KeyBanc Thermo Fisher upgraded to Overweight from Sector Weight at KeyBanc 03/02/21 Barclays Thermo Fisher initiated with an Overweight at Barclays SGTX Sigilon Therapeutics $20.04 / +0.02 (+0.10%) 12/29/20 Barclays Sigilon Therapeutics initiated with an Overweight at Barclays 12/29/20 Morgan Stanley Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley 12/29/20 Jefferies Sigilon Therapeutics initiated with a Buy at Jefferies ADAP Adaptimmune $5.58 / -0.03 (-0.53%) 08/12/20 Piper Sandler TCR2 Therapeutics initiated with an Overweight at Piper Sandler 06/01/20 Mizuho Adaptimmune price target raised to $9 from $3 at Mizuho 05/29/20 JonesTrading JonesTrading upgrades Adaptimmune to Buy after data alleviates 'key concern' 05/29/20 JonesTrading Adaptimmune upgraded to Buy from Hold at JonesTrading AGTC Applied Genetic $4.95 / -0.05 (-1.00%) 03/01/21 Stifel Applied Genetic initiated with a Buy at Stifel 02/02/21 H.C. Wainwright Applied Genetic price target raised to $24 from $18 at H.C. Wainwright 02/01/21 Roth Capital Applied Genetic price target raised to $35 from $30 at Roth Capital 11/17/20 Roth Capital Applied Genetic price target raised to $30 from $26 at Roth Capital ATRA Atara Biotherapeutics $14.68 / + (+0.00%) 03/25/21 Evercore ISI Viracta Therapeutics initiated with an Outperform at Evercore ISI 03/02/21 Citi Atara Biotherapeutics upgraded to Buy at Citi following 35% pullback 03/02/21 Citi Atara Biotherapeutics upgraded to Buy from Neutral at Citi 01/04/21 Roth Capital Roth keeps Buy rating on Atara Biotherapeutics after filing delay CABA Cabaletta Bio $11.61 / + (+0.00%) 03/17/21 H.C. Wainwright Cabaletta Bio price target raised to $22 from $20 at H.C. Wainwright 01/08/21 Chardan Cabaletta Bio initiated with a Buy at Chardan 10/13/20 H.C. Wainwright Cabaletta Bio initiated with a Buy at H.C. Wainwright FLXN Flexion $8.65 / -0.17 (-1.93%) 08/20/20 Goldman Sachs Flexion initiated with a Neutral at Goldman Sachs 07/30/20 Oppenheimer Flexion initiated with an Outperform at Oppenheimer 07/29/20 Fly Intel: Top five analyst initiations 07/29/20 Credit Suisse Flexion initiated with an Outperform at Credit Suisse DTIL Precision BioSciences $10.30 / -0.17 (-1.62%) 02/24/21 Fly Intel: Top five analyst initiations 02/24/21 JonesTrading Precision BioSciences initiated with a Buy at JonesTrading 01/29/21 JPMorgan Precision BioSciences price target raised to $14 from $10 at JPMorgan 12/15/20 H.C. Wainwright Precision BioSciences transferred with Buy rating at H.C. Wainwright DOV Dover $140.45 / +0.27 (+0.19%) 04/06/21 Barclays Dover price target raised to $155 from $145 at Barclays 01/28/21 Baird Dover price target raised to $147 from $140 at Baird 01/28/21 Baird Dover results a solid beat with guidance above consensus, says Baird 01/05/21 Barclays Dover price target raised to $141 from $138 at Barclays GNPX Genprex $4.14 / -0.09 (-2.13%) 01/26/21 National Securities Genprex initiated with a Buy at National Securities 04/22/20 Alliance Global Partners Genprex initiated with a Buy at Alliance Global Partners DBTX Decibel Therapeutics $11.36 / -0.03 (-0.26%) 03/09/21 Citi Decibel Therapeutics initiated with a Buy at Citi 03/09/21 SVB Leerink Decibel Therapeutics initiated with an Outperform at SVB Leerink 03/09/21 Barclays Decibel Therapeutics initiated with an Overweight at Barclays 03/09/21 BMO Capital Decibel Therapeutics initiated with an Outperform at BMO Capital CYRX Cryoport $50.71 / +0.34 (+0.68%) 03/15/21 Fly Intel: Top five analyst initiations 03/15/21 UBS Cryoport initiated with a Buy at UBS 03/02/21 Fly Intel: Top five analyst initiations 03/02/21 Needham Cryoport assumed with a Buy at Needham GLW Corning $45.30 / -0.19 (-0.42%) 01/28/21 Oppenheimer Corning upgraded to Outperform from Perform at Oppenheimer 01/14/21 Barclays Corning upgraded to Overweight with $44 target at Barclays 01/14/21 Barclays Corning upgraded to Overweight from Equal Weight at Barclays 01/06/21 Fly Intel: Top five analyst initiations FTV Fortive $72.04 / +0.08 (+0.11%) 04/06/21 Barclays Fortive price target raised to $73 from $72 at Barclays 02/17/21 Fly Intel: Top five analyst downgrades 02/17/21 Morgan Stanley Fortive downgraded to Equal Weight at Morgan Stanley after re-rating 02/17/21 Morgan Stanley Fortive downgraded to Equal Weight from Overweight at Morgan Stanley KRYS Krystal Biotech $78.76 / +0.03 (+0.04%) 03/01/21 H.C. Wainwright Krystal Biotech price target raised to $103 from $84 at H.C. Wainwright 03/01/21 William Blair Krystal Biotech has 'catalyst-rich year ahead,' says William Blair 02/09/21 JonesTrading Krystal Biotech initiated with a Buy at JonesTrading 01/15/21 Chardan Krystal Biotech named a 'Top Pick for 2021' at Chardan NVO Novo Nordisk $68.09 / -0.19 (-0.28%) 02/11/21 UBS Novo Nordisk price target raised to DKK 425 from DKK 415 at UBS 02/04/21 Barclays Novo Nordisk price target raised to DKK 495 from DKK 485 at Barclays 01/20/21 Citi Citi opens 'Positive Catalyst Watch' on Novo Nordisk 01/20/21 Credit Suisse Novo Nordisk downgraded to Neutral from Outperform at Credit Suisse NVS Novartis $87.06 / -0.23 (-0.26%) 04/05/21 Morgan Stanley Regenxbio AAV9 patent challenged by Passage Bio, says Morgan Stanley 03/23/21 Societe Generale Novartis price target raised to CHF 107 from CHF 104 at Societe Generale 03/22/21 Bernstein Novartis initiated with a Market Perform at Bernstein 03/10/21 Fly Intel: Top five analyst downgrades ORTX Orchard Therapeutics $7.19 / -0.04 (-0.55%) 03/10/21 Stifel Stifel says Bluebird update on AML provides 'some relief' to other LV players 03/02/21 JPMorgan Orchard Therapeutics assumed with an Overweight at JPMorgan 03/01/21 Stifel Orchard Therapeutics initiated with a Buy at Stifel 02/18/21 Goldman Sachs Orchard selloff on Bluebird Bio news overdone, says Goldman Sachs MRK Merck $76.44 / -0.56 (-0.73%) 04/01/21 Morgan Stanley Merck cancer pipeline underappreciated and 'set to flow,' says Morgan Stanley 03/15/21 Piper Sandler Gilead pact with Merck can bring HIV sustainability, says Piper Sandler 02/25/21 SVB Leerink Pandion Therapeutics downgraded to Market Perform from Outperform at SVB Leerink MEDP Medpace $173.03 / +2.1 (+1.23%) 02/17/21 Truist Medpace price target raised to $180 from $135 at Truist 02/16/21 Credit Suisse Medpace price target raised to $178 from $155 at Credit Suisse 10/02/20 Truist Medpace upgraded to Buy from Hold at Truist 07/29/20 Truist Medpace price target raised to $124 from $95 at SunTrust IOVA Iovance Biotherapeutics $31.80 / -0.35 (-1.09%) 03/08/21 H.C. Wainwright Iovance Biotherapeutics upgraded to Buy from Neutral at H.C. Wainwright 01/29/21 Baird Iovance Biotherapeutics assumed at Outperform at Baird 01/14/21 Oppenheimer Iovance Biotherapeutics price target raised to $57 from $43 at Oppenheimer 12/17/20 Barclays Iovance Biotherapeutics price target raised to $55 from $43 at Barclays FOLD Amicus $9.89 / -0.055 (-0.55%) 03/01/21 Stifel Amicus initiated with a Hold at Stifel 02/12/21 Fly Intel: Top five analyst downgrades 02/12/21 JPMorgan Amicus downgraded to Neutral on Pompe disease miss at JPMorgan 02/12/21 SVB Leerink Amicus downgraded to Market Perform from Outperform at SVB Leerink TMO SGTX ORTX NVS NVO MRK MEDP KRYS IOVA GLW GILD FTV FOLD FLXN DTIL DOV CYRX CABA BLUE ATRA AGTC ADAP TMO Thermo Fisher $465.69 / +0.13 (+0.03%) 02/01/21 Thermo Fisher sees FY21 EPS $21.62, consensus $20.74 02/01/21 Thermo Fisher reports Q4 adjusted EPS $7.09, consensus $6.56 12/01/20 Thermo Fisher raises FY20 adjusted EPS view to $19.17, consensus $18.34 10/21/20 Thermo Fisher sees FY20 EPS $18.27, consensus $15.92 SGTX Sigilon Therapeutics $20.04 / +0.02 (+0.10%) 03/18/21 Sigilon Therapeutics reports Q4 EPS ($1.15), consensus ($1.37) ORTX Orchard Therapeutics $7.19 / -0.04 (-0.55%) 03/02/21 Orchard Therapeutics reports Q4 net loss $33.6M vs. $45.4M last year 11/03/20 Orchard Therapeutics reports Q3 EPS (20c), consensus (46c) NVS Novartis $87.06 / -0.23 (-0.26%) 01/26/21 Novartis sees 2021 core operating income to grow mid single digit 01/26/21 Novartis reports Q4 core EPS $1.34, consensus $1.36 11/05/20 Xoma reports Q3 EPS (10c), consensus (21c) 10/27/20 Novartis raises FY20 core operating income growth outlook NVO Novo Nordisk $68.09 / -0.19 (-0.28%) 02/03/21 Novo Nordisk sees FY21 sales growth up 5%-9%, operating profit up 4%-8% 02/03/21 Novo Nordisk report FY20 EPS DKK 18.01 vs. DKK 16.38 last year 10/30/20 Novo Nordisk reports operating profit up 7% at CER in first nine months of 2020 10/08/20 Novo Nordisk boosts 2020 sales growth outlook to 5%-8% from 3%-6% MRK Merck $76.44 / -0.56 (-0.73%) 02/04/21 Merck sees FY21 adjusted EPS $6.48-$6.68, consensus $6.41 02/04/21 Merck reports Q4 adjusted EPS $1.32, consensus $1.38 02/03/21 Notable companies reporting before tomorrow's open MEDP Medpace $173.03 / +2.1 (+1.23%) 02/17/21 Medpace sees FY21 GAAP EPS $4.08-$4.50 02/17/21 Medpace reports Q4 EPS $1.35 vs. 78c last year 10/26/20 Medpace sees FY21 revenue $1.05B-$1.125B, consensus $1.11B 10/26/20 Medpace sees FY20 EPS $3.62-$3.83, consensus $3.74 KRYS Krystal Biotech $78.76 / +0.03 (+0.04%) 03/01/21 Krystal Biotech reports Q4 EPS (53c), consensus (59c) 11/09/20 Krystal Biotech reports Q3 EPS (49c), consensus (47c) IOVA Iovance Biotherapeutics $31.80 / -0.35 (-1.09%) 02/25/21 Iovance Biotherapeutics reports Q4 EPS (47c), consensus (44c) GLW Corning $45.30 / -0.19 (-0.42%) 01/27/21 Corning sees Q1 EPS 40c-44c, consensus 39c 01/27/21 Corning reports Q4 core EPS 52c, consensus 48c 01/26/21 Notable companies reporting before tomorrow's open GILD Gilead $66.10 / -0.25 (-0.38%) 02/04/21 Gilead sees FY21 adjusted EPS $6.75-$7.45, consensus $6.85 02/04/21 Gilead reports Q4 adjusted EPS $2.19, consensus $2.15 02/04/21 Notable companies reporting after market close 01/11/21 Gilead raises FY20 adjusted EPS view to $6.98 - $7.08 from $6.25 - $6.60 FTV Fortive $72.04 / +0.08 (+0.11%) 02/04/21 Fortive sees FY21 adjusted EPS $2.40-$2.55, consensus $2.42 02/04/21 Fortive sees Q1 adjusted EPS 56c-60c, consensus 55c 02/04/21 Fortive reports Q4 adjusted EPS 70c, consensus 62c FOLD Amicus $9.89 / -0.055 (-0.55%) 03/01/21 Amicus reports FY20 EPS ($1.07), consensus ($1.02) 11/05/20 Amicus reports Q3 EPS (25c), consensus (22c) FLXN Flexion $8.65 / -0.17 (-1.93%) 01/13/21 Flexion sees 2020 revenue $85.5M, consensus $84.88M 01/13/21 Flexion sees Q4 revenue $26.3M, consensus $25.66M 11/04/20 Flexion reports Q3 EPS (50c), consensus (51c) DTIL Precision BioSciences $10.30 / -0.17 (-1.62%) 03/18/21 Precision BioSciences reports 2020 EPS ($2.09), consensus ($1.77) 11/10/20 Precision BioSciences reports Q3 EPS (50c), consensus (66c) DOV Dover $140.45 / +0.27 (+0.19%) 01/28/21 Dover sees FY21 adjusted EPS $6.25-$6.45, consensus $6.24 01/28/21 Dover reports Q4 adjusted EPS $1.55, consensus $1.38 10/20/20 Dover raises FY20 adj. EPS view to $5.40-$5.45 from $5.00-$5.25, consensus $5.24 10/20/20 Dover reports Q3 adj. EPS $1.60, consensus $1.32 CYRX Cryoport $50.71 / +0.34 (+0.68%) 03/01/21 Cryoport reports Q4 EPS ($1.32), consensus (11c) 11/05/20 Cryoport reports Q3 EPS (29c), consensus (12c) CABA Cabaletta Bio $11.61 / + (+0.00%) 03/16/21 Cabaletta Bio reports Q4 EPS (40c), consensus (36c) 11/10/20 Cabaletta Bio reports Q3 EPS (36c), consensus (44c) BLUE Bluebird Bio $30.45 / -0.65 (-2.09%) 02/23/21 Bluebird Bio reports Q4 EPS ($3.01), consensus ($2.92) 11/04/20 Bluebird Bio reports Q3 EPS ($2.94), consensus ($3.01) ATRA Atara Biotherapeutics $14.68 / + (+0.00%) 03/01/21 Atara Biotherapeutics reports Q4 EPS (95c), consensus (74c) 11/12/20 Atara Biotherapeutics to present preclinical data on ATA3271 at SITC 2020 11/09/20 Atara Biotherapeutics reports Q3 EPS (92c), consensus ($1.09) AGTC Applied Genetic $4.95 / -0.05 (-1.00%) 02/11/21 Applied Genetic reports Q4 EPS (60c), consensus (59c) 11/16/20 Applied Genetic reports Q4 EPS (60c), consensus (53c) ADAP Adaptimmune $5.58 / -0.03 (-0.53%) 02/25/21 Adaptimmune reports Q4 EPS (15c), consensus (23c) 11/05/20 Adaptimmune reports Q3 EPS (4c), consensus (25c) 12 Feb 03 Feb 28 Jan 21 Jan 09 Dec 04 Dec 02 Jun 29 May 27 May 21 May 19 May 19 May TMO NVS MRK GLW GILD FTV FOLD CYRX BLUE TMO Thermo Fisher $465.69 / +0.13 (+0.03%) 02/08/21 Quidel weighs combining with Qiagen, Bloomberg reports NVS Novartis $87.06 / -0.23 (-0.26%) 03/15/21 BioNTech recruits Novartis, Sanofi to boost vaccine production, WSJ reports 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says 11/20/20 Trump to release new rules aimed at lowering drug prices, WSJ reports MRK Merck $76.44 / -0.56 (-0.73%) 03/10/21 Biden to announce U.S. buying 100M more doses of J&J vaccine, NBC reports 03/08/21 Biden to meet with CEOs of J&J, Merck at White House, Reuters reports 03/02/21 Merck to help produce J&J Covid vaccine, Washington Post reports GLW Corning $45.30 / -0.19 (-0.42%) 02/13/21 Corning growing like a chip stock, Barron's says GILD Gilead $66.10 / -0.25 (-0.38%) 03/15/21 Gilead, Merck to develop long-acting HIV therapy treatment, WSJ reports 11/19/20 WHO urges doctors not to use Gilead's remdesivir for coronavirus, Bloomberg says 10/15/20 WHO study says Gilead's remdesivir has little impact on COVID mortality, FT says 10/09/20 Takeda, others testing convalescent plasma treatment in Covid, WSJ reports FTV Fortive $72.04 / +0.08 (+0.11%) 03/26/21 Danaher, Fortive interested in joint bid for Renishaw, Bloomberg reports 03/26/21 Danaher said to mull joint bid with Fortive for Renishaw, Bloomberg says FOLD Amicus $9.89 / -0.055 (-0.55%) 02/02/21 Amicus, BioMarin speculated by Dealreporter as possible Vertex targets 10/16/20 Amicus 'a name to watch' if Vertex seeks M&A, Dealreporter says CYRX Cryoport $50.71 / +0.34 (+0.68%) 12/21/20 Advisors skeptical vaccine logistics lead to consolidation, Dealreporter says BLUE Bluebird Bio $30.45 / -0.65 (-2.09%) 01/11/21 Bluebird Bio plans cancer-drug unit spinoff, WSJ reports TMO SGTX NVS MRK IOVA GLW GILD FOLD DTIL DOV DBTX BLUE ATRA AGTC TMO Thermo Fisher $465.69 / +0.13 (+0.03%) 02/01/21 Fly Intel: Pre-market Movers 12/01/20 Fly Intel: Wall Street's top stories for Tuesday 10/21/20 Fly Intel: Pre-market Movers SGTX Sigilon Therapeutics $20.04 / +0.02 (+0.10%) 12/06/20 Opening Day: Kinnate Biopharma soars in trading debut 11/29/20 Opening Day: Russian online retailer raises $990M in U.S. IPO 11/22/20 Opening Day: Yatsen soars in debut, raises $617M in U.S. IPO 11/15/20 Opening Day: DoorDash files to go public as Airbnb delays IPO NVS Novartis $87.06 / -0.23 (-0.26%) 03/10/21 Novartis downgrade, HP Enterprise upgrade among today's top calls on Wall Street 02/11/21 Fly Intel: Wall Street's top stories for Thursday 02/11/21 Fly Intel: Wall Street's top stories at midday 02/11/21 Fly Intel: Pre-market Movers MRK Merck $76.44 / -0.56 (-0.73%) 03/08/21 Fly Intel: Wall Street's top stories for Monday 03/08/21 Fly Intel: Wall Street's top stories at midday 03/02/21 Fly Intel: Wall Street's top stories for Tuesday 03/02/21 Fly Intel: Wall Street's top stories at midday IOVA Iovance Biotherapeutics $31.80 / -0.35 (-1.09%) 10/06/20 Fly Intel: Wall Street's top stories at midday GLW Corning $45.30 / -0.19 (-0.42%) 01/27/21 Fly Intel: Pre-market Movers 11/30/20 Fly Intel: Pre-market Movers 10/27/20 Fly Intel: What to watch in Apple earnings report 10/27/20 Fly Intel: Pre-market Movers GILD Gilead $66.10 / -0.25 (-0.38%) 04/01/21 Fly Intel: Wall Street's top stories for Thursday 04/01/21 Fly Intel: Wall Street's top stories at midday 02/04/21 Fly Intel: After-Hours Movers 01/11/21 Fly Intel: Pre-market Movers FOLD Amicus $9.89 / -0.055 (-0.55%) 02/12/21 Fly Intel: Wall Street's top stories for Friday 02/12/21 Fly Intel: Wall Street's top stories at midday 02/11/21 Fly Intel: After-Hours Movers 12/28/20 Kinnate initiations, Nikola target change among today's top calls on Wall Street DTIL Precision BioSciences $10.30 / -0.17 (-1.62%) 12/04/20 Fly Intel: Wall Street's top stories for Friday 12/04/20 Fly Intel: Wall Street's top stories at midday 12/04/20 Fly Intel: Pre-market Movers 11/20/20 Fly Intel: Pre-market Movers DOV Dover $140.45 / +0.27 (+0.19%) 01/28/21 Fly Intel: Pre-market Movers DBTX Decibel Therapeutics $11.36 / -0.03 (-0.26%) 02/14/21 Opening Day: Bumble, Viant soar in market debuts BLUE Bluebird Bio $30.45 / -0.65 (-2.09%) 03/29/21 Fly Intel: Pre-market Movers 02/17/21 Under Armour downgrade, Amazon target raise among top calls on Wall Street 02/16/21 Fly Intel: Wall Street's top stories for Tuesday 02/16/21 Bluebird bio slides after pausing sickle cell studies ATRA Atara Biotherapeutics $14.68 / + (+0.00%) 12/07/20 Fly Intel: Pre-market Movers AGTC Applied Genetic $4.95 / -0.05 (-1.00%) 11/11/20 Hilton upgrade, AIG downgrade among today's top calls on Wall Street 04/09/21 Pharma/Biopharma 04/06/21 Biotech Corporate Access Day Virtual Conference 05/24/21 Global Technology, Media & Communications Virtual Conference 05/24/21 Global Healthcare Virtual Conference 2021 04/13/21 Precision BioSciences - DTIL 04/27/21 Corning - GLW 04/27/21 Medpace - MEDP 04/29/21 Merck - MRK 04/29/21 Thermo Fisher - TMO 04/29/21 Fortive - FTV 04/13/21 PDUFA Date for Keytrude w/Chemotherapy 04/28/21 Oncologic Drugs Advisory Committee Virtual Meeting 04/29/21 Oncologic Drugs Advisory Committee Virtual Meeting 07/18/21 PDUFA Date for V114 09/15/21 PDUFA Date for Belzutifan (MK-6482) 11/28/21 PDUFA Date for KEYTRUDA (Phase 3 KEYNOTE-355 Trial) 12/21/21 PDUFA Date for Gefapixant 04/29/21 Corning Inc. 04/30/21 Cryoport, Inc. 05/03/21 Merck & Co. Inc. 05/07/21 Dover Corp 05/12/21 Gilead Sciences Inc. 05/14/21 Medpace Holdings, Inc. 05/20/21 Medpace 05/25/21 Merck & Co. Inc. NVO MRK IOVA GLW GILD FOLD CABA BLUE NVO Novo Nordisk $68.09 / -0.19 (-0.28%) 12/16/20 Unusually active option classes on open December 16th MRK Merck $76.44 / -0.56 (-0.73%) 03/02/21 Unusually active option classes on open March 2nd 02/17/21 Merck call volume above normal and directionally bullish 12/23/20 Merck call volume above normal and directionally bullish 10/20/20 Merck put volume heavy and directionally bearish IOVA Iovance Biotherapeutics $31.80 / -0.35 (-1.09%) 10/07/20 Iovance Biotherapeutics put volume heavy and directionally bearish GLW Corning $45.30 / -0.19 (-0.42%) 12/14/20 Early notable gainers among liquid option names on December 14th GILD Gilead $66.10 / -0.25 (-0.38%) 03/04/21 Gilead call volume above normal and directionally bullish 01/19/21 Early notable gainers among liquid option names on January 19th 01/11/21 Gilead call volume above normal and directionally bullish 12/31/20 Unusually active option classes on open December 31st FOLD Amicus $9.89 / -0.055 (-0.55%) 02/11/21 Amicus put volume heavy and directionally bearish 02/03/21 Amicus call volume above normal and directionally bullish CABA Cabaletta Bio $11.61 / + (+0.00%) 02/03/21 new option listings on February 3rd BLUE Bluebird Bio $30.45 / -0.65 (-2.09%) 02/19/21 Bluebird Bio options imply 5.4% move in share price post-earnings

Over a week ago
Conference/Events	Hanson Wade to hold a virtual conference » 04:55 04/01/21 04/01 04:55 04/01/21 04:55 BIIB Biogen $280.05 / +4.17 (+1.51%) , PFE Pfizer $36.24 / +0.13 (+0.36%) , RARE Ultragenyx $114.03 / +2.24 (+2.00%) , FOLD Amicus $9.89 / +0.49 (+5.21%) , ORTX Orchard Therapeutics $7.23 / +0.07 (+0.98%) , QGEN Qiagen $48.73 / +0.765 (+1.60%) Gene Therapy… Gene Therapy Comparabililty Virtual Conference will be held on March 31-April 1. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options RARE QGEN PFE ORTX FOLD BIIB RARE Ultragenyx $114.03 / +2.24 (+2.00%) 03/08/21 Ultragenyx announces FDA clearance of IND application for UX053 02/17/21 Ultragenyx announces approval of Dojolvi in Canada 02/10/21 Ultragenyx down 2% in early trading as FAERS report on Dojolvi circulated 01/21/21 Ultragenyx announces FDA clearance of IND application for UX701 QGEN Qiagen $48.73 / +0.765 (+1.60%) 03/29/21 Qiagen receives Emergency Use Authorization for NeuMoDx multiplex test 03/10/21 Quidel slips, drags on peers as demand for testing 'softens significantly' 03/03/21 Qiagen launches QIAsphere cloud-based platform 03/02/21 Qiagen launches QIAcube Connect MDx platform PFE Pfizer $36.24 / +0.13 (+0.36%) 03/31/21 BioNTech, Pfizer: 'Positive' results of COVID-19 vaccine study in adolescents 03/30/21 BioNTech says evaluation of safety of third BNT162b2 dose initiated 03/30/21 BioNTech: Signed orders for 1.4B doses of BNT162b2 to date for delivery in 2021 03/30/21 BioNTech, Pfizer to increase BNT162b2 manufacturing capacity to 2.5B doses ORTX Orchard Therapeutics $7.23 / +0.07 (+0.98%) 03/03/21 Orchard Therapeutics, Be The Match BioTherapies, extend Libmeldy pact 03/02/21 Orchard Therapeutics expects cash to fund requirements into 1H23 03/02/21 Orchard Therapeutics CTO, CMO step down from positions 03/02/21 Orchard Therapeutics appoints Anne Dupraz as CDO FOLD Amicus $9.89 / +0.49 (+5.21%) 03/01/21 Amicus sees FY21 total Galafold revenue $300M-$315M 02/11/21 Amicus AT-GAA not stat. significant for superiority vs. alglucosidasa alfa 02/11/21 Amicus trading resumes 02/11/21 Amicus trading halted, news pending BIIB Biogen $280.05 / +4.17 (+1.51%) 03/25/21 Biogen up 3% after tweet claims Tecfidera patents to be granted 03/21/21 Fly Intel: Top five weekend stock stories 03/04/21 Biogen to build gene therapy manufacturing center in North Carolina 03/04/21 Dyne Therapeutics appoints Wildon Farwell as CMO BIIB PFE RARE FOLD ORTX QGEN BIIB Biogen $280.05 / +4.17 (+1.51%) 03/25/21 Piper Sandler Piper says Biogen Tecfidera patents could change thesis, but sees unknowns 03/25/21 Mizuho Two 'low probability' Biogen events could drive upside, says Mizuho 03/23/21 Piper Sandler Neurologist survey shows erosion for Biogen franchises, says Piper Sandler 02/17/21 Cantor Fitzgerald Biogen price target lowered to $268 from $278 at Cantor Fitzgerald PFE Pfizer $36.24 / +0.13 (+0.36%) 03/17/21 Mizuho AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho 02/23/21 B. Riley B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance 02/10/21 KeyBanc Maravai Lifesciences price target raised to $39 from $33 at KeyBanc 02/04/21 DZ Bank Pfizer upgraded to Buy from Hold at DZ Bank RARE Ultragenyx $114.03 / +2.24 (+2.00%) 03/24/21 Stifel Stifel remains optimistic on GTX-102 and Ultragenyx ahead of 'important' update 03/01/21 Stifel Ultragenyx resumed with a Buy at Stifel 02/12/21 Wedbush Ultragenyx price target raised to $130 from $113 at Wedbush 02/12/21 Barclays Ultragenyx price target raised to $186 from $176 at Barclays FOLD Amicus $9.89 / +0.49 (+5.21%) 03/01/21 Stifel Amicus initiated with a Hold at Stifel 02/12/21 Fly Intel: Top five analyst downgrades 02/12/21 JPMorgan Amicus downgraded to Neutral on Pompe disease miss at JPMorgan 02/12/21 SVB Leerink Amicus downgraded to Market Perform from Outperform at SVB Leerink ORTX Orchard Therapeutics $7.23 / +0.07 (+0.98%) 03/10/21 Stifel Stifel says Bluebird update on AML provides 'some relief' to other LV players 03/02/21 JPMorgan Orchard Therapeutics assumed with an Overweight at JPMorgan 03/01/21 Stifel Orchard Therapeutics initiated with a Buy at Stifel 02/18/21 Goldman Sachs Orchard selloff on Bluebird Bio news overdone, says Goldman Sachs QGEN Qiagen $48.73 / +0.765 (+1.60%) 02/19/21 Berenberg Qiagen price target raised to EUR 56 from EUR 52 at Berenberg 02/09/21 William Blair Quidel, Qiagen merger would not make sense, says William Blair 02/09/21 Wells Fargo Qiagen shares should be sold on latest merger talk, says Wells Fargo 02/09/21 Citi Merger with Qiagen would benefit Quidel, says Citi RARE QGEN PFE ORTX FOLD BIIB RARE Ultragenyx $114.03 / +2.24 (+2.00%) 02/11/21 Ultragenyx backs FY21 revenue guidance range for Crysvita 02/11/21 Ultragenyx backs FY21 revenue guidance range for Crysvita 02/11/21 Ultragenyx reports Q4 EPS (37c), consensus ($1.16) 10/27/20 Ultragenyx reports Q3 EPS ($1.13), consensus ($1.27) QGEN Qiagen $48.73 / +0.765 (+1.60%) 02/09/21 Qiagen backs FY21 EPS view $2.42-$2.46, consensus $2.40 02/09/21 Qiagen reports Q4 EPS 68c, consensus 65c 12/08/20 Qiagen sees FY21 adj. EPS $2.42-$2.46 CER, consensus $2.40 12/08/20 Qiagen raises FY20 adj. EPS view to $2.13-$2.14 CER from $2.07-$2.09 CER PFE Pfizer $36.24 / +0.13 (+0.36%) 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer reports Q4 adjusted EPS 42c, consensus 48c 02/01/21 Notable companies reporting before tomorrow's open ORTX Orchard Therapeutics $7.23 / +0.07 (+0.98%) 03/02/21 Orchard Therapeutics reports Q4 net loss $33.6M vs. $45.4M last year 11/03/20 Orchard Therapeutics reports Q3 EPS (20c), consensus (46c) FOLD Amicus $9.89 / +0.49 (+5.21%) 03/01/21 Amicus reports FY20 EPS ($1.07), consensus ($1.02) 11/05/20 Amicus reports Q3 EPS (25c), consensus (22c) BIIB Biogen $280.05 / +4.17 (+1.51%) 02/03/21 Biogen sees FY21 adjusted EPS $17.00-$18.50, consensus $24.67 02/03/21 Biogen reports Q4 adjusted EPS $4.58, consensus $4.87 02/02/21 Notable companies reporting before tomorrow's open 29 Oct QGEN PFE FOLD BIIB QGEN Qiagen $48.73 / +0.765 (+1.60%) 02/08/21 Quidel weighs combining with Qiagen, Bloomberg reports 02/08/21 Qiagen jumps after Bloomberg says Quidel made preliminary approach 02/08/21 Quidel weighs combining with Qiagen, Bloomberg reports PFE Pfizer $36.24 / +0.13 (+0.36%) 03/31/21 Pfizer, BioNTech to test COVID-19 vaccine, less storage requirements, WSJ report 03/26/21 White House weighs lifting IP protections for COVID-19 vaccines, CNBC says 03/25/21 Biden to up 100-day COVID-19 vaccination goal to 200M shots, CNBC says 03/23/21 WTO's Okonjo-Iweala 'disappointed' in EU vaccine export scheme, Reuters says FOLD Amicus $9.89 / +0.49 (+5.21%) 02/02/21 Amicus, BioMarin speculated by Dealreporter as possible Vertex targets 10/16/20 Amicus 'a name to watch' if Vertex seeks M&A, Dealreporter says BIIB Biogen $280.05 / +4.17 (+1.51%) 03/20/21 Still reasons to be hopeful about Lilly, Biogen Alzheimer's drugs, Barron's says 03/17/21 Biogen, Alkermes sue Teva to block MS drug, Bloomberg reports 11/07/20 Biogen Alzheimer's drug closer to approval, still not a buy, Barron's says 11/07/20 FDA may find it 'extremely' hard to approve Biogen drug after panel, STAT says QGEN PFE FOLD BIIB QGEN Qiagen $48.73 / +0.765 (+1.60%) 02/09/21 Fly Intel: After-Hours Movers 02/08/21 Fly Intel: Wall Street's top stories for Monday 11/11/20 Fly Intel: After-Hours Movers PFE Pfizer $36.24 / +0.13 (+0.36%) 03/31/21 Fly Intel: Wall Street's top stories for Wednesday 03/31/21 Fly Intel: Wall Street's top stories at midday 03/30/21 Fly Intel: Wall Street's top stories for Tuesday 03/30/21 Fly Intel: Wall Street's top stories at midday FOLD Amicus $9.89 / +0.49 (+5.21%) 02/12/21 Fly Intel: Wall Street's top stories for Friday 02/12/21 Fly Intel: Wall Street's top stories at midday 02/11/21 Fly Intel: After-Hours Movers 12/28/20 Kinnate initiations, Nikola target change among today's top calls on Wall Street BIIB Biogen $280.05 / +4.17 (+1.51%) 02/03/21 Fly Intel: Wall Street's top stories for Wednesday 02/03/21 Fly Intel: Wall Street's top stories at midday 02/03/21 Fly Intel: Pre-market Movers 01/29/21 Fly Intel: Wall Street's top stories for Friday 04/08/21 Biotech;Biopharma 05/24/21 Global Healthcare Virtual Conference 2021 05/04/21 Pfizer - PFE 06/07/21 PDUFA Date for Aducanumab 12/29/21 PDUFA Date for Lorbrena (Lorlatinib) April 2021 04/22/21 Pfizer Inc QGEN PFE FOLD BIIB QGEN Qiagen $48.73 / +0.765 (+1.60%) 10/14/20 Call spread buyer crosses wide spread in Qiagen PFE Pfizer $36.24 / +0.13 (+0.36%) 03/15/21 Pfizer call volume above normal and directionally bullish 03/04/21 Pfizer call volume above normal and directionally bullish 01/29/21 Unusually active option classes on open January 29th 01/25/21 Pfizer call volume above normal and directionally bullish FOLD Amicus $9.89 / +0.49 (+5.21%) 02/11/21 Amicus put volume heavy and directionally bearish 02/03/21 Amicus call volume above normal and directionally bullish BIIB Biogen $280.05 / +4.17 (+1.51%) 03/25/21 Early notable gainers among liquid option names on March 25th 01/29/21 Early notable gainers among liquid option names on January 29th 01/08/21 Biogen put volume heavy and directionally bearish 11/11/20 Early notable gainers among liquid option names on November 11th

Conference/Events	Hanson Wade to hold a virtual conference » 10:37 03/31/21 03/31 10:37 03/31/21 10:37 BIIB Biogen $277.54 / +1.66 (+0.60%) , PFE Pfizer $36.18 / +0.065 (+0.18%) , RARE Ultragenyx $114.14 / +2.35 (+2.10%) , FOLD Amicus $9.68 / +0.28 (+2.98%) , ORTX Orchard Therapeutics $7.24 / +0.08 (+1.12%) , QGEN Qiagen $48.43 / +0.47 (+0.98%) Gene Therapy… Gene Therapy Comparabililty Virtual Conference will be held on March 31-April 1. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options RARE QGEN PFE ORTX FOLD BIIB RARE Ultragenyx $114.14 / +2.35 (+2.10%) 03/08/21 Ultragenyx announces FDA clearance of IND application for UX053 02/17/21 Ultragenyx announces approval of Dojolvi in Canada 02/10/21 Ultragenyx down 2% in early trading as FAERS report on Dojolvi circulated 01/21/21 Ultragenyx announces FDA clearance of IND application for UX701 QGEN Qiagen $48.43 / +0.47 (+0.98%) 03/29/21 Qiagen receives Emergency Use Authorization for NeuMoDx multiplex test 03/10/21 Quidel slips, drags on peers as demand for testing 'softens significantly' 03/03/21 Qiagen launches QIAsphere cloud-based platform 03/02/21 Qiagen launches QIAcube Connect MDx platform PFE Pfizer $36.18 / +0.065 (+0.18%) 03/31/21 BioNTech, Pfizer: 'Positive' results of COVID-19 vaccine study in adolescents 03/30/21 BioNTech says evaluation of safety of third BNT162b2 dose initiated 03/30/21 BioNTech: Signed orders for 1.4B doses of BNT162b2 to date for delivery in 2021 03/30/21 BioNTech, Pfizer to increase BNT162b2 manufacturing capacity to 2.5B doses ORTX Orchard Therapeutics $7.24 / +0.08 (+1.12%) 03/03/21 Orchard Therapeutics, Be The Match BioTherapies, extend Libmeldy pact 03/02/21 Orchard Therapeutics expects cash to fund requirements into 1H23 03/02/21 Orchard Therapeutics CTO, CMO step down from positions 03/02/21 Orchard Therapeutics appoints Anne Dupraz as CDO FOLD Amicus $9.68 / +0.28 (+2.98%) 03/01/21 Amicus sees FY21 total Galafold revenue $300M-$315M 02/11/21 Amicus AT-GAA not stat. significant for superiority vs. alglucosidasa alfa 02/11/21 Amicus trading resumes 02/11/21 Amicus trading halted, news pending BIIB Biogen $277.54 / +1.66 (+0.60%) 03/25/21 Biogen up 3% after tweet claims Tecfidera patents to be granted 03/21/21 Fly Intel: Top five weekend stock stories 03/04/21 Biogen to build gene therapy manufacturing center in North Carolina 03/04/21 Dyne Therapeutics appoints Wildon Farwell as CMO BIIB PFE RARE FOLD ORTX QGEN BIIB Biogen $277.54 / +1.66 (+0.60%) 03/25/21 Piper Sandler Piper says Biogen Tecfidera patents could change thesis, but sees unknowns 03/25/21 Mizuho Two 'low probability' Biogen events could drive upside, says Mizuho 03/23/21 Piper Sandler Neurologist survey shows erosion for Biogen franchises, says Piper Sandler 02/17/21 Cantor Fitzgerald Biogen price target lowered to $268 from $278 at Cantor Fitzgerald PFE Pfizer $36.18 / +0.065 (+0.18%) 03/17/21 Mizuho AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho 02/23/21 B. Riley B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance 02/10/21 KeyBanc Maravai Lifesciences price target raised to $39 from $33 at KeyBanc 02/04/21 DZ Bank Pfizer upgraded to Buy from Hold at DZ Bank RARE Ultragenyx $114.14 / +2.35 (+2.10%) 03/24/21 Stifel Stifel remains optimistic on GTX-102 and Ultragenyx ahead of 'important' update 03/01/21 Stifel Ultragenyx resumed with a Buy at Stifel 02/12/21 Wedbush Ultragenyx price target raised to $130 from $113 at Wedbush 02/12/21 Barclays Ultragenyx price target raised to $186 from $176 at Barclays FOLD Amicus $9.68 / +0.28 (+2.98%) 03/01/21 Stifel Amicus initiated with a Hold at Stifel 02/12/21 Fly Intel: Top five analyst downgrades 02/12/21 JPMorgan Amicus downgraded to Neutral on Pompe disease miss at JPMorgan 02/12/21 SVB Leerink Amicus downgraded to Market Perform from Outperform at SVB Leerink ORTX Orchard Therapeutics $7.24 / +0.08 (+1.12%) 03/10/21 Stifel Stifel says Bluebird update on AML provides 'some relief' to other LV players 03/02/21 JPMorgan Orchard Therapeutics assumed with an Overweight at JPMorgan 03/01/21 Stifel Orchard Therapeutics initiated with a Buy at Stifel 02/18/21 Goldman Sachs Orchard selloff on Bluebird Bio news overdone, says Goldman Sachs QGEN Qiagen $48.43 / +0.47 (+0.98%) 02/19/21 Berenberg Qiagen price target raised to EUR 56 from EUR 52 at Berenberg 02/09/21 William Blair Quidel, Qiagen merger would not make sense, says William Blair 02/09/21 Wells Fargo Qiagen shares should be sold on latest merger talk, says Wells Fargo 02/09/21 Citi Merger with Qiagen would benefit Quidel, says Citi RARE QGEN PFE ORTX FOLD BIIB RARE Ultragenyx $114.14 / +2.35 (+2.10%) 02/11/21 Ultragenyx backs FY21 revenue guidance range for Crysvita 02/11/21 Ultragenyx backs FY21 revenue guidance range for Crysvita 02/11/21 Ultragenyx reports Q4 EPS (37c), consensus ($1.16) 10/27/20 Ultragenyx reports Q3 EPS ($1.13), consensus ($1.27) QGEN Qiagen $48.43 / +0.47 (+0.98%) 02/09/21 Qiagen backs FY21 EPS view $2.42-$2.46, consensus $2.40 02/09/21 Qiagen reports Q4 EPS 68c, consensus 65c 12/08/20 Qiagen sees FY21 adj. EPS $2.42-$2.46 CER, consensus $2.40 12/08/20 Qiagen raises FY20 adj. EPS view to $2.13-$2.14 CER from $2.07-$2.09 CER PFE Pfizer $36.18 / +0.065 (+0.18%) 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer reports Q4 adjusted EPS 42c, consensus 48c 02/01/21 Notable companies reporting before tomorrow's open ORTX Orchard Therapeutics $7.24 / +0.08 (+1.12%) 03/02/21 Orchard Therapeutics reports Q4 net loss $33.6M vs. $45.4M last year 11/03/20 Orchard Therapeutics reports Q3 EPS (20c), consensus (46c) FOLD Amicus $9.68 / +0.28 (+2.98%) 03/01/21 Amicus reports FY20 EPS ($1.07), consensus ($1.02) 11/05/20 Amicus reports Q3 EPS (25c), consensus (22c) BIIB Biogen $277.54 / +1.66 (+0.60%) 02/03/21 Biogen sees FY21 adjusted EPS $17.00-$18.50, consensus $24.67 02/03/21 Biogen reports Q4 adjusted EPS $4.58, consensus $4.87 02/02/21 Notable companies reporting before tomorrow's open 29 Oct QGEN PFE FOLD BIIB QGEN Qiagen $48.43 / +0.47 (+0.98%) 02/08/21 Quidel weighs combining with Qiagen, Bloomberg reports 02/08/21 Qiagen jumps after Bloomberg says Quidel made preliminary approach 02/08/21 Quidel weighs combining with Qiagen, Bloomberg reports PFE Pfizer $36.18 / +0.065 (+0.18%) 03/31/21 Pfizer, BioNTech to test COVID-19 vaccine, less storage requirements, WSJ report 03/26/21 White House weighs lifting IP protections for COVID-19 vaccines, CNBC says 03/25/21 Biden to up 100-day COVID-19 vaccination goal to 200M shots, CNBC says 03/23/21 WTO's Okonjo-Iweala 'disappointed' in EU vaccine export scheme, Reuters says FOLD Amicus $9.68 / +0.28 (+2.98%) 02/02/21 Amicus, BioMarin speculated by Dealreporter as possible Vertex targets 10/16/20 Amicus 'a name to watch' if Vertex seeks M&A, Dealreporter says BIIB Biogen $277.54 / +1.66 (+0.60%) 03/20/21 Still reasons to be hopeful about Lilly, Biogen Alzheimer's drugs, Barron's says 03/17/21 Biogen, Alkermes sue Teva to block MS drug, Bloomberg reports 11/07/20 Biogen Alzheimer's drug closer to approval, still not a buy, Barron's says 11/07/20 FDA may find it 'extremely' hard to approve Biogen drug after panel, STAT says QGEN PFE FOLD BIIB QGEN Qiagen $48.43 / +0.47 (+0.98%) 02/09/21 Fly Intel: After-Hours Movers 02/08/21 Fly Intel: Wall Street's top stories for Monday 11/11/20 Fly Intel: After-Hours Movers PFE Pfizer $36.18 / +0.065 (+0.18%) 03/30/21 Fly Intel: Wall Street's top stories for Tuesday 03/30/21 Fly Intel: Wall Street's top stories at midday 03/30/21 Fly Intel: Pre-market Movers 03/29/21 Fly Intel: Wall Street's top stories for Monday FOLD Amicus $9.68 / +0.28 (+2.98%) 02/12/21 Fly Intel: Wall Street's top stories for Friday 02/12/21 Fly Intel: Wall Street's top stories at midday 02/11/21 Fly Intel: After-Hours Movers 12/28/20 Kinnate initiations, Nikola target change among today's top calls on Wall Street BIIB Biogen $277.54 / +1.66 (+0.60%) 02/03/21 Fly Intel: Wall Street's top stories for Wednesday 02/03/21 Fly Intel: Wall Street's top stories at midday 02/03/21 Fly Intel: Pre-market Movers 01/29/21 Fly Intel: Wall Street's top stories for Friday 04/08/21 Biotech;Biopharma 04/01/21 Stifel Virtual CNS Day 2021 04/01/21 Gene Therapy Comparabililty Virtual Conference 05/24/21 Global Healthcare Virtual Conference 2021 05/04/21 Pfizer - PFE 06/07/21 PDUFA Date for Aducanumab 12/29/21 PDUFA Date for Lorbrena (Lorlatinib) April 2021 04/22/21 Pfizer Inc QGEN PFE FOLD BIIB QGEN Qiagen $48.43 / +0.47 (+0.98%) 10/14/20 Call spread buyer crosses wide spread in Qiagen PFE Pfizer $36.18 / +0.065 (+0.18%) 03/15/21 Pfizer call volume above normal and directionally bullish 03/04/21 Pfizer call volume above normal and directionally bullish 01/29/21 Unusually active option classes on open January 29th 01/25/21 Pfizer call volume above normal and directionally bullish FOLD Amicus $9.68 / +0.28 (+2.98%) 02/11/21 Amicus put volume heavy and directionally bearish 02/03/21 Amicus call volume above normal and directionally bullish BIIB Biogen $277.54 / +1.66 (+0.60%) 03/25/21 Early notable gainers among liquid option names on March 25th 01/29/21 Early notable gainers among liquid option names on January 29th 01/08/21 Biogen put volume heavy and directionally bearish 11/11/20 Early notable gainers among liquid option names on November 11th
Conference/Events	Muscular Dystrophy Association to hold a virtual conference » 04:55 03/18/21 03/18 04:55 03/18/21 04:55 ALXN Alexion $153.23 / -0.09 (-0.06%) , BHVN Biohaven Pharmaceutical $77.11 / +1.39 (+1.84%) , BIIB Biogen $264.14 / +4.36 (+1.68%) , CPRX Catalyst Pharmaceuticals $4.22 / +0.1 (+2.43%) , CYTK Cytokinetics $25.69 / +1.87 (+7.85%) , DYN Dyne Therapeutics $16.58 / -0.055 (-0.33%) , FOLD Amicus $10.55 / +0.06 (+0.57%) , NVS Novartis $85.74 / -0.23 (-0.27%) , ORPH Orphazyme $12.75 / -0.55 (-4.14%) , PKI PerkinElmer $126.38 / +0.4 (+0.32%) , PTCT PTC Therapeutics $55.75 / -1.98 (-3.43%) , REGN Regeneron $496.30 / +14.06 (+2.92%) , SLDB Solid Biosciences $6.67 / +0.22 (+3.41%) , SNY Sanofi $49.06 / -0.33 (-0.67%) , SRPT Sarepta $84.92 / +0.505 (+0.60%) MDA Clinical &… MDA Clinical & Scientific Virtual Conference 2021 will be held on March 14-18. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options SRPT SNY SLDB REGN PTCT PKI ORPH NVS FOLD DYN CYTK CPRX BIIB BHVN ALXN SRPT Sarepta $84.92 / +0.505 (+0.60%) 02/25/21 Sarepta rallies 2% to $86.15 after winning FDA approval for DMD treatment 02/25/21 Sarepta announces FDA approval of Amondys 45 01/13/21 Sarepta, Genevant announce collaboration for gene editing therapeutics SNY Sanofi $49.06 / -0.33 (-0.67%) 03/16/21 Global Blood Therapeutics to in-license two SCD programs from Sanofi 03/12/21 Sanofi, Translate Bio initiate SARS-CoV-2 vaccine candidate trial SLDB Solid Biosciences $6.67 / +0.22 (+3.41%) 03/15/21 Solid Biosciences reports interim functioning, biomarker data from IGNITE DMD 03/04/21 Solid Biosciences reports inducement grant to new CLO 03/04/21 Solid Biosciences names Erin Powers Brennan CLO, Joel Schneider COO 12/11/20 Solid Biosciences announces $90M private placement REGN Regeneron $496.30 / +14.06 (+2.92%) 03/15/21 Regeneron, Sanofi announce Libtayo study to be stopped early due to OS benefit 03/04/21 Regeneron, Sanofi announce FDA acceptance of Dupixent sBLA 03/03/21 Kiniksa jumps 10% to $24 per share after disclosing supply deal with Regeneron 02/28/21 Regeneron announces Phase 2 data evaluating antibody cocktail REGN1908-1909 PTCT PTC Therapeutics $55.75 / -1.98 (-3.43%) 03/16/21 PTC Therapeutics announces two-year data from Part 2 of SUNFISH trial 02/26/21 PTC Therapeutics announces CHMP recommendation for approval of Evrysdi 02/17/21 PTC Therapeutics initiates second stage of Phase 2/3 trial of COVID-19 candidate 12/04/20 PTC Therapeutics: Translarna approved in Russia for treatment of nmDMD PKI PerkinElmer $126.38 / +0.4 (+0.32%) 03/10/21 Quidel slips, drags on peers as demand for testing 'softens significantly' 03/09/21 PerkinElmer launches comprehensive solutions for detecting SARS-CoV-2 mutations 02/23/21 PerkinElmer launches point of care Covid-19 antigen test for mass screening 02/22/21 PerkinElmer gives update on Valencia Branch Laboratory's accreditation process ORPH Orphazyme $12.75 / -0.55 (-4.14%) 12/31/20 CytRx says Orphazyme's arimoclomol PDUFA target date extended to June 17, 2021 12/07/20 CytRx announces Orphazyme U.S. expansion ahead of potential arimoclomol approval 11/11/20 CytRx says Orphazyme submited MAA to EMA for arimoclomol for NPC treatment 11/09/20 Orphazyme submits arimoclomol MAA to EMA NVS Novartis $85.74 / -0.23 (-0.27%) 03/16/21 FTC plans 'new approach' to analyzing effects of pharmaceutical mergers 03/16/21 Pliant Therapeutics completes PLN-1474 Phase 1 study, transfer to Novartis 03/12/21 NLS Pharmaceutics enters license agreement with Novartis for Sanorex 03/09/21 Novartis reports CANOPY-2 trial did not meet primary endpoint FOLD Amicus $10.55 / +0.06 (+0.57%) 03/01/21 Amicus sees FY21 total Galafold revenue $300M-$315M 02/11/21 Amicus AT-GAA not stat. significant for superiority vs. alglucosidasa alfa 02/11/21 Amicus trading resumes 02/11/21 Amicus trading halted, news pending DYN Dyne Therapeutics $16.58 / -0.055 (-0.33%) 03/04/21 Dyne Therapeutics expects cash to fund requirements into 2H24 02/08/21 Dyne Therapeutics appoints Ashish Dugar as SVP, global head of medical affairs 01/10/21 Dyne Therapeutics announced new preclinical data from DM1 program CYTK Cytokinetics $25.69 / +1.87 (+7.85%) 02/18/21 Cytokinetics appoints Muna Bhanji to board of directors 01/13/21 Cytokinetics announces dosing of first patient in Cohort 2 of Redwood-HCM 01/11/21 Cytokinetics granted orphan drug designation for CK-3773274 in HCM 12/23/20 Cytokinetics regains European rights to omecamtiv mecarbil CPRX Catalyst Pharmaceuticals $4.22 / +0.1 (+2.43%) 01/06/21 Catalyst Pharmaceuticals awaiting schedule or decision in FDA suit 01/06/21 Catalyst Pharmaceuticals decides not to pursue Kennedy's disease indication 01/06/21 Catalyst Pharmaceuticals decides not to pursue SMA Type 3 indication 01/06/21 Catalyst plans to present hypotheses on MuSK-MG Phase 3 trial to FDA in 1H21 BIIB Biogen $264.14 / +4.36 (+1.68%) 03/04/21 Biogen to build gene therapy manufacturing center in North Carolina 03/04/21 Dyne Therapeutics appoints Wildon Farwell as CMO 02/03/21 Biogen sees FY21 adjusted R&D expense $2.35B-$2.45B 02/03/21 Biogen CEO sees 'a financial reset in 2021' BHVN Biohaven Pharmaceutical $77.11 / +1.39 (+1.84%) 03/17/21 Biohaven Pharmaceutical's Childs buys over 13,000 common shares 03/11/21 Biohaven Pharmaceutical's Nurtec approved In United Arab Emirates for migraine 03/10/21 Biohaven says over 50% of participants enrolled in verdiperstat regimen 03/10/21 Biohaven's Nurtec ODT approved in Israel for acute treatment of migraine ALXN Alexion $153.23 / -0.09 (-0.06%) 03/16/21 AstraZeneca withdraws FTC notification on Alexion deal, plans to refile 02/22/21 Arcturus Therapeutics acquires exclusive license from Alexion 02/16/21 Paulson & Co. buys Exxon, exits Qiagen in Q4 01/13/21 Alexion further pauses global Phase 3 study of Ultomiris ALXN BHVN BIIB CPRX CYTK DYN FOLD NVS ORPH PKI PTCT REGN SLDB SNY SRPT ALXN Alexion $153.23 / -0.09 (-0.06%) 02/04/21 Piper Sandler Alexion downgraded to Neutral ahead of expected deal closing at Piper Sandler 02/04/21 Piper Sandler Alexion downgraded to Neutral from Overweight at Piper Sandler 01/08/21 Raymond James Alexion downgraded to Market Perform from Outperform at Raymond James 12/16/20 Truist Alexion downgraded to Hold from Buy at Truist BHVN Biohaven Pharmaceutical $77.11 / +1.39 (+1.84%) 03/11/21 Fly Intel: Top five analyst initiations 03/11/21 UBS Biohaven Pharmaceutical initiated with a Buy at UBS 03/02/21 Mizuho Biohaven Pharmaceutical price target raised to $103 from $93 at Mizuho 03/01/21 Piper Sandler Biohaven price target raised to $110 from $90 at Piper Sandler BIIB Biogen $264.14 / +4.36 (+1.68%) 02/17/21 Cantor Fitzgerald Biogen price target lowered to $268 from $278 at Cantor Fitzgerald 02/08/21 Citi Expert sees Biogen aducanumab approval 50/50 at best, says Citi 02/04/21 SVB Leerink Biogen price target lowered to $380 from $430 at SVB Leerink 02/04/21 Credit Suisse Biogen price target lowered to $338 from $350 at Credit Suisse CPRX Catalyst Pharmaceuticals $4.22 / +0.1 (+2.43%) 03/16/21 Piper Sandler Catalyst business continues to generate cash flow, says Piper Sandler 01/07/21 Piper Sandler Piper says Catalyst's Firdapse commercial business performing as expected 01/06/21 Piper Sandler Catalyst Firdapse commercial business performing as expected, says Piper Sandler 11/10/20 Piper Sandler Catalyst Pharmaceuticals price target lowered to $5.50 from $6 at Piper Sandler CYTK Cytokinetics $25.69 / +1.87 (+7.85%) 03/11/21 Wolfe Research Cytokinetics initiated with an Outperform at Wolfe Research 02/18/21 Barclays Cytokinetics initiated with an Overweight at Barclays 01/20/21 H.C. Wainwright Cytokinetics price target raised to $41 from $22 at H.C. Wainwright 12/28/20 Oppenheimer Amgen price target lowered to $266 from $274 at Oppenheimer DYN Dyne Therapeutics $16.58 / -0.055 (-0.33%) 03/05/21 Stifel Dyne Therapeutics weakness a buying opportunity, says Stifel 02/09/21 Dyne Therapeutics initiated with a Buy at JonesTrading 01/07/21 Piper Sandler Dyne Therapeutics potential beneficiary of Sarepta's SRP-9001 miss, says Piper 10/12/20 Jefferies Dyne Therapeutics initiated with a Buy at Jefferies FOLD Amicus $10.55 / +0.06 (+0.57%) 03/01/21 Stifel Amicus initiated with a Hold at Stifel 02/12/21 Fly Intel: Top five analyst downgrades 02/12/21 JPMorgan Amicus downgraded to Neutral on Pompe disease miss at JPMorgan 02/12/21 SVB Leerink Amicus downgraded to Market Perform from Outperform at SVB Leerink NVS Novartis $85.74 / -0.23 (-0.27%) 03/10/21 Fly Intel: Top five analyst downgrades 03/10/21 Argus Novartis cut to Hold at Argus on slowing top-line growth, greater competition 03/10/21 Argus Novartis downgraded to Hold from Buy at Argus 03/01/21 Oppenheimer Homology Medicines loses potential source of upside, says Oppenheimer ORPH Orphazyme $12.75 / -0.55 (-4.14%) 10/26/20 Guggenheim Orphazyme initiated with a Buy at Guggenheim 10/26/20 BofA Orphazyme initiated with a Buy at BofA 10/26/20 BofA Orphazyme initiated with a Buy at BofA PKI PerkinElmer $126.38 / +0.4 (+0.32%) 02/03/21 Citi PerkinElmer price target raised to $155 from $150 at Citi 01/07/21 Piper Sandler Oxford Immunotec downgraded to Neutral from Overweight at Piper Sandler 01/07/21 Wells Fargo PerkinElmer upgraded to Overweight from Equal Weight at Wells Fargo 01/07/21 Wells Fargo PerkinElmer upgraded to Overweight from Equal Weight at Wells Fargo PTCT PTC Therapeutics $55.75 / -1.98 (-3.43%) 02/26/21 Cantor Fitzgerald PTC Therapeutics price target lowered to $75 from $81 at Cantor Fitzgerald 02/12/21 BofA PTC Therapeutics downgraded to Neutral from Buy at BofA 02/12/21 BofA PTC Therapeutics downgraded to Neutral from Buy at BofA 01/05/21 Citi PTC Therapeutics upgraded to Buy from Neutral at Citi REGN Regeneron $496.30 / +14.06 (+2.92%) 03/11/21 Evercore ISI Kodiak Sciences initiated with an Outperform at Evercore ISI 03/11/21 Needham Vir Biotechnology price target raised to $80 from $75 at Needham 02/23/21 Credit Suisse Regeneron price target raised to $760 from $753 at Credit Suisse 02/16/21 Cantor Fitzgerald Regeneron price target lowered to $656 from $696 at Cantor Fitzgerald SLDB Solid Biosciences $6.67 / +0.22 (+3.41%) 03/16/21 Chardan Solid Biosciences price target raised to $20 from $12.50 at Chardan 03/16/21 Fly Intel: Top five analyst upgrades 03/16/21 SVB Leerink Solid Biosciences upgraded to Outperform at SVB Leerink 03/16/21 SVB Leerink Solid Biosciences upgraded to Outperform from Market Perform at SVB Leerink SNY Sanofi $49.06 / -0.33 (-0.67%) 02/23/21 BofA BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list 02/10/21 Morgan Stanley Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley 02/05/21 Piper Sandler Piper reiterates Overweight on Kymera after Sanofi capital markets day 01/19/21 UBS Sanofi price target lowered to EUR 99 from EUR 100 at UBS SRPT Sarepta $84.92 / +0.505 (+0.60%) 03/02/21 RBC Capital Sarepta price target lowered to $132 from $143 at RBC Capital 03/02/21 Piper Sandler Sarepta price target lowered to $130 from $140 at Piper Sandler 02/26/21 Mizuho Sarepta price target raised to $160 from $158 at Mizuho 02/25/21 Piper Sandler Piper says Sarepta's Amondys 45 approval comes with 'relatively clean label' SRPT SNY SLDB REGN PTCT PKI NVS FOLD DYN CYTK CPRX BIIB BHVN ALXN SRPT Sarepta $84.92 / +0.505 (+0.60%) 03/01/21 Sarepta reports Q4 EPS ($1.84), consensus ($1.77) 03/01/21 Sarepta reports Q4 EPS ($1.84), consensus ($1.77) 11/05/20 Sarepta reports Q3 EPS ($2.50), consensus ($1.71) SNY Sanofi $49.06 / -0.33 (-0.67%) 02/05/21 Sanofi reports Q4 business EPS EUR 1.22, flat vs. last year 10/29/20 Sanofi reports Q3 business EPS EUR 1.83, up 0.5% from last year SLDB Solid Biosciences $6.67 / +0.22 (+3.41%) 11/05/20 Solid Biosciences reports Q3 EPS (44c), consensus (34c) REGN Regeneron $496.30 / +14.06 (+2.92%) 02/05/21 Regeneron reports Q4 EPS $9.53, consensus $8.39 02/04/21 Notable companies reporting before tomorrow's open 11/05/20 Regeneron reports Q3 EPS $8.36, consensus $7.13 PTCT PTC Therapeutics $55.75 / -1.98 (-3.43%) 02/25/21 PTC Therapeutics reports Q4 EPS ($1.08), consensus (94c) 10/29/20 PTC Therapeutics reports Q3 EPS ($1.03), consensus (6c) PKI PerkinElmer $126.38 / +0.4 (+0.32%) 02/02/21 PerkinElmer sees Q1 adjusted EPS of at least $3.00, consensus $2.40 02/02/21 PerkinElmer sees FY21 adjusted EPS at least $8.50, consensus $8.88 02/02/21 PerkinElmer reports Q4 adjusted EPS $3.96, consensus $3.00 01/11/21 PerkinElmer sees Q4 adjusted EPS 'at least' $3.60, consensus $2.79 NVS Novartis $85.74 / -0.23 (-0.27%) 01/26/21 Novartis sees 2021 core operating income to grow mid single digit 01/26/21 Novartis reports Q4 core EPS $1.34, consensus $1.36 11/05/20 Xoma reports Q3 EPS (10c), consensus (21c) 10/27/20 Novartis raises FY20 core operating income growth outlook FOLD Amicus $10.55 / +0.06 (+0.57%) 03/01/21 Amicus reports FY20 EPS ($1.07), consensus ($1.02) 11/05/20 Amicus reports Q3 EPS (25c), consensus (22c) DYN Dyne Therapeutics $16.58 / -0.055 (-0.33%) 03/04/21 Dyne Therapeutics reports Q4 EPS (64c), consensus (37c) 11/05/20 Dyne Therapeutics reports Q3 EPS ($2.01), consensus (87c) CYTK Cytokinetics $25.69 / +1.87 (+7.85%) 11/04/20 Cytokinetics reports Q3 EPS (5c), consensus (34c) CPRX Catalyst Pharmaceuticals $4.22 / +0.1 (+2.43%) 03/15/21 Catalyst Pharmaceuticals reports Q4 adjusted EPS 12c, consensus 9c 03/15/21 Catalyst Pharmaceuticals reports Q4 EPS 11c, consensus 9c 01/06/21 Catalyst Pharmaceuticals sees 2020 Firdapse revenues approx. $118M 11/09/20 Catalyst Pharmaceuticals reports Q3 diluted EPS 42c, consensus 10c BIIB Biogen $264.14 / +4.36 (+1.68%) 02/03/21 Biogen sees FY21 adjusted EPS $17.00-$18.50, consensus $24.67 02/03/21 Biogen reports Q4 adjusted EPS $4.58, consensus $4.87 02/02/21 Notable companies reporting before tomorrow's open BHVN Biohaven Pharmaceutical $77.11 / +1.39 (+1.84%) 03/01/21 Biohaven Pharmaceutical reports Q4 adjusted EPS ($2.69), consensus ($2.97) 11/09/20 Biohaven Pharmaceutical reports Q3 adj. EPS ($2.67), consensus ($2.89) ALXN Alexion $153.23 / -0.09 (-0.06%) 02/04/21 Alexion reports Q4 EPS $2.96, consensus $2.56 02/04/21 Alexion reports Q4 EPS $2.96, consensus $2.56 10/29/20 Alexion raises 2020 non-GAAP EPS view to $11.70-$12.00 from $10.65-$10.95 10/29/20 Alexion reports Q3 non-GAAP EPS $3.24, consensus $2.60 19 Mar 16 Mar 21 Jan 29 Sep 17 Sep 17 Jul 27 May SNY REGN NVS FOLD BIIB ALXN SNY Sanofi $49.06 / -0.33 (-0.67%) 02/15/21 CEO says Sanofi mRNA vaccine won't be ready this year, Bloomberg reports 02/15/21 Bristol-Myers, Sanofi to pay $834M over Plavix, Bloomberg reports REGN Regeneron $496.30 / +14.06 (+2.92%) 02/11/21 Amgen loses appeal to revive PCSK9 antibody patent suit, Bloomberg reports 12/30/20 Fresenius to administer Lilly, Regeneron COVID antibody drugs, Reuters says 12/04/20 Regeneron must face DOJ suit citing kickbacks, Bloomberg says 11/17/20 Regeneron says Roche completed early tests to make COVID drug, Reuters says NVS Novartis $85.74 / -0.23 (-0.27%) 03/15/21 BioNTech recruits Novartis, Sanofi to boost vaccine production, WSJ reports 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says 11/20/20 Trump to release new rules aimed at lowering drug prices, WSJ reports FOLD Amicus $10.55 / +0.06 (+0.57%) 02/02/21 Amicus, BioMarin speculated by Dealreporter as possible Vertex targets 10/16/20 Amicus 'a name to watch' if Vertex seeks M&A, Dealreporter says BIIB Biogen $264.14 / +4.36 (+1.68%) 03/17/21 Biogen, Alkermes sue Teva to block MS drug, Bloomberg reports 11/07/20 Biogen Alzheimer's drug closer to approval, still not a buy, Barron's says 11/07/20 FDA may find it 'extremely' hard to approve Biogen drug after panel, STAT says 09/28/20 Biogen loses appeal in fight seeking royalties from Merck KGaA, Bloomberg says ALXN Alexion $153.23 / -0.09 (-0.06%) 10/09/20 Betaville says Vertex, Sanofi seen as interested in Alexion, Bloomberg reports SRPT SNY SLDB REGN PTCT PKI ORPH NVS FOLD DYN CYTK CPRX BIIB ALXN SRPT Sarepta $84.92 / +0.505 (+0.60%) 03/01/21 Fly Intel: After-Hours Movers 01/12/21 NIO downgrade, Wells Fargo upgrade among today's top calls on Wall Street 01/08/21 Fly Intel: Wall Street's top stories for Friday 01/08/21 Fly Intel: Wall Street's top stories at midday SNY Sanofi $49.06 / -0.33 (-0.67%) 02/22/21 Fly Intel: Wall Street's top stories for Monday 02/22/21 Fly Intel: Wall Street's top stories at midday 12/31/20 Fly Intel: Wall Street's top stories for Thursday 12/26/20 Week in review: How Trump's policies moved stocks SLDB Solid Biosciences $6.67 / +0.22 (+3.41%) 03/16/21 Fly Intel: Wall Street's top stories for Tuesday 03/16/21 Fly Intel: Wall Street's top stories at midday 12/11/20 Fly Intel: Wall Street's top stories at midday 12/11/20 Fly Intel: Pre-market Movers REGN Regeneron $496.30 / +14.06 (+2.92%) 02/05/21 Fly Intel: Pre-market Movers 01/26/21 Fly Intel: Wall Street's top stories for Tuesday 01/26/21 Fly Intel: Wall Street's top stories at midday 01/12/21 Fly Intel: After-Hours Movers PTCT PTC Therapeutics $55.75 / -1.98 (-3.43%) 09/23/20 Regenxbio slips as Novartis' Zolgensma expansion hits FDA roadblock PKI PerkinElmer $126.38 / +0.4 (+0.32%) 01/07/21 Fly Intel: Pre-market Movers ORPH Orphazyme $12.75 / -0.55 (-4.14%) 10/04/20 Opening Day: Palantir, Asana go public via direct listings 09/27/20 Opening Day: GoodRx rises over 50% in market debut NVS Novartis $85.74 / -0.23 (-0.27%) 03/10/21 Novartis downgrade, HP Enterprise upgrade among today's top calls on Wall Street 02/11/21 Fly Intel: Wall Street's top stories for Thursday 02/11/21 Fly Intel: Wall Street's top stories at midday 02/11/21 Fly Intel: Pre-market Movers FOLD Amicus $10.55 / +0.06 (+0.57%) 02/12/21 Fly Intel: Wall Street's top stories for Friday 02/12/21 Fly Intel: Wall Street's top stories at midday 02/11/21 Fly Intel: After-Hours Movers 12/28/20 Kinnate initiations, Nikola target change among today's top calls on Wall Street DYN Dyne Therapeutics $16.58 / -0.055 (-0.33%) 01/21/21 Fly Intel: Wall Street's top stories for Thursday 01/21/21 Fly Intel: Wall Street's top stories at midday 09/28/20 Fly Intel: After-Hours Movers 09/20/20 Opening Day: Snowflake shares double in biggest software IPO ever CYTK Cytokinetics $25.69 / +1.87 (+7.85%) 10/08/20 Fly Intel: Wall Street's top stories for Thursday 10/08/20 Fly Intel: Wall Street's top stories at midday 10/08/20 Cytokinetics plunges following mixed results from heart drug trial 10/05/20 Fly Intel: Wall Street's top stories for Monday CPRX Catalyst Pharmaceuticals $4.22 / +0.1 (+2.43%) 09/29/20 Fly Intel: After-Hours Movers BIIB Biogen $264.14 / +4.36 (+1.68%) 02/03/21 Fly Intel: Wall Street's top stories for Wednesday 02/03/21 Fly Intel: Wall Street's top stories at midday 02/03/21 Fly Intel: Pre-market Movers 01/29/21 Fly Intel: Wall Street's top stories for Friday ALXN Alexion $153.23 / -0.09 (-0.06%) 12/14/20 Fly Intel: Wall Street's top stories for Monday 12/14/20 Fly Intel: Wall Street's top stories at midday 12/14/20 Fly Intel: Pre-market Movers 12/07/20 Fly Insider: Foot Locker, Alexion among weeks notable insider trades 03/18/21 Solid Biosciences - SLDB 05/18/21 PDUFA Date for Avalglucosidase Alfa 06/07/21 PDUFA Date for Aducanumab 06/17/21 PDUFA Date for Arimoclomol 10/21/21 PDUFA Date for Dupixent (Dupilumab) 03/24/21 FuboTV 04/27/21 PerkinElmer, Inc. REGN FOLD CYTK BIIB ALXN REGN Regeneron $496.30 / +14.06 (+2.92%) 01/13/21 Early notable gainers among liquid option names on January 13th 12/18/20 Early notable gainers among liquid option names on December 18th 11/06/20 Regeneron put volume heavy and directionally bearish 10/08/20 Unusually active option classes on open October 8th FOLD Amicus $10.55 / +0.06 (+0.57%) 02/11/21 Amicus put volume heavy and directionally bearish 02/03/21 Amicus call volume above normal and directionally bullish CYTK Cytokinetics $25.69 / +1.87 (+7.85%) 10/29/20 Cytokinetics call volume above normal and directionally bullish BIIB Biogen $264.14 / +4.36 (+1.68%) 01/29/21 Early notable gainers among liquid option names on January 29th 01/08/21 Biogen put volume heavy and directionally bearish 11/11/20 Early notable gainers among liquid option names on November 11th 11/05/20 Unusually active option classes on open November 5th ALXN Alexion $153.23 / -0.09 (-0.06%) 12/14/20 Early notable gainers among liquid option names on December 14th 10/20/20 Alexion call volume above normal and directionally bullish 10/19/20 Alexion call volume above normal and directionally bullish
Conference/Events	Muscular Dystrophy Association to hold a virtual conference » 04:55 03/18/21 03/18 04:55 03/18/21 04:55 ALXN Alexion $153.23 / -0.09 (-0.06%) , SDNA Sedona Corporation $0.00 / + (+0.00%) , BIIB Biogen $264.14 / +4.36 (+1.68%) , PTCT PTC Therapeutics $55.75 / -1.98 (-3.43%) , SRPT Sarepta $84.92 / +0.505 (+0.60%) , NVS Novartis $85.74 / -0.23 (-0.27%) , SNY Sanofi $49.06 / -0.33 (-0.67%) , SLDB Solid Biosciences $6.67 / +0.22 (+3.41%) , REGN Regeneron $496.30 / +14.06 (+2.92%) , BHVN Biohaven Pharmaceutical $77.11 / +1.39 (+1.84%) , ORPH Orphazyme $12.75 / -0.55 (-4.14%) , CPRX Catalyst Pharmaceuticals $4.22 / +0.1 (+2.43%) , DYN Dyne Therapeutics $16.58 / -0.055 (-0.33%) , CYTK Cytokinetics $25.69 / +1.87 (+7.85%) , FOLD Amicus $10.55 / +0.06 (+0.57%) , PKI PerkinElmer $126.38 / +0.4 (+0.32%) MDA Clinical &… MDA Clinical & Scientific Virtual Conference 2021 will be held on March 14-18. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options SRPT SNY SLDB REGN PTCT PKI ORPH NVS FOLD DYN CYTK CPRX BIIB BHVN ALXN SRPT Sarepta $84.92 / +0.505 (+0.60%) 02/25/21 Sarepta rallies 2% to $86.15 after winning FDA approval for DMD treatment 02/25/21 Sarepta announces FDA approval of Amondys 45 02/08/21 Dyne Therapeutics appoints Ashish Dugar as SVP, global head of medical affairs 01/13/21 Sarepta, Genevant announce collaboration for gene editing therapeutics SNY Sanofi $49.06 / -0.33 (-0.67%) 03/16/21 Global Blood Therapeutics to in-license two SCD programs from Sanofi 03/15/21 Regeneron, Sanofi announce Libtayo study to be stopped early due to OS benefit 03/12/21 Sanofi, Translate Bio initiate SARS-CoV-2 vaccine candidate trial SLDB Solid Biosciences $6.67 / +0.22 (+3.41%) 03/15/21 Solid Biosciences reports interim functioning, biomarker data from IGNITE DMD 03/04/21 Solid Biosciences reports inducement grant to new CLO 03/04/21 Solid Biosciences names Erin Powers Brennan CLO, Joel Schneider COO 12/11/20 Solid Biosciences announces $90M private placement REGN Regeneron $496.30 / +14.06 (+2.92%) 03/04/21 Regeneron, Sanofi announce FDA acceptance of Dupixent sBLA 03/03/21 Kiniksa jumps 10% to $24 per share after disclosing supply deal with Regeneron 02/28/21 Regeneron announces Phase 2 data evaluating antibody cocktail REGN1908-1909 PTCT PTC Therapeutics $55.75 / -1.98 (-3.43%) 03/16/21 PTC Therapeutics announces two-year data from Part 2 of SUNFISH trial 02/26/21 PTC Therapeutics announces CHMP recommendation for approval of Evrysdi 02/17/21 PTC Therapeutics initiates second stage of Phase 2/3 trial of COVID-19 candidate 12/04/20 PTC Therapeutics: Translarna approved in Russia for treatment of nmDMD PKI PerkinElmer $126.38 / +0.4 (+0.32%) 03/10/21 Quidel slips, drags on peers as demand for testing 'softens significantly' 03/09/21 PerkinElmer launches comprehensive solutions for detecting SARS-CoV-2 mutations 02/23/21 PerkinElmer launches point of care Covid-19 antigen test for mass screening 02/22/21 PerkinElmer gives update on Valencia Branch Laboratory's accreditation process ORPH Orphazyme $12.75 / -0.55 (-4.14%) 12/31/20 CytRx says Orphazyme's arimoclomol PDUFA target date extended to June 17, 2021 12/07/20 CytRx announces Orphazyme U.S. expansion ahead of potential arimoclomol approval 11/11/20 CytRx says Orphazyme submited MAA to EMA for arimoclomol for NPC treatment 11/09/20 Orphazyme submits arimoclomol MAA to EMA NVS Novartis $85.74 / -0.23 (-0.27%) 03/16/21 FTC plans 'new approach' to analyzing effects of pharmaceutical mergers 03/16/21 Pliant Therapeutics completes PLN-1474 Phase 1 study, transfer to Novartis 03/12/21 NLS Pharmaceutics enters license agreement with Novartis for Sanorex 03/09/21 Novartis reports CANOPY-2 trial did not meet primary endpoint FOLD Amicus $10.55 / +0.06 (+0.57%) 03/01/21 Amicus sees FY21 total Galafold revenue $300M-$315M 02/11/21 Amicus AT-GAA not stat. significant for superiority vs. alglucosidasa alfa 02/11/21 Amicus trading resumes 02/11/21 Amicus trading halted, news pending DYN Dyne Therapeutics $16.58 / -0.055 (-0.33%) 03/04/21 Dyne Therapeutics expects cash to fund requirements into 2H24 01/10/21 Dyne Therapeutics announced new preclinical data from DM1 program CYTK Cytokinetics $25.69 / +1.87 (+7.85%) 02/18/21 Cytokinetics appoints Muna Bhanji to board of directors 01/13/21 Cytokinetics announces dosing of first patient in Cohort 2 of Redwood-HCM 01/11/21 Cytokinetics granted orphan drug designation for CK-3773274 in HCM 12/23/20 Cytokinetics regains European rights to omecamtiv mecarbil CPRX Catalyst Pharmaceuticals $4.22 / +0.1 (+2.43%) 01/06/21 Catalyst Pharmaceuticals awaiting schedule or decision in FDA suit 01/06/21 Catalyst Pharmaceuticals decides not to pursue Kennedy's disease indication 01/06/21 Catalyst Pharmaceuticals decides not to pursue SMA Type 3 indication 01/06/21 Catalyst plans to present hypotheses on MuSK-MG Phase 3 trial to FDA in 1H21 BIIB Biogen $264.14 / +4.36 (+1.68%) 03/04/21 Biogen to build gene therapy manufacturing center in North Carolina 03/04/21 Dyne Therapeutics appoints Wildon Farwell as CMO 02/03/21 Biogen sees FY21 adjusted R&D expense $2.35B-$2.45B 02/03/21 Biogen CEO sees 'a financial reset in 2021' BHVN Biohaven Pharmaceutical $77.11 / +1.39 (+1.84%) 03/17/21 Biohaven Pharmaceutical's Childs buys over 13,000 common shares 03/11/21 Biohaven Pharmaceutical's Nurtec approved In United Arab Emirates for migraine 03/10/21 Biohaven says over 50% of participants enrolled in verdiperstat regimen 03/10/21 Biohaven's Nurtec ODT approved in Israel for acute treatment of migraine ALXN Alexion $153.23 / -0.09 (-0.06%) 03/16/21 AstraZeneca withdraws FTC notification on Alexion deal, plans to refile 02/22/21 Arcturus Therapeutics acquires exclusive license from Alexion 02/16/21 Paulson & Co. buys Exxon, exits Qiagen in Q4 01/13/21 Alexion further pauses global Phase 3 study of Ultomiris ALXN SDNA BIIB PTCT SRPT NVS SNY SLDB REGN BHVN ORPH CPRX DYN CYTK FOLD PKI ALXN Alexion $153.23 / -0.09 (-0.06%) 02/04/21 Piper Sandler Alexion downgraded to Neutral ahead of expected deal closing at Piper Sandler 02/04/21 Piper Sandler Alexion downgraded to Neutral from Overweight at Piper Sandler 01/08/21 Raymond James Alexion downgraded to Market Perform from Outperform at Raymond James 12/16/20 Truist Alexion downgraded to Hold from Buy at Truist SDNA Sedona Corporation $0.00 / + (+0.00%) BIIB Biogen $264.14 / +4.36 (+1.68%) 02/17/21 Cantor Fitzgerald Biogen price target lowered to $268 from $278 at Cantor Fitzgerald 02/08/21 Citi Expert sees Biogen aducanumab approval 50/50 at best, says Citi 02/04/21 SVB Leerink Biogen price target lowered to $380 from $430 at SVB Leerink 02/04/21 Credit Suisse Biogen price target lowered to $338 from $350 at Credit Suisse PTCT PTC Therapeutics $55.75 / -1.98 (-3.43%) 02/26/21 Cantor Fitzgerald PTC Therapeutics price target lowered to $75 from $81 at Cantor Fitzgerald 02/12/21 BofA PTC Therapeutics downgraded to Neutral from Buy at BofA 02/12/21 BofA PTC Therapeutics downgraded to Neutral from Buy at BofA 01/05/21 Citi PTC Therapeutics upgraded to Buy from Neutral at Citi SRPT Sarepta $84.92 / +0.505 (+0.60%) 03/02/21 RBC Capital Sarepta price target lowered to $132 from $143 at RBC Capital 03/02/21 Piper Sandler Sarepta price target lowered to $130 from $140 at Piper Sandler 02/26/21 Mizuho Sarepta price target raised to $160 from $158 at Mizuho 02/25/21 Piper Sandler Piper says Sarepta's Amondys 45 approval comes with 'relatively clean label' NVS Novartis $85.74 / -0.23 (-0.27%) 03/10/21 Fly Intel: Top five analyst downgrades 03/10/21 Argus Novartis cut to Hold at Argus on slowing top-line growth, greater competition 03/10/21 Argus Novartis downgraded to Hold from Buy at Argus 03/01/21 Oppenheimer Homology Medicines loses potential source of upside, says Oppenheimer SNY Sanofi $49.06 / -0.33 (-0.67%) 02/23/21 BofA BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list 02/10/21 Morgan Stanley Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley 02/05/21 Piper Sandler Piper reiterates Overweight on Kymera after Sanofi capital markets day 01/19/21 UBS Sanofi price target lowered to EUR 99 from EUR 100 at UBS SLDB Solid Biosciences $6.67 / +0.22 (+3.41%) 03/16/21 Chardan Solid Biosciences price target raised to $20 from $12.50 at Chardan 03/16/21 Fly Intel: Top five analyst upgrades 03/16/21 SVB Leerink Solid Biosciences upgraded to Outperform at SVB Leerink 03/16/21 SVB Leerink Solid Biosciences upgraded to Outperform from Market Perform at SVB Leerink REGN Regeneron $496.30 / +14.06 (+2.92%) 03/11/21 Evercore ISI Kodiak Sciences initiated with an Outperform at Evercore ISI 03/11/21 Needham Vir Biotechnology price target raised to $80 from $75 at Needham 02/23/21 Credit Suisse Regeneron price target raised to $760 from $753 at Credit Suisse 02/16/21 Cantor Fitzgerald Regeneron price target lowered to $656 from $696 at Cantor Fitzgerald BHVN Biohaven Pharmaceutical $77.11 / +1.39 (+1.84%) 03/11/21 Fly Intel: Top five analyst initiations 03/11/21 UBS Biohaven Pharmaceutical initiated with a Buy at UBS 03/02/21 Mizuho Biohaven Pharmaceutical price target raised to $103 from $93 at Mizuho 03/01/21 Piper Sandler Biohaven price target raised to $110 from $90 at Piper Sandler ORPH Orphazyme $12.75 / -0.55 (-4.14%) 10/26/20 Guggenheim Orphazyme initiated with a Buy at Guggenheim 10/26/20 BofA Orphazyme initiated with a Buy at BofA 10/26/20 BofA Orphazyme initiated with a Buy at BofA CPRX Catalyst Pharmaceuticals $4.22 / +0.1 (+2.43%) 03/16/21 Piper Sandler Catalyst business continues to generate cash flow, says Piper Sandler 01/07/21 Piper Sandler Piper says Catalyst's Firdapse commercial business performing as expected 01/06/21 Piper Sandler Catalyst Firdapse commercial business performing as expected, says Piper Sandler 11/10/20 Piper Sandler Catalyst Pharmaceuticals price target lowered to $5.50 from $6 at Piper Sandler DYN Dyne Therapeutics $16.58 / -0.055 (-0.33%) 03/05/21 Stifel Dyne Therapeutics weakness a buying opportunity, says Stifel 02/09/21 Dyne Therapeutics initiated with a Buy at JonesTrading 01/07/21 Piper Sandler Dyne Therapeutics potential beneficiary of Sarepta's SRP-9001 miss, says Piper 10/12/20 Jefferies Dyne Therapeutics initiated with a Buy at Jefferies CYTK Cytokinetics $25.69 / +1.87 (+7.85%) 03/11/21 Wolfe Research Cytokinetics initiated with an Outperform at Wolfe Research 02/18/21 Barclays Cytokinetics initiated with an Overweight at Barclays 01/20/21 H.C. Wainwright Cytokinetics price target raised to $41 from $22 at H.C. Wainwright 12/28/20 Oppenheimer Amgen price target lowered to $266 from $274 at Oppenheimer FOLD Amicus $10.55 / +0.06 (+0.57%) 03/01/21 Stifel Amicus initiated with a Hold at Stifel 02/12/21 Fly Intel: Top five analyst downgrades 02/12/21 JPMorgan Amicus downgraded to Neutral on Pompe disease miss at JPMorgan 02/12/21 SVB Leerink Amicus downgraded to Market Perform from Outperform at SVB Leerink PKI PerkinElmer $126.38 / +0.4 (+0.32%) 02/03/21 Citi PerkinElmer price target raised to $155 from $150 at Citi 01/07/21 Piper Sandler Oxford Immunotec downgraded to Neutral from Overweight at Piper Sandler 01/07/21 Wells Fargo PerkinElmer upgraded to Overweight from Equal Weight at Wells Fargo 01/07/21 Wells Fargo PerkinElmer upgraded to Overweight from Equal Weight at Wells Fargo SRPT SNY SLDB REGN PTCT PKI NVS FOLD DYN CYTK CPRX BIIB BHVN ALXN SRPT Sarepta $84.92 / +0.505 (+0.60%) 03/01/21 Sarepta reports Q4 EPS ($1.84), consensus ($1.77) 03/01/21 Sarepta reports Q4 EPS ($1.84), consensus ($1.77) 11/05/20 Sarepta reports Q3 EPS ($2.50), consensus ($1.71) SNY Sanofi $49.06 / -0.33 (-0.67%) 02/05/21 Sanofi reports Q4 business EPS EUR 1.22, flat vs. last year 10/29/20 Sanofi reports Q3 business EPS EUR 1.83, up 0.5% from last year SLDB Solid Biosciences $6.67 / +0.22 (+3.41%) 11/05/20 Solid Biosciences reports Q3 EPS (44c), consensus (34c) REGN Regeneron $496.30 / +14.06 (+2.92%) 02/05/21 Regeneron reports Q4 EPS $9.53, consensus $8.39 02/04/21 Notable companies reporting before tomorrow's open 11/05/20 Regeneron reports Q3 EPS $8.36, consensus $7.13 PTCT PTC Therapeutics $55.75 / -1.98 (-3.43%) 02/25/21 PTC Therapeutics reports Q4 EPS ($1.08), consensus (94c) 10/29/20 PTC Therapeutics reports Q3 EPS ($1.03), consensus (6c) PKI PerkinElmer $126.38 / +0.4 (+0.32%) 02/02/21 PerkinElmer sees Q1 adjusted EPS of at least $3.00, consensus $2.40 02/02/21 PerkinElmer sees FY21 adjusted EPS at least $8.50, consensus $8.88 02/02/21 PerkinElmer reports Q4 adjusted EPS $3.96, consensus $3.00 01/11/21 PerkinElmer sees Q4 adjusted EPS 'at least' $3.60, consensus $2.79 NVS Novartis $85.74 / -0.23 (-0.27%) 01/26/21 Novartis sees 2021 core operating income to grow mid single digit 01/26/21 Novartis reports Q4 core EPS $1.34, consensus $1.36 11/05/20 Xoma reports Q3 EPS (10c), consensus (21c) 10/27/20 Novartis raises FY20 core operating income growth outlook FOLD Amicus $10.55 / +0.06 (+0.57%) 03/01/21 Amicus reports FY20 EPS ($1.07), consensus ($1.02) 11/05/20 Amicus reports Q3 EPS (25c), consensus (22c) DYN Dyne Therapeutics $16.58 / -0.055 (-0.33%) 03/04/21 Dyne Therapeutics reports Q4 EPS (64c), consensus (37c) 11/05/20 Dyne Therapeutics reports Q3 EPS ($2.01), consensus (87c) CYTK Cytokinetics $25.69 / +1.87 (+7.85%) 11/04/20 Cytokinetics reports Q3 EPS (5c), consensus (34c) CPRX Catalyst Pharmaceuticals $4.22 / +0.1 (+2.43%) 03/15/21 Catalyst Pharmaceuticals reports Q4 adjusted EPS 12c, consensus 9c 03/15/21 Catalyst Pharmaceuticals reports Q4 EPS 11c, consensus 9c 01/06/21 Catalyst Pharmaceuticals sees 2020 Firdapse revenues approx. $118M 11/09/20 Catalyst Pharmaceuticals reports Q3 diluted EPS 42c, consensus 10c BIIB Biogen $264.14 / +4.36 (+1.68%) 02/03/21 Biogen sees FY21 adjusted EPS $17.00-$18.50, consensus $24.67 02/03/21 Biogen reports Q4 adjusted EPS $4.58, consensus $4.87 02/02/21 Notable companies reporting before tomorrow's open BHVN Biohaven Pharmaceutical $77.11 / +1.39 (+1.84%) 03/01/21 Biohaven Pharmaceutical reports Q4 adjusted EPS ($2.69), consensus ($2.97) 11/09/20 Biohaven Pharmaceutical reports Q3 adj. EPS ($2.67), consensus ($2.89) ALXN Alexion $153.23 / -0.09 (-0.06%) 02/04/21 Alexion reports Q4 EPS $2.96, consensus $2.56 02/04/21 Alexion reports Q4 EPS $2.96, consensus $2.56 10/29/20 Alexion raises 2020 non-GAAP EPS view to $11.70-$12.00 from $10.65-$10.95 10/29/20 Alexion reports Q3 non-GAAP EPS $3.24, consensus $2.60 19 Mar 16 Mar 21 Jan 29 Sep 17 Sep 17 Jul 27 May SNY REGN NVS FOLD BIIB ALXN SNY Sanofi $49.06 / -0.33 (-0.67%) 02/15/21 CEO says Sanofi mRNA vaccine won't be ready this year, Bloomberg reports 02/15/21 Bristol-Myers, Sanofi to pay $834M over Plavix, Bloomberg reports 02/11/21 Amgen loses appeal to revive PCSK9 antibody patent suit, Bloomberg reports REGN Regeneron $496.30 / +14.06 (+2.92%) 12/30/20 Fresenius to administer Lilly, Regeneron COVID antibody drugs, Reuters says 12/04/20 Regeneron must face DOJ suit citing kickbacks, Bloomberg says 11/17/20 Regeneron says Roche completed early tests to make COVID drug, Reuters says NVS Novartis $85.74 / -0.23 (-0.27%) 03/15/21 BioNTech recruits Novartis, Sanofi to boost vaccine production, WSJ reports 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says 11/20/20 Trump to release new rules aimed at lowering drug prices, WSJ reports FOLD Amicus $10.55 / +0.06 (+0.57%) 02/02/21 Amicus, BioMarin speculated by Dealreporter as possible Vertex targets 10/16/20 Amicus 'a name to watch' if Vertex seeks M&A, Dealreporter says BIIB Biogen $264.14 / +4.36 (+1.68%) 03/17/21 Biogen, Alkermes sue Teva to block MS drug, Bloomberg reports 11/07/20 Biogen Alzheimer's drug closer to approval, still not a buy, Barron's says 11/07/20 FDA may find it 'extremely' hard to approve Biogen drug after panel, STAT says 09/28/20 Biogen loses appeal in fight seeking royalties from Merck KGaA, Bloomberg says ALXN Alexion $153.23 / -0.09 (-0.06%) 10/09/20 Betaville says Vertex, Sanofi seen as interested in Alexion, Bloomberg reports SRPT SNY SLDB REGN PTCT PKI ORPH NVS FOLD DYN CYTK CPRX BIIB ALXN SRPT Sarepta $84.92 / +0.505 (+0.60%) 03/01/21 Fly Intel: After-Hours Movers 01/12/21 NIO downgrade, Wells Fargo upgrade among today's top calls on Wall Street 01/08/21 Fly Intel: Wall Street's top stories for Friday 01/08/21 Fly Intel: Wall Street's top stories at midday SNY Sanofi $49.06 / -0.33 (-0.67%) 02/22/21 Fly Intel: Wall Street's top stories for Monday 02/22/21 Fly Intel: Wall Street's top stories at midday 12/31/20 Fly Intel: Wall Street's top stories for Thursday 12/26/20 Week in review: How Trump's policies moved stocks SLDB Solid Biosciences $6.67 / +0.22 (+3.41%) 03/16/21 Fly Intel: Wall Street's top stories for Tuesday 03/16/21 Fly Intel: Wall Street's top stories at midday 12/11/20 Fly Intel: Wall Street's top stories at midday 12/11/20 Fly Intel: Pre-market Movers REGN Regeneron $496.30 / +14.06 (+2.92%) 02/05/21 Fly Intel: Pre-market Movers 01/26/21 Fly Intel: Wall Street's top stories for Tuesday 01/26/21 Fly Intel: Wall Street's top stories at midday 01/12/21 Fly Intel: After-Hours Movers PTCT PTC Therapeutics $55.75 / -1.98 (-3.43%) 09/23/20 Regenxbio slips as Novartis' Zolgensma expansion hits FDA roadblock PKI PerkinElmer $126.38 / +0.4 (+0.32%) 01/07/21 Fly Intel: Pre-market Movers ORPH Orphazyme $12.75 / -0.55 (-4.14%) 10/04/20 Opening Day: Palantir, Asana go public via direct listings 09/27/20 Opening Day: GoodRx rises over 50% in market debut 09/20/20 Opening Day: Snowflake shares double in biggest software IPO ever NVS Novartis $85.74 / -0.23 (-0.27%) 03/10/21 Novartis downgrade, HP Enterprise upgrade among today's top calls on Wall Street 02/11/21 Fly Intel: Wall Street's top stories for Thursday 02/11/21 Fly Intel: Wall Street's top stories at midday 02/11/21 Fly Intel: Pre-market Movers FOLD Amicus $10.55 / +0.06 (+0.57%) 02/12/21 Fly Intel: Wall Street's top stories for Friday 02/12/21 Fly Intel: Wall Street's top stories at midday 02/11/21 Fly Intel: After-Hours Movers 12/28/20 Kinnate initiations, Nikola target change among today's top calls on Wall Street DYN Dyne Therapeutics $16.58 / -0.055 (-0.33%) 01/21/21 Fly Intel: Wall Street's top stories for Thursday 01/21/21 Fly Intel: Wall Street's top stories at midday 09/28/20 Fly Intel: After-Hours Movers CYTK Cytokinetics $25.69 / +1.87 (+7.85%) 10/08/20 Fly Intel: Wall Street's top stories for Thursday 10/08/20 Fly Intel: Wall Street's top stories at midday 10/08/20 Cytokinetics plunges following mixed results from heart drug trial 10/05/20 Fly Intel: Wall Street's top stories for Monday CPRX Catalyst Pharmaceuticals $4.22 / +0.1 (+2.43%) 09/29/20 Fly Intel: After-Hours Movers BIIB Biogen $264.14 / +4.36 (+1.68%) 02/03/21 Fly Intel: Wall Street's top stories for Wednesday 02/03/21 Fly Intel: Wall Street's top stories at midday 02/03/21 Fly Intel: Pre-market Movers 01/29/21 Fly Intel: Wall Street's top stories for Friday ALXN Alexion $153.23 / -0.09 (-0.06%) 12/14/20 Fly Intel: Wall Street's top stories for Monday 12/14/20 Fly Intel: Wall Street's top stories at midday 12/14/20 Fly Intel: Pre-market Movers 12/07/20 Fly Insider: Foot Locker, Alexion among weeks notable insider trades 03/18/21 Solid Biosciences - SLDB 05/18/21 PDUFA Date for Avalglucosidase Alfa 06/07/21 PDUFA Date for Aducanumab 06/17/21 PDUFA Date for Arimoclomol 10/21/21 PDUFA Date for Dupixent (Dupilumab) 03/24/21 FuboTV 04/27/21 PerkinElmer, Inc. REGN FOLD CYTK BIIB ALXN REGN Regeneron $496.30 / +14.06 (+2.92%) 01/13/21 Early notable gainers among liquid option names on January 13th 12/18/20 Early notable gainers among liquid option names on December 18th 11/06/20 Regeneron put volume heavy and directionally bearish 10/08/20 Unusually active option classes on open October 8th FOLD Amicus $10.55 / +0.06 (+0.57%) 02/11/21 Amicus put volume heavy and directionally bearish 02/03/21 Amicus call volume above normal and directionally bullish CYTK Cytokinetics $25.69 / +1.87 (+7.85%) 10/29/20 Cytokinetics call volume above normal and directionally bullish BIIB Biogen $264.14 / +4.36 (+1.68%) 01/29/21 Early notable gainers among liquid option names on January 29th 01/08/21 Biogen put volume heavy and directionally bearish 11/11/20 Early notable gainers among liquid option names on November 11th 11/05/20 Unusually active option classes on open November 5th ALXN Alexion $153.23 / -0.09 (-0.06%) 12/14/20 Early notable gainers among liquid option names on December 14th 10/20/20 Alexion call volume above normal and directionally bullish 10/19/20 Alexion call volume above normal and directionally bullish
Conference/Events	Muscular Dystrophy Association to hold a virtual conference » 04:55 03/17/21 03/17 04:55 03/17/21 04:55 ALXN Alexion $153.32 / +1.14 (+0.75%) , SDNA Sedona Corporation $0.00 / + (+0.00%) , BIIB Biogen $259.78 / -0.37 (-0.14%) , PTCT PTC Therapeutics $57.73 / -0.3 (-0.52%) , SRPT Sarepta $84.40 / -1.39 (-1.62%) , NVS Novartis $85.96 / +0.66 (+0.77%) , SNY Sanofi $49.40 / +0.59 (+1.21%) , SLDB Solid Biosciences $6.45 / -3.115 (-32.58%) , REGN Regeneron $482.31 / -1.17 (-0.24%) , BHVN Biohaven Pharmaceutical $75.72 / -5.655 (-6.95%) , ORPH Orphazyme $13.30 / +0.84 (+6.74%) , CPRX Catalyst Pharmaceuticals $4.12 / +0.19 (+4.83%) , DYN Dyne Therapeutics $16.62 / -0.12 (-0.72%) , CYTK Cytokinetics $23.85 / -0.42 (-1.73%) , FOLD Amicus $10.49 / -0.28 (-2.60%) , PKI PerkinElmer $125.97 / -0.715 (-0.56%) MDA Clinical &… MDA Clinical & Scientific Virtual Conference 2021 will be held on March 14-18. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options SRPT SNY SLDB REGN PTCT PKI ORPH NVS FOLD DYN CYTK CPRX BIIB BHVN ALXN SRPT Sarepta $84.40 / -1.39 (-1.62%) 02/25/21 Sarepta rallies 2% to $86.15 after winning FDA approval for DMD treatment 02/25/21 Sarepta announces FDA approval of Amondys 45 02/08/21 Dyne Therapeutics appoints Ashish Dugar as SVP, global head of medical affairs 01/13/21 Sarepta, Genevant announce collaboration for gene editing therapeutics SNY Sanofi $49.40 / +0.59 (+1.21%) 03/16/21 Global Blood Therapeutics to in-license two SCD programs from Sanofi 03/15/21 Regeneron, Sanofi announce Libtayo study to be stopped early due to OS benefit 03/12/21 Sanofi, Translate Bio initiate SARS-CoV-2 vaccine candidate trial SLDB Solid Biosciences $6.45 / -3.115 (-32.58%) 03/15/21 Solid Biosciences reports interim functioning, biomarker data from IGNITE DMD 03/04/21 Solid Biosciences reports inducement grant to new CLO 03/04/21 Solid Biosciences names Erin Powers Brennan CLO, Joel Schneider COO 12/11/20 Solid Biosciences announces $90M private placement REGN Regeneron $482.31 / -1.17 (-0.24%) 03/04/21 Regeneron, Sanofi announce FDA acceptance of Dupixent sBLA 03/03/21 Kiniksa jumps 10% to $24 per share after disclosing supply deal with Regeneron 02/28/21 Regeneron announces Phase 2 data evaluating antibody cocktail REGN1908-1909 PTCT PTC Therapeutics $57.73 / -0.3 (-0.52%) 03/16/21 PTC Therapeutics announces two-year data from Part 2 of SUNFISH trial 02/26/21 PTC Therapeutics announces CHMP recommendation for approval of Evrysdi 02/17/21 PTC Therapeutics initiates second stage of Phase 2/3 trial of COVID-19 candidate 12/04/20 PTC Therapeutics: Translarna approved in Russia for treatment of nmDMD PKI PerkinElmer $125.97 / -0.715 (-0.56%) 03/10/21 Quidel slips, drags on peers as demand for testing 'softens significantly' 03/09/21 PerkinElmer launches comprehensive solutions for detecting SARS-CoV-2 mutations 02/23/21 PerkinElmer launches point of care Covid-19 antigen test for mass screening 02/22/21 PerkinElmer gives update on Valencia Branch Laboratory's accreditation process ORPH Orphazyme $13.30 / +0.84 (+6.74%) 12/31/20 CytRx says Orphazyme's arimoclomol PDUFA target date extended to June 17, 2021 12/07/20 CytRx announces Orphazyme U.S. expansion ahead of potential arimoclomol approval 11/11/20 CytRx says Orphazyme submited MAA to EMA for arimoclomol for NPC treatment 11/09/20 Orphazyme submits arimoclomol MAA to EMA NVS Novartis $85.96 / +0.66 (+0.77%) 03/16/21 FTC plans 'new approach' to analyzing effects of pharmaceutical mergers 03/16/21 Pliant Therapeutics completes PLN-1474 Phase 1 study, transfer to Novartis 03/12/21 NLS Pharmaceutics enters license agreement with Novartis for Sanorex 03/09/21 Novartis reports CANOPY-2 trial did not meet primary endpoint FOLD Amicus $10.49 / -0.28 (-2.60%) 03/01/21 Amicus sees FY21 total Galafold revenue $300M-$315M 02/11/21 Amicus AT-GAA not stat. significant for superiority vs. alglucosidasa alfa 02/11/21 Amicus trading resumes 02/11/21 Amicus trading halted, news pending DYN Dyne Therapeutics $16.62 / -0.12 (-0.72%) 03/04/21 Dyne Therapeutics expects cash to fund requirements into 2H24 01/10/21 Dyne Therapeutics announced new preclinical data from DM1 program CYTK Cytokinetics $23.85 / -0.42 (-1.73%) 02/18/21 Cytokinetics appoints Muna Bhanji to board of directors 01/13/21 Cytokinetics announces dosing of first patient in Cohort 2 of Redwood-HCM 01/11/21 Cytokinetics granted orphan drug designation for CK-3773274 in HCM 12/23/20 Cytokinetics regains European rights to omecamtiv mecarbil CPRX Catalyst Pharmaceuticals $4.12 / +0.19 (+4.83%) 01/06/21 Catalyst Pharmaceuticals awaiting schedule or decision in FDA suit 01/06/21 Catalyst Pharmaceuticals decides not to pursue Kennedy's disease indication 01/06/21 Catalyst Pharmaceuticals decides not to pursue SMA Type 3 indication 01/06/21 Catalyst plans to present hypotheses on MuSK-MG Phase 3 trial to FDA in 1H21 BIIB Biogen $259.78 / -0.37 (-0.14%) 03/04/21 Biogen to build gene therapy manufacturing center in North Carolina 03/04/21 Dyne Therapeutics appoints Wildon Farwell as CMO 02/03/21 Biogen sees FY21 adjusted R&D expense $2.35B-$2.45B 02/03/21 Biogen CEO sees 'a financial reset in 2021' BHVN Biohaven Pharmaceutical $75.72 / -5.655 (-6.95%) 03/11/21 Biohaven Pharmaceutical's Nurtec approved In United Arab Emirates for migraine 03/10/21 Biohaven says over 50% of participants enrolled in verdiperstat regimen 03/10/21 Biohaven's Nurtec ODT approved in Israel for acute treatment of migraine 02/22/21 Biohaven's BHV-1200 shows effective neuralization of multiple Covid strains ALXN Alexion $153.32 / +1.14 (+0.75%) 03/16/21 AstraZeneca withdraws FTC notification on Alexion deal, plans to refile 02/22/21 Arcturus Therapeutics acquires exclusive license from Alexion 02/16/21 Paulson & Co. buys Exxon, exits Qiagen in Q4 01/13/21 Alexion further pauses global Phase 3 study of Ultomiris ALXN SDNA BIIB PTCT SRPT NVS SNY SLDB REGN BHVN ORPH CPRX DYN CYTK FOLD PKI ALXN Alexion $153.32 / +1.14 (+0.75%) 02/04/21 Piper Sandler Alexion downgraded to Neutral ahead of expected deal closing at Piper Sandler 02/04/21 Piper Sandler Alexion downgraded to Neutral from Overweight at Piper Sandler 01/08/21 Raymond James Alexion downgraded to Market Perform from Outperform at Raymond James 12/16/20 Truist Alexion downgraded to Hold from Buy at Truist SDNA Sedona Corporation $0.00 / + (+0.00%) BIIB Biogen $259.78 / -0.37 (-0.14%) 02/17/21 Cantor Fitzgerald Biogen price target lowered to $268 from $278 at Cantor Fitzgerald 02/08/21 Citi Expert sees Biogen aducanumab approval 50/50 at best, says Citi 02/04/21 SVB Leerink Biogen price target lowered to $380 from $430 at SVB Leerink 02/04/21 Credit Suisse Biogen price target lowered to $338 from $350 at Credit Suisse PTCT PTC Therapeutics $57.73 / -0.3 (-0.52%) 02/26/21 Cantor Fitzgerald PTC Therapeutics price target lowered to $75 from $81 at Cantor Fitzgerald 02/12/21 BofA PTC Therapeutics downgraded to Neutral from Buy at BofA 02/12/21 BofA PTC Therapeutics downgraded to Neutral from Buy at BofA 01/05/21 Citi PTC Therapeutics upgraded to Buy from Neutral at Citi SRPT Sarepta $84.40 / -1.39 (-1.62%) 03/02/21 RBC Capital Sarepta price target lowered to $132 from $143 at RBC Capital 03/02/21 Piper Sandler Sarepta price target lowered to $130 from $140 at Piper Sandler 02/26/21 Mizuho Sarepta price target raised to $160 from $158 at Mizuho 02/25/21 Piper Sandler Piper says Sarepta's Amondys 45 approval comes with 'relatively clean label' NVS Novartis $85.96 / +0.66 (+0.77%) 03/10/21 Fly Intel: Top five analyst downgrades 03/10/21 Argus Novartis cut to Hold at Argus on slowing top-line growth, greater competition 03/10/21 Argus Novartis downgraded to Hold from Buy at Argus 03/01/21 Oppenheimer Homology Medicines loses potential source of upside, says Oppenheimer SNY Sanofi $49.40 / +0.59 (+1.21%) 02/23/21 BofA BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list 02/10/21 Morgan Stanley Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley 02/05/21 Piper Sandler Piper reiterates Overweight on Kymera after Sanofi capital markets day 01/19/21 UBS Sanofi price target lowered to EUR 99 from EUR 100 at UBS SLDB Solid Biosciences $6.45 / -3.115 (-32.58%) 03/16/21 Chardan Solid Biosciences price target raised to $20 from $12.50 at Chardan 03/16/21 Fly Intel: Top five analyst upgrades 03/16/21 SVB Leerink Solid Biosciences upgraded to Outperform at SVB Leerink 03/16/21 SVB Leerink Solid Biosciences upgraded to Outperform from Market Perform at SVB Leerink REGN Regeneron $482.31 / -1.17 (-0.24%) 03/11/21 Evercore ISI Kodiak Sciences initiated with an Outperform at Evercore ISI 03/11/21 Needham Vir Biotechnology price target raised to $80 from $75 at Needham 02/23/21 Credit Suisse Regeneron price target raised to $760 from $753 at Credit Suisse 02/16/21 Cantor Fitzgerald Regeneron price target lowered to $656 from $696 at Cantor Fitzgerald BHVN Biohaven Pharmaceutical $75.72 / -5.655 (-6.95%) 03/11/21 Fly Intel: Top five analyst initiations 03/11/21 UBS Biohaven Pharmaceutical initiated with a Buy at UBS 03/02/21 Mizuho Biohaven Pharmaceutical price target raised to $103 from $93 at Mizuho 03/01/21 Piper Sandler Biohaven price target raised to $110 from $90 at Piper Sandler ORPH Orphazyme $13.30 / +0.84 (+6.74%) 10/26/20 Guggenheim Orphazyme initiated with a Buy at Guggenheim 10/26/20 BofA Orphazyme initiated with a Buy at BofA 10/26/20 BofA Orphazyme initiated with a Buy at BofA CPRX Catalyst Pharmaceuticals $4.12 / +0.19 (+4.83%) 03/16/21 Piper Sandler Catalyst business continues to generate cash flow, says Piper Sandler 01/07/21 Piper Sandler Piper says Catalyst's Firdapse commercial business performing as expected 01/06/21 Piper Sandler Catalyst Firdapse commercial business performing as expected, says Piper Sandler 11/10/20 Piper Sandler Catalyst Pharmaceuticals price target lowered to $5.50 from $6 at Piper Sandler DYN Dyne Therapeutics $16.62 / -0.12 (-0.72%) 03/05/21 Stifel Dyne Therapeutics weakness a buying opportunity, says Stifel 02/09/21 Dyne Therapeutics initiated with a Buy at JonesTrading 01/07/21 Piper Sandler Dyne Therapeutics potential beneficiary of Sarepta's SRP-9001 miss, says Piper 10/12/20 Jefferies Dyne Therapeutics initiated with a Buy at Jefferies CYTK Cytokinetics $23.85 / -0.42 (-1.73%) 03/11/21 Wolfe Research Cytokinetics initiated with an Outperform at Wolfe Research 02/18/21 Barclays Cytokinetics initiated with an Overweight at Barclays 01/20/21 H.C. Wainwright Cytokinetics price target raised to $41 from $22 at H.C. Wainwright 12/28/20 Oppenheimer Amgen price target lowered to $266 from $274 at Oppenheimer FOLD Amicus $10.49 / -0.28 (-2.60%) 03/01/21 Stifel Amicus initiated with a Hold at Stifel 02/12/21 Fly Intel: Top five analyst downgrades 02/12/21 JPMorgan Amicus downgraded to Neutral on Pompe disease miss at JPMorgan 02/12/21 SVB Leerink Amicus downgraded to Market Perform from Outperform at SVB Leerink PKI PerkinElmer $125.97 / -0.715 (-0.56%) 02/03/21 Citi PerkinElmer price target raised to $155 from $150 at Citi 01/07/21 Piper Sandler Oxford Immunotec downgraded to Neutral from Overweight at Piper Sandler 01/07/21 Wells Fargo PerkinElmer upgraded to Overweight from Equal Weight at Wells Fargo 01/07/21 Wells Fargo PerkinElmer upgraded to Overweight from Equal Weight at Wells Fargo SRPT SNY SLDB REGN PTCT PKI NVS FOLD DYN CYTK CPRX BIIB BHVN ALXN SRPT Sarepta $84.40 / -1.39 (-1.62%) 03/01/21 Sarepta reports Q4 EPS ($1.84), consensus ($1.77) 03/01/21 Sarepta reports Q4 EPS ($1.84), consensus ($1.77) 11/05/20 Sarepta reports Q3 EPS ($2.50), consensus ($1.71) SNY Sanofi $49.40 / +0.59 (+1.21%) 02/05/21 Sanofi reports Q4 business EPS EUR 1.22, flat vs. last year 10/29/20 Sanofi reports Q3 business EPS EUR 1.83, up 0.5% from last year SLDB Solid Biosciences $6.45 / -3.115 (-32.58%) 11/05/20 Solid Biosciences reports Q3 EPS (44c), consensus (34c) REGN Regeneron $482.31 / -1.17 (-0.24%) 02/05/21 Regeneron reports Q4 EPS $9.53, consensus $8.39 02/04/21 Notable companies reporting before tomorrow's open 11/05/20 Regeneron reports Q3 EPS $8.36, consensus $7.13 PTCT PTC Therapeutics $57.73 / -0.3 (-0.52%) 02/25/21 PTC Therapeutics reports Q4 EPS ($1.08), consensus (94c) 10/29/20 PTC Therapeutics reports Q3 EPS ($1.03), consensus (6c) PKI PerkinElmer $125.97 / -0.715 (-0.56%) 02/02/21 PerkinElmer sees Q1 adjusted EPS of at least $3.00, consensus $2.40 02/02/21 PerkinElmer sees FY21 adjusted EPS at least $8.50, consensus $8.88 02/02/21 PerkinElmer reports Q4 adjusted EPS $3.96, consensus $3.00 01/11/21 PerkinElmer sees Q4 adjusted EPS 'at least' $3.60, consensus $2.79 NVS Novartis $85.96 / +0.66 (+0.77%) 01/26/21 Novartis sees 2021 core operating income to grow mid single digit 01/26/21 Novartis reports Q4 core EPS $1.34, consensus $1.36 11/05/20 Xoma reports Q3 EPS (10c), consensus (21c) 10/27/20 Novartis raises FY20 core operating income growth outlook FOLD Amicus $10.49 / -0.28 (-2.60%) 03/01/21 Amicus reports FY20 EPS ($1.07), consensus ($1.02) 11/05/20 Amicus reports Q3 EPS (25c), consensus (22c) DYN Dyne Therapeutics $16.62 / -0.12 (-0.72%) 03/04/21 Dyne Therapeutics reports Q4 EPS (64c), consensus (37c) 11/05/20 Dyne Therapeutics reports Q3 EPS ($2.01), consensus (87c) CYTK Cytokinetics $23.85 / -0.42 (-1.73%) 11/04/20 Cytokinetics reports Q3 EPS (5c), consensus (34c) CPRX Catalyst Pharmaceuticals $4.12 / +0.19 (+4.83%) 03/15/21 Catalyst Pharmaceuticals reports Q4 adjusted EPS 12c, consensus 9c 03/15/21 Catalyst Pharmaceuticals reports Q4 EPS 11c, consensus 9c 01/06/21 Catalyst Pharmaceuticals sees 2020 Firdapse revenues approx. $118M 11/09/20 Catalyst Pharmaceuticals reports Q3 diluted EPS 42c, consensus 10c BIIB Biogen $259.78 / -0.37 (-0.14%) 02/03/21 Biogen sees FY21 adjusted EPS $17.00-$18.50, consensus $24.67 02/03/21 Biogen reports Q4 adjusted EPS $4.58, consensus $4.87 02/02/21 Notable companies reporting before tomorrow's open BHVN Biohaven Pharmaceutical $75.72 / -5.655 (-6.95%) 03/01/21 Biohaven Pharmaceutical reports Q4 adjusted EPS ($2.69), consensus ($2.97) 11/09/20 Biohaven Pharmaceutical reports Q3 adj. EPS ($2.67), consensus ($2.89) ALXN Alexion $153.32 / +1.14 (+0.75%) 02/04/21 Alexion reports Q4 EPS $2.96, consensus $2.56 02/04/21 Alexion reports Q4 EPS $2.96, consensus $2.56 10/29/20 Alexion raises 2020 non-GAAP EPS view to $11.70-$12.00 from $10.65-$10.95 10/29/20 Alexion reports Q3 non-GAAP EPS $3.24, consensus $2.60 16 Mar 21 Jan 29 Sep 17 Sep 17 Jul 27 May SNY REGN NVS FOLD BIIB ALXN SNY Sanofi $49.40 / +0.59 (+1.21%) 02/15/21 CEO says Sanofi mRNA vaccine won't be ready this year, Bloomberg reports 02/15/21 Bristol-Myers, Sanofi to pay $834M over Plavix, Bloomberg reports 02/11/21 Amgen loses appeal to revive PCSK9 antibody patent suit, Bloomberg reports REGN Regeneron $482.31 / -1.17 (-0.24%) 12/30/20 Fresenius to administer Lilly, Regeneron COVID antibody drugs, Reuters says 12/04/20 Regeneron must face DOJ suit citing kickbacks, Bloomberg says 11/17/20 Regeneron says Roche completed early tests to make COVID drug, Reuters says NVS Novartis $85.96 / +0.66 (+0.77%) 03/15/21 BioNTech recruits Novartis, Sanofi to boost vaccine production, WSJ reports 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says 11/20/20 Trump to release new rules aimed at lowering drug prices, WSJ reports FOLD Amicus $10.49 / -0.28 (-2.60%) 02/02/21 Amicus, BioMarin speculated by Dealreporter as possible Vertex targets 10/16/20 Amicus 'a name to watch' if Vertex seeks M&A, Dealreporter says BIIB Biogen $259.78 / -0.37 (-0.14%) 11/07/20 Biogen Alzheimer's drug closer to approval, still not a buy, Barron's says 11/07/20 FDA may find it 'extremely' hard to approve Biogen drug after panel, STAT says 09/28/20 Biogen loses appeal in fight seeking royalties from Merck KGaA, Bloomberg says 09/28/20 Biogen loses appeal ruling on MS drug Rebif, Bloomberg says ALXN Alexion $153.32 / +1.14 (+0.75%) 10/09/20 Betaville says Vertex, Sanofi seen as interested in Alexion, Bloomberg reports SRPT SNY SLDB REGN PTCT PKI ORPH NVS FOLD DYN CYTK CPRX BIIB ALXN SRPT Sarepta $84.40 / -1.39 (-1.62%) 03/01/21 Fly Intel: After-Hours Movers 01/12/21 NIO downgrade, Wells Fargo upgrade among today's top calls on Wall Street 01/08/21 Fly Intel: Wall Street's top stories for Friday 01/08/21 Fly Intel: Wall Street's top stories at midday SNY Sanofi $49.40 / +0.59 (+1.21%) 02/22/21 Fly Intel: Wall Street's top stories for Monday 02/22/21 Fly Intel: Wall Street's top stories at midday 12/31/20 Fly Intel: Wall Street's top stories for Thursday 12/26/20 Week in review: How Trump's policies moved stocks SLDB Solid Biosciences $6.45 / -3.115 (-32.58%) 03/16/21 Fly Intel: Wall Street's top stories for Tuesday 03/16/21 Fly Intel: Wall Street's top stories at midday 12/11/20 Fly Intel: Wall Street's top stories at midday 12/11/20 Fly Intel: Pre-market Movers REGN Regeneron $482.31 / -1.17 (-0.24%) 02/05/21 Fly Intel: Pre-market Movers 01/26/21 Fly Intel: Wall Street's top stories for Tuesday 01/26/21 Fly Intel: Wall Street's top stories at midday 01/12/21 Fly Intel: After-Hours Movers PTCT PTC Therapeutics $57.73 / -0.3 (-0.52%) 09/23/20 Regenxbio slips as Novartis' Zolgensma expansion hits FDA roadblock PKI PerkinElmer $125.97 / -0.715 (-0.56%) 01/07/21 Fly Intel: Pre-market Movers ORPH Orphazyme $13.30 / +0.84 (+6.74%) 10/04/20 Opening Day: Palantir, Asana go public via direct listings 09/27/20 Opening Day: GoodRx rises over 50% in market debut 09/20/20 Opening Day: Snowflake shares double in biggest software IPO ever NVS Novartis $85.96 / +0.66 (+0.77%) 03/10/21 Novartis downgrade, HP Enterprise upgrade among today's top calls on Wall Street 02/11/21 Fly Intel: Wall Street's top stories for Thursday 02/11/21 Fly Intel: Wall Street's top stories at midday 02/11/21 Fly Intel: Pre-market Movers FOLD Amicus $10.49 / -0.28 (-2.60%) 02/12/21 Fly Intel: Wall Street's top stories for Friday 02/12/21 Fly Intel: Wall Street's top stories at midday 02/11/21 Fly Intel: After-Hours Movers 12/28/20 Kinnate initiations, Nikola target change among today's top calls on Wall Street DYN Dyne Therapeutics $16.62 / -0.12 (-0.72%) 01/21/21 Fly Intel: Wall Street's top stories for Thursday 01/21/21 Fly Intel: Wall Street's top stories at midday 09/28/20 Fly Intel: After-Hours Movers CYTK Cytokinetics $23.85 / -0.42 (-1.73%) 10/08/20 Fly Intel: Wall Street's top stories for Thursday 10/08/20 Fly Intel: Wall Street's top stories at midday 10/08/20 Cytokinetics plunges following mixed results from heart drug trial 10/05/20 Fly Intel: Wall Street's top stories for Monday CPRX Catalyst Pharmaceuticals $4.12 / +0.19 (+4.83%) 09/29/20 Fly Intel: After-Hours Movers BIIB Biogen $259.78 / -0.37 (-0.14%) 02/03/21 Fly Intel: Wall Street's top stories for Wednesday 02/03/21 Fly Intel: Wall Street's top stories at midday 02/03/21 Fly Intel: Pre-market Movers 01/29/21 Fly Intel: Wall Street's top stories for Friday ALXN Alexion $153.32 / +1.14 (+0.75%) 12/14/20 Fly Intel: Wall Street's top stories for Monday 12/14/20 Fly Intel: Wall Street's top stories at midday 12/14/20 Fly Intel: Pre-market Movers 12/07/20 Fly Insider: Foot Locker, Alexion among weeks notable insider trades 05/18/21 PDUFA Date for Avalglucosidase Alfa 06/07/21 PDUFA Date for Aducanumab 06/17/21 PDUFA Date for Arimoclomol 10/21/21 PDUFA Date for Dupixent (Dupilumab) 04/27/21 PerkinElmer, Inc. REGN FOLD CYTK BIIB ALXN REGN Regeneron $482.31 / -1.17 (-0.24%) 01/13/21 Early notable gainers among liquid option names on January 13th 12/18/20 Early notable gainers among liquid option names on December 18th 11/06/20 Regeneron put volume heavy and directionally bearish 10/08/20 Unusually active option classes on open October 8th FOLD Amicus $10.49 / -0.28 (-2.60%) 02/11/21 Amicus put volume heavy and directionally bearish 02/03/21 Amicus call volume above normal and directionally bullish CYTK Cytokinetics $23.85 / -0.42 (-1.73%) 10/29/20 Cytokinetics call volume above normal and directionally bullish BIIB Biogen $259.78 / -0.37 (-0.14%) 01/29/21 Early notable gainers among liquid option names on January 29th 01/08/21 Biogen put volume heavy and directionally bearish 11/11/20 Early notable gainers among liquid option names on November 11th 11/05/20 Unusually active option classes on open November 5th ALXN Alexion $153.32 / +1.14 (+0.75%) 12/14/20 Early notable gainers among liquid option names on December 14th 10/20/20 Alexion call volume above normal and directionally bullish 10/19/20 Alexion call volume above normal and directionally bullish
Conference/Events	Muscular Dystrophy Association to hold a virtual conference » 04:55 03/17/21 03/17 04:55 03/17/21 04:55 ALXN Alexion $153.32 / +1.14 (+0.75%) , BHVN Biohaven Pharmaceutical $75.72 / -5.655 (-6.95%) , BIIB Biogen $259.78 / -0.37 (-0.14%) , CPRX Catalyst Pharmaceuticals $4.12 / +0.19 (+4.83%) , CYTK Cytokinetics $23.85 / -0.42 (-1.73%) , DYN Dyne Therapeutics $16.62 / -0.12 (-0.72%) , FOLD Amicus $10.49 / -0.28 (-2.60%) , NVS Novartis $85.96 / +0.66 (+0.77%) , ORPH Orphazyme $13.30 / +0.84 (+6.74%) , PKI PerkinElmer $125.97 / -0.715 (-0.56%) , PTCT PTC Therapeutics $57.73 / -0.3 (-0.52%) , REGN Regeneron $482.31 / -1.17 (-0.24%) , SLDB Solid Biosciences $6.45 / -3.115 (-32.58%) , SNY Sanofi $49.40 / +0.59 (+1.21%) , SRPT Sarepta $84.40 / -1.39 (-1.62%) MDA Clinical &… MDA Clinical & Scientific Virtual Conference 2021 will be held on March 14-18. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options SRPT SNY SLDB REGN PTCT PKI ORPH NVS FOLD DYN CYTK CPRX BIIB BHVN ALXN SRPT Sarepta $84.40 / -1.39 (-1.62%) 02/25/21 Sarepta rallies 2% to $86.15 after winning FDA approval for DMD treatment 02/25/21 Sarepta announces FDA approval of Amondys 45 01/13/21 Sarepta, Genevant announce collaboration for gene editing therapeutics SNY Sanofi $49.40 / +0.59 (+1.21%) 03/16/21 Global Blood Therapeutics to in-license two SCD programs from Sanofi 03/12/21 Sanofi, Translate Bio initiate SARS-CoV-2 vaccine candidate trial SLDB Solid Biosciences $6.45 / -3.115 (-32.58%) 03/15/21 Solid Biosciences reports interim functioning, biomarker data from IGNITE DMD 03/04/21 Solid Biosciences reports inducement grant to new CLO 03/04/21 Solid Biosciences names Erin Powers Brennan CLO, Joel Schneider COO 12/11/20 Solid Biosciences announces $90M private placement REGN Regeneron $482.31 / -1.17 (-0.24%) 03/15/21 Regeneron, Sanofi announce Libtayo study to be stopped early due to OS benefit 03/04/21 Regeneron, Sanofi announce FDA acceptance of Dupixent sBLA 03/03/21 Kiniksa jumps 10% to $24 per share after disclosing supply deal with Regeneron 02/28/21 Regeneron announces Phase 2 data evaluating antibody cocktail REGN1908-1909 PTCT PTC Therapeutics $57.73 / -0.3 (-0.52%) 03/16/21 PTC Therapeutics announces two-year data from Part 2 of SUNFISH trial 02/26/21 PTC Therapeutics announces CHMP recommendation for approval of Evrysdi 02/17/21 PTC Therapeutics initiates second stage of Phase 2/3 trial of COVID-19 candidate 12/04/20 PTC Therapeutics: Translarna approved in Russia for treatment of nmDMD PKI PerkinElmer $125.97 / -0.715 (-0.56%) 03/10/21 Quidel slips, drags on peers as demand for testing 'softens significantly' 03/09/21 PerkinElmer launches comprehensive solutions for detecting SARS-CoV-2 mutations 02/23/21 PerkinElmer launches point of care Covid-19 antigen test for mass screening 02/22/21 PerkinElmer gives update on Valencia Branch Laboratory's accreditation process ORPH Orphazyme $13.30 / +0.84 (+6.74%) 12/31/20 CytRx says Orphazyme's arimoclomol PDUFA target date extended to June 17, 2021 12/07/20 CytRx announces Orphazyme U.S. expansion ahead of potential arimoclomol approval 11/11/20 CytRx says Orphazyme submited MAA to EMA for arimoclomol for NPC treatment 11/09/20 Orphazyme submits arimoclomol MAA to EMA NVS Novartis $85.96 / +0.66 (+0.77%) 03/16/21 FTC plans 'new approach' to analyzing effects of pharmaceutical mergers 03/16/21 Pliant Therapeutics completes PLN-1474 Phase 1 study, transfer to Novartis 03/12/21 NLS Pharmaceutics enters license agreement with Novartis for Sanorex 03/09/21 Novartis reports CANOPY-2 trial did not meet primary endpoint FOLD Amicus $10.49 / -0.28 (-2.60%) 03/01/21 Amicus sees FY21 total Galafold revenue $300M-$315M 02/11/21 Amicus AT-GAA not stat. significant for superiority vs. alglucosidasa alfa 02/11/21 Amicus trading resumes 02/11/21 Amicus trading halted, news pending DYN Dyne Therapeutics $16.62 / -0.12 (-0.72%) 03/04/21 Dyne Therapeutics expects cash to fund requirements into 2H24 02/08/21 Dyne Therapeutics appoints Ashish Dugar as SVP, global head of medical affairs 01/10/21 Dyne Therapeutics announced new preclinical data from DM1 program CYTK Cytokinetics $23.85 / -0.42 (-1.73%) 02/18/21 Cytokinetics appoints Muna Bhanji to board of directors 01/13/21 Cytokinetics announces dosing of first patient in Cohort 2 of Redwood-HCM 01/11/21 Cytokinetics granted orphan drug designation for CK-3773274 in HCM 12/23/20 Cytokinetics regains European rights to omecamtiv mecarbil CPRX Catalyst Pharmaceuticals $4.12 / +0.19 (+4.83%) 01/06/21 Catalyst Pharmaceuticals awaiting schedule or decision in FDA suit 01/06/21 Catalyst Pharmaceuticals decides not to pursue Kennedy's disease indication 01/06/21 Catalyst Pharmaceuticals decides not to pursue SMA Type 3 indication 01/06/21 Catalyst plans to present hypotheses on MuSK-MG Phase 3 trial to FDA in 1H21 BIIB Biogen $259.78 / -0.37 (-0.14%) 03/04/21 Biogen to build gene therapy manufacturing center in North Carolina 03/04/21 Dyne Therapeutics appoints Wildon Farwell as CMO 02/03/21 Biogen sees FY21 adjusted R&D expense $2.35B-$2.45B 02/03/21 Biogen CEO sees 'a financial reset in 2021' BHVN Biohaven Pharmaceutical $75.72 / -5.655 (-6.95%) 03/11/21 Biohaven Pharmaceutical's Nurtec approved In United Arab Emirates for migraine 03/10/21 Biohaven says over 50% of participants enrolled in verdiperstat regimen 03/10/21 Biohaven's Nurtec ODT approved in Israel for acute treatment of migraine 02/22/21 Biohaven's BHV-1200 shows effective neuralization of multiple Covid strains ALXN Alexion $153.32 / +1.14 (+0.75%) 03/16/21 AstraZeneca withdraws FTC notification on Alexion deal, plans to refile 02/22/21 Arcturus Therapeutics acquires exclusive license from Alexion 02/16/21 Paulson & Co. buys Exxon, exits Qiagen in Q4 01/13/21 Alexion further pauses global Phase 3 study of Ultomiris ALXN BHVN BIIB CPRX CYTK DYN FOLD NVS ORPH PKI PTCT REGN SLDB SNY SRPT ALXN Alexion $153.32 / +1.14 (+0.75%) 02/04/21 Piper Sandler Alexion downgraded to Neutral ahead of expected deal closing at Piper Sandler 02/04/21 Piper Sandler Alexion downgraded to Neutral from Overweight at Piper Sandler 01/08/21 Raymond James Alexion downgraded to Market Perform from Outperform at Raymond James 12/16/20 Truist Alexion downgraded to Hold from Buy at Truist BHVN Biohaven Pharmaceutical $75.72 / -5.655 (-6.95%) 03/11/21 Fly Intel: Top five analyst initiations 03/11/21 UBS Biohaven Pharmaceutical initiated with a Buy at UBS 03/02/21 Mizuho Biohaven Pharmaceutical price target raised to $103 from $93 at Mizuho 03/01/21 Piper Sandler Biohaven price target raised to $110 from $90 at Piper Sandler BIIB Biogen $259.78 / -0.37 (-0.14%) 02/17/21 Cantor Fitzgerald Biogen price target lowered to $268 from $278 at Cantor Fitzgerald 02/08/21 Citi Expert sees Biogen aducanumab approval 50/50 at best, says Citi 02/04/21 SVB Leerink Biogen price target lowered to $380 from $430 at SVB Leerink 02/04/21 Credit Suisse Biogen price target lowered to $338 from $350 at Credit Suisse CPRX Catalyst Pharmaceuticals $4.12 / +0.19 (+4.83%) 03/16/21 Piper Sandler Catalyst business continues to generate cash flow, says Piper Sandler 01/07/21 Piper Sandler Piper says Catalyst's Firdapse commercial business performing as expected 01/06/21 Piper Sandler Catalyst Firdapse commercial business performing as expected, says Piper Sandler 11/10/20 Piper Sandler Catalyst Pharmaceuticals price target lowered to $5.50 from $6 at Piper Sandler CYTK Cytokinetics $23.85 / -0.42 (-1.73%) 03/11/21 Wolfe Research Cytokinetics initiated with an Outperform at Wolfe Research 02/18/21 Barclays Cytokinetics initiated with an Overweight at Barclays 01/20/21 H.C. Wainwright Cytokinetics price target raised to $41 from $22 at H.C. Wainwright 12/28/20 Oppenheimer Amgen price target lowered to $266 from $274 at Oppenheimer DYN Dyne Therapeutics $16.62 / -0.12 (-0.72%) 03/05/21 Stifel Dyne Therapeutics weakness a buying opportunity, says Stifel 02/09/21 Dyne Therapeutics initiated with a Buy at JonesTrading 01/07/21 Piper Sandler Dyne Therapeutics potential beneficiary of Sarepta's SRP-9001 miss, says Piper 10/12/20 Jefferies Dyne Therapeutics initiated with a Buy at Jefferies FOLD Amicus $10.49 / -0.28 (-2.60%) 03/01/21 Stifel Amicus initiated with a Hold at Stifel 02/12/21 Fly Intel: Top five analyst downgrades 02/12/21 JPMorgan Amicus downgraded to Neutral on Pompe disease miss at JPMorgan 02/12/21 SVB Leerink Amicus downgraded to Market Perform from Outperform at SVB Leerink NVS Novartis $85.96 / +0.66 (+0.77%) 03/10/21 Fly Intel: Top five analyst downgrades 03/10/21 Argus Novartis cut to Hold at Argus on slowing top-line growth, greater competition 03/10/21 Argus Novartis downgraded to Hold from Buy at Argus 03/01/21 Oppenheimer Homology Medicines loses potential source of upside, says Oppenheimer ORPH Orphazyme $13.30 / +0.84 (+6.74%) 10/26/20 Guggenheim Orphazyme initiated with a Buy at Guggenheim 10/26/20 BofA Orphazyme initiated with a Buy at BofA 10/26/20 BofA Orphazyme initiated with a Buy at BofA PKI PerkinElmer $125.97 / -0.715 (-0.56%) 02/03/21 Citi PerkinElmer price target raised to $155 from $150 at Citi 01/07/21 Piper Sandler Oxford Immunotec downgraded to Neutral from Overweight at Piper Sandler 01/07/21 Wells Fargo PerkinElmer upgraded to Overweight from Equal Weight at Wells Fargo 01/07/21 Wells Fargo PerkinElmer upgraded to Overweight from Equal Weight at Wells Fargo PTCT PTC Therapeutics $57.73 / -0.3 (-0.52%) 02/26/21 Cantor Fitzgerald PTC Therapeutics price target lowered to $75 from $81 at Cantor Fitzgerald 02/12/21 BofA PTC Therapeutics downgraded to Neutral from Buy at BofA 02/12/21 BofA PTC Therapeutics downgraded to Neutral from Buy at BofA 01/05/21 Citi PTC Therapeutics upgraded to Buy from Neutral at Citi REGN Regeneron $482.31 / -1.17 (-0.24%) 03/11/21 Evercore ISI Kodiak Sciences initiated with an Outperform at Evercore ISI 03/11/21 Needham Vir Biotechnology price target raised to $80 from $75 at Needham 02/23/21 Credit Suisse Regeneron price target raised to $760 from $753 at Credit Suisse 02/16/21 Cantor Fitzgerald Regeneron price target lowered to $656 from $696 at Cantor Fitzgerald SLDB Solid Biosciences $6.45 / -3.115 (-32.58%) 03/16/21 Chardan Solid Biosciences price target raised to $20 from $12.50 at Chardan 03/16/21 Fly Intel: Top five analyst upgrades 03/16/21 SVB Leerink Solid Biosciences upgraded to Outperform at SVB Leerink 03/16/21 SVB Leerink Solid Biosciences upgraded to Outperform from Market Perform at SVB Leerink SNY Sanofi $49.40 / +0.59 (+1.21%) 02/23/21 BofA BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list 02/10/21 Morgan Stanley Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley 02/05/21 Piper Sandler Piper reiterates Overweight on Kymera after Sanofi capital markets day 01/19/21 UBS Sanofi price target lowered to EUR 99 from EUR 100 at UBS SRPT Sarepta $84.40 / -1.39 (-1.62%) 03/02/21 RBC Capital Sarepta price target lowered to $132 from $143 at RBC Capital 03/02/21 Piper Sandler Sarepta price target lowered to $130 from $140 at Piper Sandler 02/26/21 Mizuho Sarepta price target raised to $160 from $158 at Mizuho 02/25/21 Piper Sandler Piper says Sarepta's Amondys 45 approval comes with 'relatively clean label' SRPT SNY SLDB REGN PTCT PKI NVS FOLD DYN CYTK CPRX BIIB BHVN ALXN SRPT Sarepta $84.40 / -1.39 (-1.62%) 03/01/21 Sarepta reports Q4 EPS ($1.84), consensus ($1.77) 03/01/21 Sarepta reports Q4 EPS ($1.84), consensus ($1.77) 11/05/20 Sarepta reports Q3 EPS ($2.50), consensus ($1.71) SNY Sanofi $49.40 / +0.59 (+1.21%) 02/05/21 Sanofi reports Q4 business EPS EUR 1.22, flat vs. last year 10/29/20 Sanofi reports Q3 business EPS EUR 1.83, up 0.5% from last year SLDB Solid Biosciences $6.45 / -3.115 (-32.58%) 11/05/20 Solid Biosciences reports Q3 EPS (44c), consensus (34c) REGN Regeneron $482.31 / -1.17 (-0.24%) 02/05/21 Regeneron reports Q4 EPS $9.53, consensus $8.39 02/04/21 Notable companies reporting before tomorrow's open 11/05/20 Regeneron reports Q3 EPS $8.36, consensus $7.13 PTCT PTC Therapeutics $57.73 / -0.3 (-0.52%) 02/25/21 PTC Therapeutics reports Q4 EPS ($1.08), consensus (94c) 10/29/20 PTC Therapeutics reports Q3 EPS ($1.03), consensus (6c) PKI PerkinElmer $125.97 / -0.715 (-0.56%) 02/02/21 PerkinElmer sees Q1 adjusted EPS of at least $3.00, consensus $2.40 02/02/21 PerkinElmer sees FY21 adjusted EPS at least $8.50, consensus $8.88 02/02/21 PerkinElmer reports Q4 adjusted EPS $3.96, consensus $3.00 01/11/21 PerkinElmer sees Q4 adjusted EPS 'at least' $3.60, consensus $2.79 NVS Novartis $85.96 / +0.66 (+0.77%) 01/26/21 Novartis sees 2021 core operating income to grow mid single digit 01/26/21 Novartis reports Q4 core EPS $1.34, consensus $1.36 11/05/20 Xoma reports Q3 EPS (10c), consensus (21c) 10/27/20 Novartis raises FY20 core operating income growth outlook FOLD Amicus $10.49 / -0.28 (-2.60%) 03/01/21 Amicus reports FY20 EPS ($1.07), consensus ($1.02) 11/05/20 Amicus reports Q3 EPS (25c), consensus (22c) DYN Dyne Therapeutics $16.62 / -0.12 (-0.72%) 03/04/21 Dyne Therapeutics reports Q4 EPS (64c), consensus (37c) 11/05/20 Dyne Therapeutics reports Q3 EPS ($2.01), consensus (87c) CYTK Cytokinetics $23.85 / -0.42 (-1.73%) 11/04/20 Cytokinetics reports Q3 EPS (5c), consensus (34c) CPRX Catalyst Pharmaceuticals $4.12 / +0.19 (+4.83%) 03/15/21 Catalyst Pharmaceuticals reports Q4 adjusted EPS 12c, consensus 9c 03/15/21 Catalyst Pharmaceuticals reports Q4 EPS 11c, consensus 9c 01/06/21 Catalyst Pharmaceuticals sees 2020 Firdapse revenues approx. $118M 11/09/20 Catalyst Pharmaceuticals reports Q3 diluted EPS 42c, consensus 10c BIIB Biogen $259.78 / -0.37 (-0.14%) 02/03/21 Biogen sees FY21 adjusted EPS $17.00-$18.50, consensus $24.67 02/03/21 Biogen reports Q4 adjusted EPS $4.58, consensus $4.87 02/02/21 Notable companies reporting before tomorrow's open BHVN Biohaven Pharmaceutical $75.72 / -5.655 (-6.95%) 03/01/21 Biohaven Pharmaceutical reports Q4 adjusted EPS ($2.69), consensus ($2.97) 11/09/20 Biohaven Pharmaceutical reports Q3 adj. EPS ($2.67), consensus ($2.89) ALXN Alexion $153.32 / +1.14 (+0.75%) 02/04/21 Alexion reports Q4 EPS $2.96, consensus $2.56 02/04/21 Alexion reports Q4 EPS $2.96, consensus $2.56 10/29/20 Alexion raises 2020 non-GAAP EPS view to $11.70-$12.00 from $10.65-$10.95 10/29/20 Alexion reports Q3 non-GAAP EPS $3.24, consensus $2.60 16 Mar 21 Jan 29 Sep 17 Sep 17 Jul 27 May SNY REGN NVS FOLD BIIB ALXN SNY Sanofi $49.40 / +0.59 (+1.21%) 02/15/21 CEO says Sanofi mRNA vaccine won't be ready this year, Bloomberg reports 02/15/21 Bristol-Myers, Sanofi to pay $834M over Plavix, Bloomberg reports REGN Regeneron $482.31 / -1.17 (-0.24%) 02/11/21 Amgen loses appeal to revive PCSK9 antibody patent suit, Bloomberg reports 12/30/20 Fresenius to administer Lilly, Regeneron COVID antibody drugs, Reuters says 12/04/20 Regeneron must face DOJ suit citing kickbacks, Bloomberg says 11/17/20 Regeneron says Roche completed early tests to make COVID drug, Reuters says NVS Novartis $85.96 / +0.66 (+0.77%) 03/15/21 BioNTech recruits Novartis, Sanofi to boost vaccine production, WSJ reports 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says 11/20/20 Trump to release new rules aimed at lowering drug prices, WSJ reports FOLD Amicus $10.49 / -0.28 (-2.60%) 02/02/21 Amicus, BioMarin speculated by Dealreporter as possible Vertex targets 10/16/20 Amicus 'a name to watch' if Vertex seeks M&A, Dealreporter says BIIB Biogen $259.78 / -0.37 (-0.14%) 11/07/20 Biogen Alzheimer's drug closer to approval, still not a buy, Barron's says 11/07/20 FDA may find it 'extremely' hard to approve Biogen drug after panel, STAT says 09/28/20 Biogen loses appeal in fight seeking royalties from Merck KGaA, Bloomberg says 09/28/20 Biogen loses appeal ruling on MS drug Rebif, Bloomberg says ALXN Alexion $153.32 / +1.14 (+0.75%) 10/09/20 Betaville says Vertex, Sanofi seen as interested in Alexion, Bloomberg reports SRPT SNY SLDB REGN PTCT PKI ORPH NVS FOLD DYN CYTK CPRX BIIB ALXN SRPT Sarepta $84.40 / -1.39 (-1.62%) 03/01/21 Fly Intel: After-Hours Movers 01/12/21 NIO downgrade, Wells Fargo upgrade among today's top calls on Wall Street 01/08/21 Fly Intel: Wall Street's top stories for Friday 01/08/21 Fly Intel: Wall Street's top stories at midday SNY Sanofi $49.40 / +0.59 (+1.21%) 02/22/21 Fly Intel: Wall Street's top stories for Monday 02/22/21 Fly Intel: Wall Street's top stories at midday 12/31/20 Fly Intel: Wall Street's top stories for Thursday 12/26/20 Week in review: How Trump's policies moved stocks SLDB Solid Biosciences $6.45 / -3.115 (-32.58%) 03/16/21 Fly Intel: Wall Street's top stories for Tuesday 03/16/21 Fly Intel: Wall Street's top stories at midday 12/11/20 Fly Intel: Wall Street's top stories at midday 12/11/20 Fly Intel: Pre-market Movers REGN Regeneron $482.31 / -1.17 (-0.24%) 02/05/21 Fly Intel: Pre-market Movers 01/26/21 Fly Intel: Wall Street's top stories for Tuesday 01/26/21 Fly Intel: Wall Street's top stories at midday 01/12/21 Fly Intel: After-Hours Movers PTCT PTC Therapeutics $57.73 / -0.3 (-0.52%) 09/23/20 Regenxbio slips as Novartis' Zolgensma expansion hits FDA roadblock PKI PerkinElmer $125.97 / -0.715 (-0.56%) 01/07/21 Fly Intel: Pre-market Movers ORPH Orphazyme $13.30 / +0.84 (+6.74%) 10/04/20 Opening Day: Palantir, Asana go public via direct listings 09/27/20 Opening Day: GoodRx rises over 50% in market debut NVS Novartis $85.96 / +0.66 (+0.77%) 03/10/21 Novartis downgrade, HP Enterprise upgrade among today's top calls on Wall Street 02/11/21 Fly Intel: Wall Street's top stories for Thursday 02/11/21 Fly Intel: Wall Street's top stories at midday 02/11/21 Fly Intel: Pre-market Movers FOLD Amicus $10.49 / -0.28 (-2.60%) 02/12/21 Fly Intel: Wall Street's top stories for Friday 02/12/21 Fly Intel: Wall Street's top stories at midday 02/11/21 Fly Intel: After-Hours Movers 12/28/20 Kinnate initiations, Nikola target change among today's top calls on Wall Street DYN Dyne Therapeutics $16.62 / -0.12 (-0.72%) 01/21/21 Fly Intel: Wall Street's top stories for Thursday 01/21/21 Fly Intel: Wall Street's top stories at midday 09/28/20 Fly Intel: After-Hours Movers 09/20/20 Opening Day: Snowflake shares double in biggest software IPO ever CYTK Cytokinetics $23.85 / -0.42 (-1.73%) 10/08/20 Fly Intel: Wall Street's top stories for Thursday 10/08/20 Fly Intel: Wall Street's top stories at midday 10/08/20 Cytokinetics plunges following mixed results from heart drug trial 10/05/20 Fly Intel: Wall Street's top stories for Monday CPRX Catalyst Pharmaceuticals $4.12 / +0.19 (+4.83%) 09/29/20 Fly Intel: After-Hours Movers BIIB Biogen $259.78 / -0.37 (-0.14%) 02/03/21 Fly Intel: Wall Street's top stories for Wednesday 02/03/21 Fly Intel: Wall Street's top stories at midday 02/03/21 Fly Intel: Pre-market Movers 01/29/21 Fly Intel: Wall Street's top stories for Friday ALXN Alexion $153.32 / +1.14 (+0.75%) 12/14/20 Fly Intel: Wall Street's top stories for Monday 12/14/20 Fly Intel: Wall Street's top stories at midday 12/14/20 Fly Intel: Pre-market Movers 12/07/20 Fly Insider: Foot Locker, Alexion among weeks notable insider trades 05/18/21 PDUFA Date for Avalglucosidase Alfa 06/07/21 PDUFA Date for Aducanumab 06/17/21 PDUFA Date for Arimoclomol 10/21/21 PDUFA Date for Dupixent (Dupilumab) 04/27/21 PerkinElmer, Inc. REGN FOLD CYTK BIIB ALXN REGN Regeneron $482.31 / -1.17 (-0.24%) 01/13/21 Early notable gainers among liquid option names on January 13th 12/18/20 Early notable gainers among liquid option names on December 18th 11/06/20 Regeneron put volume heavy and directionally bearish 10/08/20 Unusually active option classes on open October 8th FOLD Amicus $10.49 / -0.28 (-2.60%) 02/11/21 Amicus put volume heavy and directionally bearish 02/03/21 Amicus call volume above normal and directionally bullish CYTK Cytokinetics $23.85 / -0.42 (-1.73%) 10/29/20 Cytokinetics call volume above normal and directionally bullish BIIB Biogen $259.78 / -0.37 (-0.14%) 01/29/21 Early notable gainers among liquid option names on January 29th 01/08/21 Biogen put volume heavy and directionally bearish 11/11/20 Early notable gainers among liquid option names on November 11th 11/05/20 Unusually active option classes on open November 5th ALXN Alexion $153.32 / +1.14 (+0.75%) 12/14/20 Early notable gainers among liquid option names on December 14th 10/20/20 Alexion call volume above normal and directionally bullish 10/19/20 Alexion call volume above normal and directionally bullish

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial